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   interleukin-­‐7	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   Light	  chain	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  MACS	   Magnetic	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  sorting	  MALT	   Mucosal	  associated	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  tissue	  MFI	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  fluorescent	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  MHCII	   Major	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  II	  miRNA	   Micro-­‐RNAs	  MLN	   Mesenteric	  lymph	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  MMR	   Mismatch	  repair	  MZ	   Marginal	  zone	  NFAT	   Nuclear	  factor	  of	  activated	  T-­‐cells	  NFkB	   Nuclear	  factor	  kB	  NHEJ	   Non	  homologous	  end	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  NHL	   Non	  Hodgkin	  Lymphoma	  PCR	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  chain	  reaction	  PCs	   Plasma	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   3‑phosphoinositide‑dependent	  protein	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  PH	   Pleckstrin‑homology	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   Phosphatidylinositol-­‐3-­‐Kinase	  PIP2	   Phosphatidylinositol-­‐4,5-­‐bisphosphate	  PIP3	   Phosphatidylinositol‑3,4,5‑trisphosphate	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   Protein	  Kinase	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  PKC	   Protein	  Kinase	  C	  PLCγ2	   Phospholipase	  C-­‐γ2	  	  Pro59	   Proline-­‐59	  PTKs	   Protein	  tyrosine	  kinases	  RAG	   Recombination	  activation	  gene	  RLB2	   Retinoblastoma-­‐like	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  RM	   Rapamycin	  RT	   Room	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  RT-­‐qPCR	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  labeling	  with	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  in	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   SH2-­‐domain-­‐containing	  leukocyte	  protein	  of	  65	  kDa	  SPL	   Spleen	  SSC	   Side	  Scatter	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  TAK1	   TGFb-­‐activated	  kinase	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  TFH	   T	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  helper	  Thr58	   Threonine	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  TRAIL	   TNF-­‐related	  apoptosis-­‐inducing	  ligand	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  WHO	   World	  Health	  Organization	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4 ABSTRACT	  
The	   B	   cell	   antigen	   receptor	   (BCR)	   plays	   a	   central	   role	   both	   in	   early	   B-­‐cell	  development	   and	   in	   mature	   B	   cells,	   where	   it	   controls	   survival	   and	   allows	   the	  organism	   to	  mount	  protective	   immune	   responses	   against	   foreign	   antigens.	   	   Surface	  BCR	  expression	   is	   retained	   in	  most	   types	  of	  Non-­‐Hodgkin	  B-­‐cell	   lymphomas	   (NHL),	  where	   it	   has	   been	   proposed	   to	   participate	   to	   tumor	   initiation,	   maintenance	   and	  progression.	  This	  study	  has	  provided	  for	  the	  first	  time	  an	  in	  vivo	  genetic	  proof	  for	  the	  role	  of	  the	  BCR	  in	  B-­‐cell	  lymphomagenesis.	  	  Using	  the	  λ-­‐MYC	  Burkitt	  lymphoma	  (BL)	  mouse	  model,	  in	  which	  conditional	  ablation	  of	   the	   BCR	   can	   be	   induced	   in	   c-­‐MYC	   transformed	   B	   cells	   through	   the	   Cre/loxP	  recombination	  system,	  I	  provide	  evidence	  for	  the	  essential	  role	  of	  the	  BCR	  in	  tumor	  maintenance.	  Acute	  BCR	  ablation	  in λ-­‐MYC	  lymphomas	  delayed	  cell	  cycle	  progression	  and	  augmented	  apoptosis,	  causing	  the	  rapid	  disappearance	  of	  BCR-­‐	  tumor	  cells	  when	  these	   cells	   were	   grown	   both	   in	   vitro	   and	   in	   vivo	   in	   competition	   with	   their	   BCR+	  counterparts.	  Similar	  results	  were	  obtained	  using	  the	  human	  Burkitt	   lymphoma	  cell	  line,	  RAMOS.	  This	  study	  has	  also	  elucidated	  crucial	  effectors	  of	  tonic	  BCR	  signalling	  that	  influence	  the	   survival	   and	   growth	   of	   BL	   cells.	   BCR	   inactivation	   led	   to	   a	   reduction	   in	   GSK3β	  phosphorylation,	   leading	   to	   an	   increase	   in	   its	   enzymatic	   activity.	   Importantly,	  treatment	   of	   lymphoma	   cells	   with	   a	   GSK3β	   small	   molecule	   inhibitor	   restored	   the	  ability	  of	  BCR-­‐deficient	  lymphomas	  to	  compete	  with	  their	  BCR+	  counterparts.	  I	  could	  also	  show	  that	  c-­‐MYC	  transformed	  B	  cells	  acquired	  exquisite	  sensitivity	  to	  the	  mTOR	  inhibitor	  rapamycin	  upon	  BCR	  inactivation.	  	  Using	  a	  combination	  of	  quantitative	  proteome	  and	  whole	  transcriptome	  analyses	  we	  have	  started	  to	  shed	  light	  on	  the	  contribution	  of	  the	  BCR	  to	  the	  maintenance	  of	  c-­‐MYC	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transformed	  B	  cells.	  In	  λ-­‐MYC	  lymphomas,	  the	  BCR	  regulated	  a	  substantial	  number	  of	  MYC	  targets	  genes.	  Notably,	  the	  majority	  of	  these	  shared	  targets	  were	  normalized	  in	  BCR-­‐	  tumor	  cells	  upon	  pharmacological	  inhibition	  of	  GSK3β.	  These	  result	  point	  to	  the	  tempting	   hypothesis	   that	   the	   BCR	   supports	   MYC-­‐driven	   lymphomagenesis,	   by	   the	  inhibition	   of	   GSK3β-­‐mediated	   phosphorylation	   and	   hence	   degradation	   of	   c-­‐MYC	  protein.	  	  Finally,	  our	  study	  demonstrates	  that	  the	  failure	  of	  c-­‐MYC	  transformed	  B	  cells	  to	  grow	  
in	  vivo	  is	  strictly	  dependent	  on	  the	  concomitant	  presence	  of	  their	  BCR+	  counterparts.	  This	   result	  has	   important	   implications	   for	   the	  design	  of	   clinical	   trials	   limited	   to	   the	  use	   of	   inhibitors	   of	   the	   BCR	   signalling	   pathway	   for	   the	   treatment	   of	   BL	   and	   other	  forms	  of	  aggressive	  NHL.	  To	  avoid	  the	  outgrowth	  of	  BCR-­‐	  escape	  variants	  in	  response	  to	   such	   treatments,	   we	   propose	   the	   integration	   in	   the	   therapeutic	   protocol	   of	   the	  mTOR	   inhibitor	  rapamacyin	   that	  showed	  high	  efficacy	   in	   the	  killing	   Ig	  receptor-­‐less	  lymphoma	  cells.	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5 INTRODUCTION	  
Every	   year,	   around	   350000	   new	   cases	   of	   Non-­‐Hodgkin-­‐Lymphomas	   (NHL)	   are	  diagnosed	   worldwide,	   accounting	   for	   over	   190000	   cases	   of	   death,	   and	   with	   an	  incidence	  which	  has	  been	  constantly	  increasing	  in	  the	  past	  2	  decades	  (Boffetta,	  2011).	  Around	  95%	  of	  NHL	  are	  of	  B-­‐cell	  origin,	  and	  represent	  a	  very	  heterogeneous	  group	  of	  malignancies	  with	  different	  clinical	  behaviours,	  therefore	  requiring	  diverse	  treatment	  strategies.	  This	  heterogeneity	  depends	  on	  the	  combination	  of	  genetic	  events	  causing	  malignant	  transformation	  of	  B	  lymphocytes	  at	  defined	  stages	  of	  their	  differentiation.	  A	   great	   effort	   has	   been	  made	   in	   the	   past	   10	   years	   to	   identify	   the	   cell	   of	   origin	   of	  human	   B-­‐cell	   lymphomas,	   the	   identification	   of	   key	   transforming	   events	   and	   the	  definition	  of	  promising	  therapeutic	  targets	  for	  lymphoma	  treatment.	  Importantly,	  it’s	  becoming	  clear	  that	  key	  factors,	  crucial	  for	  normal	  B-­‐cell	  differentiation	  and	  survival,	  are	  also	  required	  for	  the	  growth	  of	  most	  B-­‐cell	  lymphomas	  (Küppers,	  2005).	  Among	  them,	   the	   B	   cell	   antigen	   receptor	   (BCR),	   whose	   expression	   is	   retained	   in	   virtually	  100%	  of	  B-­‐cell	  NHL,	  represents	  a	  promising	  target,	  as	  the	  survival	  signals	  supplied	  in	  normal	  B	  cells	  might	  have	  a	  similar	  role	  on	  the	  malignant	  counterparts.	  	  
5.1 B	  cell	  development	  Generation	   of	   B-­‐lymphocytes	   is	   a	   highly	   regulated	   process	   whereby	   functional	  subsets	  of	  mature	  B	  cells	  are	  generated	  from	  hematopoietic	  stem	  cells,	   in	   fetal	   liver	  during	   embryogenesis,	   and	   in	   the	   bone	   marrow	   during	   post-­‐natal	   life	   (Hardy	   and	  Hayakawa,	  2001).	  Our	  knowledge	  of	  B	  cell	  lymphopoiesis	  has	  significantly	  improved	  over	   the	   past	   two	   decades	   through	   the	   identification	   of	   a	   combination	   of	   surface	  markers	  and	  molecular	  events	  associated	  with	  specific	  stages	  of	  B-­‐cell	  development.	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5.1.1 Early	  B-­‐cell	  development	  In	  postnatal	  life,	  the	  production	  of	  B	  cells	  is	  a	  lifelong	  process	  that	  occurs	  in	  the	  bone	  marrow	   (BM)	   as	   a	   result	   of	   the	   differentiation	   of	   multipotent	   hematopoietic	   stem	  cells	   (HSCs).	   	   A	   strictly	   regulated	   and	   hierarchical	   process	   promotes	   the	  differentiation	  of	  HSC	  into	  lymphoid-­‐primed	  multipotent	  progenitors	  (LMPPs)	  that	  in	  turn	   develop	   into	   common	   lymphoid	   progenitors	   (CLPs),	   a	   highly	   committed	  population	  of	  lymphoid	  precursors.	  	  The	   progression	   of	   B-­‐cells	   through	   the	   early	   stages	   of	   development	   can	   be	   tracked	  using	  a	  unique	  combination	  of	  surface	  markers	  and	  through	  the	  analysis	  of	  the	  status	  of	  the	  immunoglobulin	  (Ig)	  variable	  (V)	  region	  gene	  loci	  (Rajewsky,	  1996).	  CLPs	  give	  rise	  to	  B220+CD43+c-­‐kit+IgM-­‐	  pro-­‐B	  cells,	   that	  express	  the	  Recombination	  Activation	  Genes	  (RAG)-­‐1	  and	  -­‐2,	  to	  promote	  Ig	  V-­‐gene	  rearrangements.	  In	  pro-­‐B	  cells,	  Ig	  heavy	  (H)	  chain	  V-­‐genes	  are	  assembled	  through	  the	  joining	  first	  of	  DH	  and	  JH	  segments	  (on	  both	   IgH	   alleles),	   followed	  by	  mono-­‐allelic	   recombination	  of	   a	   single	  VH	  segment	   to	  DHJH	   rearrangements	   (Alt	   et	   al.,	   1984).	   Cells	   carrying	   a	   productive	   IgH	   V-­‐gene	  rearrangement	   differentiate	   into	   B220+/loCD43-­‐CD25+IgM-­‐	   pre-­‐B	   cells.	   Pre-­‐B	   cells	  express	  a	  pre-­‐B	  cell	  receptor	  consisting	  of	  a	  functional	  IgH	  chain	  paired	  to	  V-­‐preB	  and	  
λ5	   surrogate	   light	   chains,	   respectively	   (Karasuyama	  et	   al.,	   1990;	  Tsubata	   and	  Reth,	  1990).	  Signalling	  through	  the	  pre-­‐BCR	  and	  the	  interleukin-­‐7	  receptor	  (IL-­‐7R)	  triggers	  clonal	  expansion	  of	  pre-­‐B	  cells,	   at	  a	   time	  when	  RAG	  proteins	  are	   temporarily	  down	  regulated.	   	   The	   switching	   from	   proliferation	   to	   differentiation	   signals	   triggers	   cell-­‐cycle	   arrest	   of	   pre-­‐B	   cells	   and	   re-­‐activation	   of	   the	   RAG	   genes,	   which	   ultimately	  promote	   VL	   to	   JL	   gene	   rearrangements	   at	   the	   IgL	   chain	   locus.	   Expression	   of	   a	  functional	   IgL	   chain,	   and	   consequently	   its	   pairing	   to	   the	   IgH	   chain,	   allows	   the	  expression	  on	  the	  surface	  of	  a	  B-­‐cell	  receptor	  (BCR).	  	  Bone	  marrow	  B	  cells	  expressing	  a	  de	  novo	  BCR	  on	  the	  surface	  are	  identified	  as	  B220lo/+CD43-­‐CD25-­‐IgMhiIgD-­‐	  immature	  
	   15	  
B	  cells.	  Before	  exiting	  the	  BM,	  newly	  generated	  B	  cells	  are	  tested	  for	  auto	  reactivity.	  	  Depending	   on	   the	   strength	   of	   the	   signal	   emanating	   from	   auto-­‐reactive	   BCRs,	  immature	  B	  cells:	  i)	  undergo	  secondary	  IgL	  chain	  rearrangements	  through	  a	  process	  called	  IgL	  receptor	  editing),	  ii)	  die	  through	  apoptosis,	  or	  iii)	  become	  unresponsive	  to	  cognate	   antigen	   (a	   process	   also	   called	   anergy;	   Goodnow	   et	   al.,	   1988;	   Retter	   and	  Nemazee,	   1998;	   Tiegs	   et	   al.,	   1993).	   Immature	   B	   cells	   expressing	   functional,	   non-­‐autoreactive	   BCRs	   exit	   the	   bone	   marrow	   and	   through	   the	   blood	   stream	   home	   to	  secondary	   lymphoid	  organs,	  where	   they	  complete	   their	  development	   (Allman	  et	  al.,	  1993).	  	  	  
	  
Figure	  1:	  Schematic	  view	  of	  B	  cell	  development	  
Hematopoietic	   stem	   cells	   give	   rise	   to	   pro-­‐B	   cells	   through	   a	   series	   of	   sequential	   developmental	   steps.	   Specific	  stages	  of	  stages	  of	  early	  B-­‐cell	  lymphopoiesis	  are	  defined	  through	  the	  analysis	  of	  Ig	  V-­‐gene	  rearrangements.	  When	  successful	  VDJ	  recombination	  occurs	  at	  the	  IgH	  locus,	  a	  functional	  IgH	  chain	  pairs	  to	  surrogate	  IgL	  chains	  to	  give	  rise	  to	  the	  pre-­‐B	  cell	  receptor	  (pBCR).	  Signalling	  through	  the	  pBCR	  promotes	  first	  clonal	  expansion	  of	  pre-­‐B	  cells	  and	   later	   the	   rearrangement	   of	   Ig	   L	   chain	   V-­‐gene	   segments.	   Productive	   VL	   to	   JL	   rearrangements,	   followed	   by	  IgH/IgL	  chain	  pairing	  leads	  to	  surface	  expression	  of	  a	  functional	  BCR.	  Newly	  generated	  B	  cells	  are	  selected	  on	  the	  basis	  of	  their	  BCR	  specificity	  to	  eliminate	  autoreactive	  clones.	  Only	  B-­‐cells	  expressing	  “innocent”	  BCRs	  are	  allowed	  to	   leave	   the	   bone	   marrow	   and	   continue	   their	   differentiation	   in	   secondary	   lymphoid	   organs	   (adapted	   from	  (Rajewsky,	  1996).	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5.1.2 Peripheral	  B	  cell	  differentiation	  Newly	   generated,	   short-­‐lived	   B220+IgMhiIgD-­‐	   immature	   B	   cells	   reach	   the	   spleen	  where	   they	   continue	   their	   development	   as	   transitional	   B	   cells	   identified	   through	   a	  unique	   combination	   of	   surface	   markers	   	   (Allman	   et	   al.,	   2001;	   Loder	   et	   al.,	   1999).	  Transitional	   T1	   cells	   (B220loIgM+CD23-­‐	   AA4.1+)	   corresponding	   to	   the	   earliest	   BM	  emigrants,	   give	   rise	   to	   T2	   cells	   (B220loIgMhiCD23+),	   which	   ultimately	   differentiate	  into	   the	   major	   subsets	   of	   mature	   B	   cells.	   Only	   a	   limited	   number	   of	   T2	   cells	   is	  ultimately	  recruited	  in	  the	  compartments	  of	  mature	  B	  cells.	  	  According	   to	   their	   origin,	   function	   and	   localization,	  mature	  B	   cells	   are	   divided	   into	  three	  main	  subsets	  represented	  by	  follicular	  (FO)/B2,	  marginal	  zone	  (MZ)	  and	  B1	  B	  cells.	  
	  
Figure	  2:	  Peripheral	  B	  cell	  development	  
Bone	   marrow-­‐derived	   immature	   B	   cells,	   express	   a	   functional	   BCR	   on	   the	   surface	   and	   migrate	   to	   secondary	  lymphoid	   organs	   such	   as	   spleen	   and	   lymph	   nodes.	   Here,	   they	   complete	   their	   differentiation	   to	   become	  respectively	  follicular	  (FO),	  marginal	  zone	  (MZ)	  or	  B1	  B	  cells.	  Upon	  recognition	  of	  foreign	  antigen,	  in	  the	  presence	  of	  T-­‐cell	  help,	  FO	  (and	  in	  some	  instances	  MZ)	  B	  cells	  are	  recruited	  to	  form	  germinal	  centers	  (GC).	  In	  GCs,	  B	  cells	  undergo	   secondary	  diversification	  of	   the	   antibody	   repertoire	   through	   the	  process	   of	   Ig	   somatic	   hypermutation.	  Only	   few	   GC	   B	   cells	   expressing	   high	   affinity	   BCRs	   are	   selected	   to	   differentiate	   into	   long-­‐lived	   memory	   and	  antibody-­‐secreting	   (ASC)	  plasma	  cells.	   	  B1	  and	  MZ	  B	  cells	  differentiate	  directly	   into	  ASC	   in	   response	   to	  antigen	  recognition,	  in	  T-­‐cell	  independent	  immune	  responses.	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5.1.2.1 Follicular	  B	  cells	  FO	  B	  cells	  (IgMhiIgDhiCD21midCD23+)	  represent	  the	  major	  population	  of	  mature	  B	  cells	  present	   in	   secondary	   lymphoid	   organs.	   They	   express	   both	   IgM	  and	  IgD	   on	   the	   cell	  surface.	  The	  life	  span	  of	  FO	  B	  cells	  ranges	  from	  weeks	  to	  months	  (Fulop	  et	  al.,	  1983;	  Hao	  and	  Rajewsky,	  2001).	  FO	  B	  cells	  reside	  within	  primary	  follicles	  of	  the	  white	  pulp	  of	   the	   spleen	  and	   in	   the	   cortical	   area	  of	   lymph	  nodes.	  FO	  B	  cells	   represent	  also	   the	  primary	  B-­‐cell	  subset	  found	  in	  mucosal	  associated	  lymphoid	  tissue	  (MALT).	  B2	  B	  cells	  participate	   to	  both	  T	   cell-­‐dependent	  and	   -­‐independent	   immune	   responses.	   In	  T-­‐cell	  dependent	   immune	   responses,	   antigen	   recognition	   through	   the	   BCR	   promotes	   the	  recruitment	  of	  B2	  B	  cells	  into	  the	  germinal	  center	  (GC)	  reaction	  (see	  below,	  5.1.2.4).	  As	   a	   result	   of	   the	   GC	   reaction,	   B2	   B	   cells	   differentiate	   into	   high	   affinity	   antibody-­‐secreting	   plasma	   cells	   (PCs)	   or	   memory	   B	   cells.	   In	   T-­‐cell	   independent	   immune	  responses	  B2	  B	  cells	  give	  rises	  directly	  to	  short-­‐lived,	  low	  affinity	  PCs	  (MacLennan	  et	  al.,	  2003).	  
5.1.2.2 B-­‐1	  B	  cells	  B-­‐1	  cells	  (IgMhiIgD-­‐B220lowCD23lowCD43+CD11b+)	  are	  a	  population	  of	  self-­‐renewing	  B	  cells,	   predominantly	   located	   in	   body	   cavity	   serosa.	   According	   to	   the	   Ly-­‐1/CD5	  marker,	   B-­‐1	   cells	   are	   classified	   as	   B-­‐1a	   (CD5+)	   and	  B-­‐1b	   (CD5-­‐)	   B	   cells	   (Stall	   et	   al.,	  1992).	  B-­‐1	  B	  cells	  originate	  mainly	  from	  fetal	  liver	  HSCs	  that	  are	  distinct	  from	  those	  giving	  rise	  to	  B-­‐2	  and	  MZ	  B	  cells	  (Montecino-­‐Rodriguez	  et	  al.,	  2006).	  B-­‐1	  B	  cells	  are	  responsible	   for	   the	   production	   of	   so-­‐called	   natural	   antibodies	   reactive	   against	   a	  plethora	  of	  microbial	  antigens.	  These	  antibodies	  represent	  the	  first	  line	  of	  defence	  of	  the	  organism	  against	  invading	  pathogens	  (Su	  and	  Tarakhovsky,	  2000).	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5.1.2.3 Marginal	  Zone	  B	  cells	  MZ	   B	   cells	   (IgMhiIgDlowCD21hiCD23low)	   are	   exclusively	   found	   in	   the	   spleen,	   in	   close	  proximity	   with	   the	   marginal	   sinus,	   surrounding	   B	   cell	   follicles.	   MZ	   B	   cells	   are	  provided	  with	  self-­‐renewal	  capacity	  (Hao	  and	  Rajewsky,	  2001)	  and	  are	  recruited	  into	  both	   T	   cell-­‐dependent	   and	   -­‐independent	   immune	   responses,	   in	   response	   to	   blood-­‐borne	  pathogens	  (Martin	  and	  Kearney,	  2002).	  MZ	  B	  cells	  can	  rapidly	  differentiate	  into	  IgM-­‐	   and	   IgG3-­‐secreting	  plasma	   cells	   in	   response	   to	  T-­‐cell	   independent	   antigens,	   or	  alternatively,	  get	  efficiently	  recruited	  into	  the	  GC	  during	  a	  T-­‐cell	  dependent	  immune	  response,	   given	   the	   efficient	   presentation	   of	   antigens	   via	   major	   histocompatibility	  complex	  class	  II	  (MHCII)	  molecules	  (Lopes-­‐Carvalho	  et	  al.,	  2005).	  The	   identification	  of	   the	  precursor	   cell	   as	  well	   as	   the	   signalling	  pathway(s)	  driving	  MZ	  versus	  FO	  B	  cell	  differentiations	  are	  a	  matter	  of	  active	  investigation	  (Allman	  et	  al.,	  2006).	  Activation	  of	   the	  Notch	  pathway	   as	  well	   as	   signalling	   through	   the	  BCR	  have	  been	  proposed	  as	   central	   determinants	  of	  MZ	  versus	  FO	  B	   cell	   (Casola	   et	   al.,	   2004;	  Pillai	  et	  al.,	  2004;	  Radtke	  et	  al.,	  2010).	  
5.1.2.4 The	  germinal	  centre	  reaction	  In	   secondary	   lymphoid	  organs,	   lymphocytes	   are	   segregated	   into	   adjacent	  B-­‐	   and	  T-­‐	  cell	  zones,	  defined	  by	  gradients	  of	  chemokines	  (Cyster,	  2010).	  During	   a	   T-­‐cell	   dependent	   immune	   response,	   B	   cells	   recognize	   protein	   antigens	  through	  the	  BCR,	  followed	  by	  internalization	  of	  the	  BCR/antigen	  complex.	  	  Proteolytic	  cleavage	   of	   the	   antigen	   is	   followed	   by	   the	   loading	   of	   short	   peptides	   onto	   MHC-­‐II	  molecules.	  B	  cells	  primed	  with	  the	  antigen,	  up	  regulate	  specific	  chemokine	  receptors	  (CCR7)	  that	  attract	  them	  to	  the	  boundary	  with	  the	  T	  cell	  zone.	  Here,	  B-­‐cells	  present	  antigens	   to	   cognate	   CD4+	   T	   follicular	   helper	   (TFH)	   cells.	   B	   and	   T	   cells	   contact	   each	  other	   via	   MHC	   class-­‐II/TCR	   pairing,	   in	   the	   presence	   of	   co-­‐stimulatory	   signals	  (CD40/CD40L	   and	   CD80	   (and	   CD86)/CTLA4).	   These	   events	   are	   crucial	   for	   the	   full	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activation,	   survival	   and	   further	   differentiation	   of	   antigen-­‐specific	  B	   cells	   (Klein	   and	  Dalla-­‐Favera,	  2008).	  Once	  activated	  by	  T-­‐cells,	  antigen-­‐specific	  B	  cells	   follow	  one	  of	  two	   developmental	   paths:	   i)	   they	   differentiate	   directly	   into	   short-­‐lived	   low-­‐affinity	  antibody	  secreting	  PCs	  (Smith	  et	  al.,	  1996),	  or	  ii)	  they	  return	  to	  the	  B	  cell	  zone	  where	  they	  give	  rise	  to	  a	  germinal	  center	  reaction	  nucleated	  around	  follicular	  dendritic	  cells	  (FDC)	   loaded	   with	   immune	   complexes	   (Kosco-­‐Vilbois	   and	   Scheidegger,	   1995).	   GCs	  represent	  a	  polarized	  structure	  consisting	  of	  an	  area	  (the	  dark	  zone)	  densely	  packed	  with	  proliferating	  B	  cells	  (also	  called	  centroblasts,	  CBs),	  separated	  by	  the	   light	  zone	  consisting	   of	   resting	   B	   cells	   (centrocytes,	   CCs)	   positioned	   in	   close	   proximity	   with	  FDCs,	  TFH	  cells	  and	  macrophages	  (Allen	  et	  al.,	  2007;	  Victora	  et	  al.,	  2010;	  Victora	  and	  Nussenzweig,	  2012).	  	  	  During	   clonal	   expansion,	   CBs	   undergo	   diversification	   of	   their	   IgH	   and	   IgL	   V-­‐gene	  repertoires	   through	   a	   process	   called	   somatic	   hypermutation	   (SHM).	   	   SHM	   is	  dependent	  on	  Activation-­‐Induced	  cytidine	  Deaminase	  (AID),	  an	  enzyme	  identified	  in	  1999	   by	   the	   Honjo	   group.	   (Muramatsu	   et	   al.,	   2000;	   Revy	   et	   al.,	   2000).	   GC	   B	   cells	  undergo	  Ig	  SHM	  at	  very	  high	  rate	  (1	  mutation/103bp/cell	  division)	  thus	  contributing	  to	  a	  further	  diversification	  of	  the	  primary	  antibody	  repertoire.	  Ig	  SHM	  creates	  B	  cells	  expressing	  novel	  BCR	  specificities,	  from	  which	  only	  a	  very	  limited	  subset	  is	  selected	  on	  the	  basis	  of	  their	  binding	  with	  high	  affinity	  to	  cognate	  antigen.	  The	  latter	  cells	  are	  destined	   to	   leave	   the	   GC,	   however	   not	   before	   completing	   their	   differentiation	   into	  long-­‐lived	   memory	   B	   cells	   or	   PCs	   (Klein	   and	   Dalla-­‐Favera,	   2008;	   Wagner	   and	  Neuberger,	  1996).	   In	  contrast,	   the	  majority	  of	  GC	  B	  cells	  die	   in	  situ	  by	  programmed	  cell	   death.	   CBs	   express	   indeed	   high	   levels	   of	   pro-­‐apoptotic	   proteins	   including	  CD95/FAS,	  whereas	  they	  lack	  expression	  of	  most	  anti-­‐apoptotic	   factors	  (Klein	  et	  al.,	  2003a;	  Klein	  et	  al.,	  2003b).	  The	  high	  sensitivity	  of	  GC	  B	  cells	  to	  pro-­‐apoptotic	  stimuli	  allows	  the	  rapid	  elimination	  of	  GC	  B	  cells	  that	  fail	  to	  receive	  survival	  signals	  from	  the	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engagement	  of	   their	  BCR.	   Indeed,	   in	  the	   light	  zone,	   the	  persistence	  of	  centrocytes	   is	  strictly	   dependent	   on	   the	   ability	   of	   such	   cells	   to	   capture,	   through	   their	   BCRs,	   the	  antigen	   in	   the	   form	   of	   immune	   complex	   from	   FDC	   and	   to	   present	   it	   to	   a	   limiting	  number	  of	  TFH	  cells	  (Allen	  et	  al.,	  2007;	  Schwickert	  et	  al.,	  2007)	  (McHeyzer-­‐Williams	  et	  al.,	  2009;	  McHeyzer-­‐Williams	  and	  Nussenzweig,	  2009)	  	  
	  
Figure	  3:	  The	  germinal	  center	  reaction	  
During	  T-­‐cell	  dependent	  immune	  response,	  antigen-­‐specific	  B	  cells	  participate	  to	  the	  GC	  reaction.	  The	  GC	  reaction	  is	  characterized	  by	  an	  initial	  phase	  of	  clonal	  B-­‐cell	  expansion	  that	  is	  coupled	  to	  Ig	  SHM,	  followed	  by	  the	  selection	  of	  B	  cells	  for	  the	  ability	  to	  recognize	  cognate	  antigen	  with	  high	  affinity	  through	  their	  “mutated”	  BCRs.	  The	  selection	  process	   requires	   FDCs,	   presenting	   the	   antigen,	   and	   follicular	   T-­‐helper	   cells	   which	   provide	   the	   necessary	   co-­‐stimulatory	  signals	  to	  support	  further	  rounds	  of	  Ig	  SHM,	  selection	  and	  differentiation	  into	  memory	  B	  cells	  and	  ASC	  plasma	   cells.	   Only	   few	   high-­‐affinity	   B	   cells	   survive	   the	   GC	   reaction,	   with	   the	  majority	   instead	   dying	   in	   situ	   by	  apoptosis.	  GC	  B	  cells	  also	  replace	  the	  effector	  domain	  of	  their	  BCR	  through	  the	  process	  of	  Ig	  isotype	  switching	  (a	  process	  also	  known	  as	  Ig	  class	  switch	  recombination).	  	  The	  net	   result	   of	   a	  GC	   reaction	   is	   the	   generation	   of	   few	  highly	   selective	  memory	  B	  cells	  and	  PCs,	  expressing	  high	  affinity	  immunoglobulins.	  GC–derived	  PCs	  home	  to	  the	  BM	  where	  they	  provide	  a	   lifelong	  resource	  of	  high-­‐affinity	  antibodies.	   	  On	  the	  other	  hand,	  memory	  B	  cells	  represent	  a	  restricted	  pool	  of	  highly	  selected,	  antigen-­‐specific	  
	   21	  
long-­‐lived	   resting	   B	   cells	   ready	   to	   be	   recruited	   into	   secondary	   immune	   responses	  once	   the	   organisms	   enters	   again	   in	   contact	   with	   the	   same	   antigen.	   Reactivation	   of	  memory	  B	  cells	   leads	   to	  either	   terminal	  differentiation	   into	  PCs	  or	  recruitment	   into	  GCs,	  to	  generate	  B	  cells	  with	  a	  progressively	  higher	  affinity	  for	  the	  antigen.	  
5.1.2.5 Ig	  somatic	  hypermutation	  and	  class	  switch	  recombination	  Ig	   SHM	   and	   class	   switch	   recombination	   (CSR)	   represent	   somatic	   rearrangements	  occurring	   at	   Ig	   gene	   loci	   in	   antigen-­‐activated	   B	   cells	   (Figure	   4).	   In	   particular,	   SHM	  targets	  rearranged	  Ig	  variable	  region	  genes,	  while	  CSR	  promotes	  the	  replacement	  of	  the	  IgH	  Cµ	  constant	  region	  gene	  with	  that	  of	  another	  isotype	  (for	  example,	  γ,	  ε	  or	  α)	  During	   the	   process	   of	   SHM,	   single	   nucleotide	   substitutions	   (or	   deletions)	   are	  introduced	   within	   rearranged	   IgH	   and	   IgL	   V	   genes	   at	   high	   frequency	   (1	   mutation	  every	  103	  nucleotides/cell	  division)	  (Kocks	  and	  Rajewsky,	  1988;	  McKean	  et	  al.,	  1984),	  within	   a	   window	   of	   2Kb	   downstream	   of	   the	   V-­‐gene	   promoter	   (Neuberger	   et	   al.,	  1998).	  Analysis	  of	  the	  mutation	  pattern	  has	  revealed	  a	  preference	  of	  AID	  to	  target	  a	  WRCY	  consensus	  sequence	  (where	  W	  =	  A/T,	  R	  =	  A/G,	  and	  Y	  =	  C/T)	  (Petersen-­‐Mahrt	  et	   al.,	   2002;	   Pham	   et	   al.,	   2003).	   AID	   deaminates	   cytidine	   to	   uridine,	   generating	  therefore	  an	  U:G	  mismatch.	  Upon	  DNA	  replication,	  in	  the	  absence	  of	  mismatch	  repair,	  SHM	   causes	   thus	   C	   to	   T	   transitions.	   All	   other	   nucleotide	   substitutions	  within	   Ig	   V-­‐genes	   that	   result	   from	  AID	   action	   depend	   on	   the	   recognition/resolution	   of	   the	  U:G	  mismatch	  by	  either	  base	  excision	  repair	  (BER)	  or	  mismatch	  repair	  (MMR)	  pathways	  (Di	  Noia	  and	  Neuberger,	  2002;	  Di	  Noia	  and	  Neuberger,	  2007).	  CSR	  occurs	  during	  both	  T cell-­‐dependent	  and	  -­‐independent	  immune	  responses.	  It	  is	  an	  irreversible	  recombination	  event	  by	  which	  B	  cells	  replace	  the	  coding	  exons	  of	  Cµ	  and	   C∂	  with	   that	   of	   a	   distinct	   Ig	   isotype.	   The	   IgH	   chain	   constant	   region	   (CH)	   locus	  consists	  of	  an	  ordered	  set	  of	  CH	  exons	  (Cµ,	  Cδ,	  Cγ3,	  Cγ1,	  Cγ2b,	  Cγ2a,	  Cε	  and	  Cα	  in	  the	  mouse),	  each	  preceded	  by	  an	  upstream	  GC-­‐rich	  switch	  (S)	  sequence.	  CSR	  takes	  place	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between	   two	   S	   regions,	   resulting	   in	   the	   deletion	   of	   the	   intervening	   DNA	   segment	  (Iwasato	   et	   al.,	   1990;	   Matsuoka	   et	   al.,	   1990).	   Transcription	   through	   S	   regions	  generates	  long	  stretches	  of	  single-­‐stranded	  DNA,	  (Bottaro	  et	  al.,	  1994;	  Harriman	  et	  al.,	  1996;	   Jung	   et	   al.,	   1993;	   Zhang	   et	   al.,	   1993),	   and	   the	   formation	   of	   stable	   RNA-­‐DNA	  structures	  (termed	  R-­‐loops),	  that	  displace	  the	  non-­‐coding	  DNA	  strand	  (Reaban	  et	  al.,	  1994;	  Yu	  et	  al.,	  2003).	  The	  R-­‐loops	  are	  thought	  to	  assist	  in	  the	  targeting	  of	  AID.	  DNA	  double	   strand	   breaks	   that	   occur	   in	   the	   S	   regions	   are	   joined	   by	   the	   NHEJ	   pathway	  (Manis	  et	  al.,	  1998).	  As	  a	  result	  of	  CSR,	  the	  intervening	  DNA	  fragment	  is	  excised	  as	  a	  circle	  and	  the	  3’	  and	  5’	  ends	  of	  the	  IgH	  locus	  are	  finally	  juxtaposed	  (Figure	  4b).	  	  
	  
Figure	  4:	  Ig	  somatic	  hypermutation	  and	  class	  switch	  recombination	  
Schematic	  view	  of	   the	   IgH	   locus	  before	   (a)	  and	  after	   (b)	  onset	  of	   Ig	  SHM	  and	  CSR.	  SHM	  (1)	   targets	   the	  variable	  region	  gene	  leading	  to	  the	  single-­‐nucleotide	  substitutions	  or	  deletions	  (represented	  as	  x).	  (2)	  CSR	  acts	  on	  the	  IgH	  constant	   (CH)	   region	   gene,	   promoting	   the	   replacement	   of	   Cµ	   with	   that	   of	   another	   isotype	   (Cγ3,	   Cγ1	   etc).
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5.2 The	  B	  cell	  antigen	  receptor	  The	   B-­‐cell	   antigen	   receptor	   (BCR)	   provides	   B	   lymphocytes	   with	   the	   capacity	   to	  recognize	   foreign	   antigens,	   thereby	   allowing	   B	   cells	   to	   neutralize	   potentially	   lethal	  pathogens.	  	  
5.2.1 The	  BCR:	  from	  structure	  to	  function	  The	  BCR	  is	  a	  transmembrane	  protein	  complex	  comprised	  of	  two	  IgH	  chains	  covalently	  linked	  by	  disulfide	  bonds	  to	  two	  IgL	  chains	  of	  the	  kappa	  (κ)	  or	  lambda	  (λ)	  type.	  The	  amino-­‐terminus	   of	   both	   IgH	   and	   IgL	   chains	   consists	   of	   the	   variable	   (V)	   region,	  featuring	   extensive	   sequence	   variability,	   as	   a	   result	   of	   VDJ	   recombination,	   N-­‐nucleotide	  addition	  and	  SHM.	  The	  hypervariable	  regions	  within	  VH	  and	  VL	  regions	  are	  termed	   complementarity-­‐determining	   regions	   (CDRs).	   They	   represent	   the	   antigen-­‐binding	   site	   of	   the	   BCR	   and	   define	   its	   specificity	   and	   ligand	   binding	   affinity.	   The	  carboxy-­‐terminus	   invariable	   portion	   of	   the	   IgH	   chain,	   termed	   constant	   (C)	   region,	  confers	  the	  effector	  functions	  to	  the	  BCR.	  	  There	  exist	  five	  different	  immunoglobulin	  isotypes	   (IgM,	   IgD,	   IgG,	   IgA	   and	   IgE).	   IgM	   and	   IgD	   are	   expressed	   by	   naive	   B-­‐cells,	  whereas	  the	  other	  isotypes	  are	  typically	  expressed	  upon	  B-­‐cell	  activation	  in	  response	  to	  antigen	  recognition	  (Brezski	  and	  Monroe,	  2008).	  Each	  BCR	  complex	  consists	  of	  a	  single	   Igα/Igβ	   heterodimer	   (also	   called	   CD79a	   and	   CD79b,	   respectively)	   that	  represents	  the	  signal	  transduction	  component	  of	  the	  Ig	  receptor.	  The	  BCR	  complex	  is	  assembled	   within	   the	   endoplasmic	   reticulum	   (ER)	   and	   is	   transported	   through	   the	  Golgi	   to	   the	  plasma	  membrane.	  A	   schematic	   representation	  of	   the	  BCR	   is	   shown	   in	  Figure	  5.	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Figure	  5:	  Structure	  of	  the	  BCR	  signalling	  complex.	  
Pairs	  of	  Ig	  heavy	  (H,	  pink)	  and	  light	  (L,	  grey)	  chains	  are	  kept	  together	  by	  disulfide	  bonds	  (thin	  lines	  joining	  the	  two	  types	  of	   Ig	   chains).	   CH:	   Ig	  heavy	   chain	   constant	   region;	  CL:	   Ig	   light	   chain	   constant	   region;	   Fab:	   antigen-­‐binding	  fragment;	  Fc:	   fragment	   to	   crystallize;	  VH:	   Ig	  heavy	  chain	  variable	   region;	  VL:	   Ig	   light	   chain	  variable	   region.	  The	  BCR	  complex	  is	  completed	  by	  a	  single	  Igα/Igβ	  heterodimer.	  
5.2.2 The	  BCR	  signalling	  pathway	  Antigen-­‐specific	  B	  cell	  responses	  depend	  on	  the	  engagement	  of	  the	  BCR	  that	  leads	  to	  the	   activation	   of	   several	   downstream	   signalling	   cascades	   (Rajewsky,	   1996).	   Upon	  antigen	  binding,	  the	  BCR	  complex,	  through	  its	  signalling	  subunits	  Igα	  and	  Igβ	  (Brezski	  and	   Monroe,	   2008),	   triggers	   B	   cell	   effector	   functions	   that	   include	   cell-­‐cycle	  progression,	  antigen	  presentation	  and	  up-­‐regulation	  of	  co-­‐stimulatory	  molecules	  and	  homing	   receptors.	   The	   initiation	   of	   signalling	   pathways	   downstream	   of	   the	   BCR	  depends	  on	  immunoreceptor	  tyrosine-­‐based	  activation	  motifs	  (ITAMs)	  present	  in	  the	  cytoplasmic	   portion	   of	   Igα	   and	   Igβ	   (Reth	   et	   al.,	   1991).	   Receptor	   engagement	  promotes	   ITAM	  phosphorylation	  mediated	   by	   Lyn,	   a	  member	   of	   Src-­‐family	   protein	  tyrosine	   kinases	   (PTKs).	   Phosphorylation	   of	   ITAM-­‐associated	   tyrosine	   residues	  creates	   docking	   sites	   and	   recruits	   Src-­‐homology-­‐domain	   (SH2)	   containing	   proteins,	  such	   as	   the	   Spleen	   tyrosine	   kinase	   (SYK).	   The	   role	   of	   SYK	   in	   promoting	   B‑cell	  proliferation	   is	   confirmed	   by	   the	   failure	   of	   SYK-­‐deficient	   pre‑B‑cells	   to	   undergo	  clonal	  expansion	  (Turner	  et	  al.,	  1995).	  SYK	  activation	  results	  in	  the	  phosphorylation	  of	  downstream	  targets	  and	  in	  the	  initiation	  of	  several	  signalling	  cascades.	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5.2.2.1 PLCγ2	  regulates	  Ca2+	  flux	  and	  ERK	  activation	  A	  crucial	  SYK	  target	   is	  SLP65/BLNK,	  a	  B	  cell	  adaptor	  that	   fine-­‐tunes	  BCR	  signals	  by	  connecting	   kinases	   to	   downstream	   BCR	   signalling	   effectors.	   Upon	   SYK-­‐mediated	  phosphorylation,	  SLP65	  recruits	  the	  Bruton	  tyrosine	  kinase	  (Btk)	  and	  phospholipase	  C-­‐γ2	   (PLCγ2).	   The	   latter	   becomes	   phosphorylated	   by	   SYK	   and	   BTK,	   and	   thereby	   is	  activated	  to	  catalyse	  the	  second	  messengers	  diacylglycerol	  (DAG)	  and	  inositol-­‐1,4,5-­‐trisphosphate	   (IP3)	   from	   phosphatidylinositol-­‐4,5-­‐bisphosphate	   (PIP2)	   (Kurosaki,	  2011).	  IP3	  binds	  to	  IP3-­‐gated	  intracellular	  Ca2+	  channels	  present	  on	  the	  ER	  membrane,	  thereby	  leading	  to	  the	  release	  of	  Ca2+	  from	  the	  ER	  storage.	  Signalling	  mediated	  by	  Ca2+	  fluxes	  activates	  transcriptional	  pathways	  (such	  as	  those	  centred	  on	  NFAT	  and	  NFκB)	  involved	  in	  proliferation	  and	  immune	  effector	  functions	  (Jun	  and	  Goodnow,	  2003).	  In	  addition,	   DAG	   facilitates	   the	   recruitment	   of	   both	   PKC?	   and	   nucleotide	   exchange	  factors	   (GRP3	   or	   Sos)	   to	   the	   plasma	   membrane,	   leading	   to	   Ras	   activation	   and	   its	  binding	   to	   Raf1.	   The	   latter,	   in	   turn,	   phosphorylates	   and	   activates	   ERK1/ERK2	  (Kurosaki	  et	  al.,	  2010).	  Phosphorylation	  of	  ERKs	  leads	  to	  their	  dimerization,	  followed	  by	  nuclear	   translocation	  and	  subsequent	  phosphorylation	  of	   transcriptional	   factors,	  including	  Fos,	  Jun,	  and	  Ets	  family	  members	  (Dong	  et	  al.,	  2002).	  	  
5.2.2.2 The	  NF-­‐κB	  pathway	  is	  central	  to	  BCR	  function	  The	  NF-­‐κB	   family	   comprises	   the	  DNA	  binding	  members	  NF-­‐κB1	   (p50)	  and	  NF-­‐κB2	  (p52)	   that	   are	   generated	   by	   proteolysis	   of	   larger	   precursors.	   NF-­‐κB1	   and	   NF-­‐κB2	  induce	   gene	   transcription	   via	   hetero	   dimerization	   with	   the	   other	   NF-­‐κB-­‐family	  members,	   RelA	   (p65),	   RelB	   and	   c-­‐Rel	   that	   have	   transactivation	   functions	   (Li	   and	  Verma,	   2002).	   In	   steady	   state	   conditions,	   NF-­‐κB	   proteins	   are	   sequestered	   in	   the	  cytoplasm	  in	  an	  inactive	  state,	  bound	  to	  Inhibitory	  κB	  (IκB)	  proteins	  (Thome,	  2004).	  The	  canonical	  pathway,	  which	  leads	  to	  the	  activation	  of	  NF-­‐κB1,	  is	  tightly	  controlled	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by	  the	  IκB	  kinase	  (IKK)	  complex,	  composed	  of	  two	  catalytically	  active	  kinases	  (IKK-­‐α	  and	  IKK-­‐β)	  and	  the	  regulatory	  subunit,	  IKK-­‐γ	   (also	  known	  as	  NEMO)	  (Li	  and	  Verma,	  2002).	   Activation	   of	   the	   IKK	   complex	   leads	   to	   phosphorylation	   and	   hence	  ubiquitylation	  and	  proteolytic	  degradation	  of	  IκBα,	  and	  allows	  NF-­‐κB	  to	  translocate	  to	  the	  nucleus	  to	  activate	  gene	  transcription	  (Li	  and	  Verma,	  2002).	  A	  second,	  so-­‐called	  alternative	  pathway	  of	  NF-­‐κB	  activation	  is	  induced	  by	  Tumor	  Necrosis	  Factor	  (TNF)	  receptor	   superfamily,	   including	   the	   receptor	   for	   lymphotoxin-­‐β,	   B-­‐cell-­‐activating	  factor	  receptor	  (BAFFR),	  and	  CD40	  (Pomerantz	  and	  Baltimore,	  2002).	  In	  contrast	  to	  the	  classical	  pathway,	  triggering	  of	  TNF	  receptors	  activates	  IKK-­‐α 	  that	  promotes	  the	  phosphorylation	  and	  subsequent	  proteolytic	  processing	  of	  NF-­‐κB2/p100	  to	  p52,	  and	  the	  formation	  of	  transcriptionally	  active	  NF-­‐κB	  dimers,	  composed	  of	  p52	  and	  RelB.	  	  BCR-­‐induced	   NF-­‐κB	   activation	   proceeds	   through	   the	   classical	   NF-­‐κB	   pathway	  (Ruland	   and	   Mak,	   2003).	   A	   recent	   breakthrough	   in	   our	   understanding	   of	   this	  signalling	   pathway	   has	   been	   the	   identification	   of	   three	   physically	   and	   functionally	  interacting	   proteins	   known	   as	   CARD11	   (caspase	   recruitment	   domain	   11),	   BCL-­‐10	  (adaptor	   protein	   B-­‐cell	   lymphoma	   10)	   and	   MALT1	   (mucosal-­‐associated	   lymphoid	  tissue	  1)	  that	  act	  as	  crucial	  signaling	  components	  connecting	  the	  antigen	  receptor	  to	  the	   IKK	   complex	   (Jun	   and	  Goodnow,	   2003)	   (Thome	   and	  Tschopp,	   2003).	   PKCβ	   has	  been	   found	   to	   be	   important	   for	   the	   activation	   of	   the	   canonical	   NF-­‐κB	   pathway	  (Shinohara	   et	   al.,	   2005).	   Phosphorylation	   of	   CARD11	   by	   PKCβ	   promotes	   the	  generation	   of	   the	   CARD11-­‐Bcl10-­‐MALT1	   ternary	   complex.	   Acting	   as	   a	   molecular	  scaffold,	  CARD11	  brings	  the	  TGFβ-­‐activated	  kinase	  1	  (TAK1)	  in	  close	  proximity	  with	  the	  IKK	  complex,	  thus	  allowing	  its	  activation	  (Figure	  6,	  from	  Thome,	  2004).	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Figure	  6:	  BCR	  signalling	  triggers	  NF-­‐κB	  activation	  
The	   activation	   of	   NF-­‐κB	   by	   the	   BCR	   depends	   on	   SYK-­‐mediated	   PKC-­‐β	   activation	   and	   association	   of	   a	   tri-­‐molecular	  complex	  consisting	  of	  CARMA1/CARD11,	  BCL-­‐10	  and	  MALT1.	  These	  proteins	  have	  a	  crucial	  role	   in	   the	  subsequent	   activation	   of	   the	   IKK	   complex	   (IKK),	   which	  regulates	   the	   activation	   of	   NF-­‐κB1	   (p50)–RelA/p65	  heterodimers	   through	   the	   phosphorylation	   of	   IκBα .	  Phosphorylated	  IκBα 	  is	  ubiquitylated	  (Ub)	  and	  degraded	  by	   the	   proteasome	   machinery,	   allowing	   NF-­‐κB	   to	  translocate	   to	   the	   nucleus	   and	   activate	   target	   gene	  expression.	  	  	  	  	  
5.2.3 BCR	  controls	  the	  Phosphoinosititide	  3-­‐kinase/FOXO	  pathway	  The	  Phosphoinosititide	  3-­‐kinase	  (PI3K)	  represents	  a	  crucial	  effector	  of	  BCR	  signaling.	  It	   has	   been	   shown	   that	   SYK	   induces	  phosphorylation	   and	  hence	   activation	  of	   PI3K,	  which	   regulates	   diverse	   biological	   processes,	   including	   cell	   growth,	   survival,	  proliferation,	   migration	   and	   metabolism	   (Deane	   and	   Fruman,	   2004).	   Activation	   of	  SYK	  and	  SRC	   family	  PTKs	   in	   response	   to	  BCR	   signalling,	   induce	  phosphorylation	  of	  the	  BCR	  co‑receptor	  CD19	  and	  the	  adaptor	  protein	  BCAP	  (also	  known	  as	  PIK3AP1),	  leading	  to	  the	  local	  recruitment	  and	  activation	  of	  PI3K	  (Aiba	  et	  al.,	  2008;	  Deane	  and	  Fruman,	   2004).	   Subsequently,	   PI3K	   phosphorylates	   its	   substrate	   PIP2,	   thereby	  generating	   the	   second	   messenger	   phosphatidylinositol‑3,4,5‑trisphosphate	   (PIP3)	  (Okkenhaug	   and	   Vanhaesebroeck,	   2003).	   Several	   signalling	   proteins,	   including	   the	  serine/threonine	   kinase	   protein	   kinase	   B	   (PKB;	   also	   known	   as	   AKT)	   and	  
	   28	  
3‑phosphoinositide‑dependent	   protein	   kinase	   1	   (PDK1),	   contain	   a	  pleckstrin‑homology	  (PH)	  domain	  that	  binds	  PIP3,	  which	  allows	  their	  recruitment	  to	  the	   plasma	   membrane.	   AKT,	   which	   becomes	   activated	   by	   PDK1‑mediated	  phosphorylation,	   is	   thought	   to	  be	   the	  main	  mediator	  of	   the	  PI3K	  signaling	  pathway	  and	  induces	  cell	  proliferation	  through	  the	  inhibition	  of	  multiple	  downstream	  targets	  that	  are	  involved	  in	  the	  control	  of	  the	  cell	  cycle	  (Manning	  and	  Cantley,	  2007).	  AKT	  kinase	  regulates	  a	  variety	  of	  proteins	   involved	   in	  metabolism	  (such	  as	  GSK3β),	  proliferation	   and	   survival	   (Manning	   and	   Cantley,	   2007).	   Among	   the	   targets	   of	   Akt	  there	   is	   the	   family	  of	  FOXO	   transcription	   factors.	  FOXO	  proteins	  are	   transcriptional	  regulators	   promoting	   cell	   death	   and	   inhibition	   of	   cell-­‐cycle	   progression.	   FOXO	  proteins	   are	   tightly	   regulated	   through	   post-­‐translational	  modifications	   (Vogt	   et	   al.,	  2005).	  Most	   importantly,	  AKT‑mediated	  phosphorylation	  of	  FOXO	  proteins	   inhibits	  their	  transcriptional	  activity	  by	  promoting	  their	  translocation	  from	  the	  nucleus	  to	  the	  cytoplasm,	  where	  these	  molecules	  are	  rapidly	  degraded	  (Coffer	  and	  Burgering,	  2004).	  Among	  FOXO	   family	  members,	   FOXO1	  has	  been	   identified	   as	   a	   crucial	   factor	   in	   the	  regulation	  of	  B	   cell	   development.	   Conditional	   FOXO1	   inactivation	  at	   the	  pro‑B‑cell	  stage	  results	  in	  a	  complete	  block	  in	  B‑cell	  development	  (Coffer	  and	  Burgering,	  2004;	  Dengler	   et	   al.,	   2008).	   In	   the	   absence	   of	   BCR-­‐dependent	   PI3K/AKT	   signaling,	   FOXO	  proteins	  promote	  transcriptional	  activation	  of	  genes	  inducing	  cell-­‐cycle	  arrest	  	  (RBL2,	  or	  p27)	  and	  apoptosis	  (BIM,	  BCL6	  or	  TRAIL).	  Thus,	  the	  PI3K/AKT	  module	  is	  a	  crucial	  node	   in	  BCR	   signaling	   as	   it	   supports	  B-­‐cell	   survival	   through	   the	   inhibition	  of	  FOXO	  activity	   (Coffer	   and	   Burgering,	   2004;	   Srinivasan	   et	   al.,	   2009).	   A	   schematic	  representation	  of	  PI3K	  signaling	  downstream	  of	  BCR	  is	  shown	  in	  Figure	  7.	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Figure	  7:	  PI3K	  activation	  in	  response	  to	  BCR	  signalling	  
Schematic representation of PI3K-mediated regulation of FOXO transcription factors in B cells. Activation of 
PI3K/AKT prevents nuclear localization of FOXO proteins.  Nuclear FOXO1 regulates the expression of genes 
involved in apoptosis (FASL, BIM, and TRAIL) and cell cycle progression (RBL2, CCNG1, p27 or CCND3). 	  
5.2.3.1 The	  BCR	  “tonic”	  signal	  	  While	   signal	   transduction	   through	   the	   BCR	   is	   generally	   thought	   to	   be	   initiated	   by	  antigen-­‐induced	   crosslinking,	   the	  BCR	   signals	   also	   in	   a	   ligand-­‐independent	  manner.	  Ligand-­‐independent	   signalling	   through	   the	   BCR	   (also	   called	   tonic	   signal)	   has	   an	  important	   role	   in	   directing	   appropriate	   fate	   decisions	   during	   B	   cell	   development	  (Brezski	  and	  Monroe,	  2008)	  and	  to	  sustain	  the	  survival	  of	  mature	  B	  cells	  (Lam	  et	  al.,	  1997).	   The	   existence	   of	   a	   tonic	   BCR	   signal	   was	   shown	   through	   elegant	   genetic	  experiments	  performed	   in	  mice	  by	   the	  Rajewsky	   group.	   Conditional	   deletion	  of	   the	  BCR	  in	  mature	  B	  cells	  led	  to	  a	  severe	  interference	  with	  B	  cell	  survival,	  thus	  suggesting	  the	  requirement	   for	  a	  constant	  BCR	  signaling	  to	  support	  mature	  B	  cell	  maintenance	  (Lam	  et	  al.,	  1997).	  This	  study	  was	  followed	  by	  the	  demonstration	  that	  BCR	  signalling	  competence	   is	  crucial	   to	  support	  the	  survival	  of	  resting	  mature	  B	  cells	  (Kraus	  et	  al.,	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2004).	  Indeed,	  conditional	  deletion	  of	  the	  BCR	  signalling	  component	  Igα	  in	  mature	  B	  cells	   resulted	   in	  a	   severe	   loss	   in	  peripheral	  B	  cell	  numbers.	  Additional	   studies	  have	  since	  then	  confirmed	  the	  existence	  of	  a	  low-­‐strength/tonic	  signal	  emanating	  from	  the	  BCR	  in	  the	  absence	  of	  cognate	  antigen	  recognition	  (Bannish	  et	  al.,	  2001;	  Grande	  et	  al.,	  2007).	  A	  first	  elucidation	  of	  the	  biochemical	  basis	  of	  the	  tonic	  BCR	  signal	  came	  again	  from	   the	  Rajewsky	   lab.	  Using	   conditional	   gene	   targeting,	   it	  was	   demonstrated	   that,	  against	   all	   expectations,	   the	   NF-­‐κB	   signaling	   cascade	   was	   not	   responsible	   for	  transmitting	  the	  tonic	  BCR	  signal.	  Instead,	  signalling	  through	  the	  PI3K/AKT	  pathway	  was	  shown	  to	  be	  essential	  to	  sustain	  survival	  of	  resting	  mature	  B	  cells	  (Srinivasan	  et	  al.,	   2009).	   	   Moreover,	   in	   the	   same	   study	   it	   was	   shown	   that	   specific	   inactivation	   of	  FOXO1	  was	  sufficient	  to	  rescue	  BCR-­‐deficient	  resting	  B	  cells	  from	  death,	  highlighting	  the	   importance	   of	   the	   PI3K/AKT	   signaling	   pathway	   to	   inhibit	   FOXO1	   to	   promote	  mature	  B-­‐cell	  survival.	  Thus,	  activation	  of	  the	  PI3K	  pathway	  downstream	  of	  the	  BCR	  is	   critical	   both	   during	   B	   cell	   development	   (Aiba	   et	   al.,	   2008;	   Herzog	   et	   al.,	   2008;	  Verkoczy	  et	  al.,	  2007)	  and	   in	   resting	  mature	  B	  cells,	  where	   it	   is	  essential	   to	   sustain	  their	  survival	  (Srinivasan	  et	  al.,	  2009).	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5.3 Non-­‐Hodgkin	  lymphoma:	  the	  dark	  side	  of	  B-­‐cell	  activation	  The	   immune	  system	  preserves	  our	  body	  on	  a	  daily	  basis	   from	   infections	   caused	  by	  harmful	  pathogens.	  Nevertheless,	  this	  protective	  role	  has	  a	  price.	  B	  cell	  differentiation	  can	  indeed	  be	  compared	  to	  a	  clocking	  bomb,	  waiting	  to	  explode.	  Every	  day,	  millions	  of	  B	   lymphocytes	   put	   their	   genomic	   integrity	   in	   danger	   as	   a	   result	   of	   the	   genetic	  rearrangements	  occurring	  during	  the	  processes	  of	  primary	  (VDJ	  recombination)	  and	  secondary	  	  (Ig	  SHM	  and	  CSR)	  antibody	  diversification.	  	  
5.3.1 The	  germinal	  center	  reaction:	  a	  lymphoma	  prone	  environment	  Ig	  CSR	  is	  a	  processes	  characterized	  by	  the	  generation	  of	  double	  stranded	  DNA	  breaks	  occurring	   at	   IgH	   chain	   constant	   region	   loci	   (Honjo	   et	   al.,	   2002;	   Papavasiliou	   and	  Schatz,	   2002).	   Occasionally,	   such	   breaks	   are	   aberrantly	   resolved	   and	   promote	   the	  occurrence	   of	   chromosomal	   translocations.	   These	   genetic	   alterations	   are	   more	  frequently	   observed	   in	   B	   cells	   recruited	   into	   the	   GC	   reaction	   during	   a	   T-­‐cell	  dependent	   immune	  response,	  due	  to	  the	  extremely	  high	  frequency	  of	  double	  strand	  breaks	   occurring	   at	   Ig	   loci	   in	   these	   cells	   as	   a	   result	   of	   AID	   activity.	   Chromosomal	  translocations	   resulting	   from	   aberrant	   CSR	   can	   lead	   to	   the	   juxtaposition	   of	   IgH	   cis	  regulatory	   regions	   to	   proto-­‐oncogenes,	   leading	   ultimately	   to	   their	   deregulated	  expression.	   Indeed,	   recurrent	   chromosomal	   translocations	   found	   in	   B-­‐cell	  lymphomas	   are	   commonly	   associated	   to	   aberrant	   expression	   of	   proto-­‐oncogenes	  including	  c-­‐MYC	  (Burkitt	  lymphoma),	  BCL2	  (Follicular	  Lymphoma)	  and	  BCL6	  (Diffuse	  Large	  B	  cell	  Lymphoma).	  Another	   mechanism	   through	   which	   AID	   contributes	   to	   lymphomagenesis	   is	  represented	  by	  aberrant	  SHM.	  Despite	  a	  high	  preference	  for	  Ig	  V-­‐genes,	  recent	  work	  has	   shown	   a	   striking	   promiscuity	   in	   AID	   binding	   to	   the	   genome.	   Several	   high	  throughput	   data	   have	   recently	   confirmed	   initial	   observations	   by	   the	   Dalla	   Favera	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group	   showing	   the	   accumulation	   of	   somatic	  mutations	   affecting	   a	   variety	   of	   non-­‐Ig	  genes	  in	  GC	  B	  cells.	  Importantly,	  these	  genes	  are	  often	  found	  mutated	  in	  GC-­‐derived	  B	  cell	  malignancies,	  and	  possibly	  contribute	   to	   the	   transformation	  process	   (Richter	  et	  al.,	  2012;	  Schmitz	  et	  al.,	  2012).	  	  From	  these	  considerations,	  it	  emerges	  that	  the	  GC	  reaction	  represents	  a	  tumorigenic	  environment,	   where	   the	   attempt	   to	   generate	   protective,	   high	   affinity	   neutralizing	  antibodies	  by	  mean	  of	  SHM	  and	  CSR	  is	  counterbalanced	  by	  the	  frequent	  occurrence	  of	  gross	  genetic	  aberrations	  or	  point	  mutations.	  The	  accumulation	  of	  the	  latter	  lesions	  in	  a	   highly	   proliferative	   compartment	   is	   expected	   to	   facilitate	   the	   selection	   of	   rare	  mutants,	  which	  ultimately	  will	  overcome	  tumor	  suppressor	  mechanisms	  to	  give	  rise	  to	  clonal	  B-­‐cell	  malignancies	  (Kuppers	  et	  al.,	  1999;	  Stevenson	  et	  al.,	  1998;	  Klein	  and	  Dalla-­‐Favera,	  2008).	  
5.3.2 Most	  lymphomas	  derive	  from	  B	  cells	  transiting	  through	  the	  germinal	  center	  Depending	   on	   histological	   appearance,	   B	   cell	   lymphomas	   are	   classified	   as	   Hodgkin	  and	  Non-­‐Hodgkin	   (NH)	   lymphomas.	  NH	   lymphomas	   include	   the	  most	   common	   and	  aggressive	   forms	  of	  B-­‐cell	   lymphomas.	   	  According	  to	  the	  World	  Health	  Organization	  (WHO),	   more	   than	   80	   percent	   of	   B	   cell	   malignancies	   (including	   both	   Hodgkin	   and	  most	  NH	  lymphoma	  subtypes)	  derive	  from	  B	  cells	  that	  have	  transited	  through	  the	  GC	  reaction.	   	   This	   is	   witnessed	   by	   the	   finding	   that	   clonal	   malignant	   B	   cells	   have	  undergone	  Ig	  SHM	  and/or	  CSR	  and	  display	  a	  gene	  expression	  profile	  closely	  related	  to	  that	  of	  activated	  mature	  B	  cells,	  or	  more	  specifically	  GC	  B	  cells	  (Alizadeh	  et	  al.,	  2000;	  Kuppers,	  2005).	  The	   most	   common	   forms	   of	   GC-­‐derived	   NHL	   feature	   reciprocal	   chromosomal	  translocations	  that	  juxtapose	  proto-­‐oncogenes	  to	  one	  of	  the	  Ig	  loci,	  resulting	  in	  their	  de-­‐regulated	   expression	   (Kuppers	   and	   Dalla-­‐Favera,	   2001;	  Willis	   and	   Dyer,	   2000).	  Classic	  examples	  include	  the	  t(14;18)	  BCL2/IgH	  translocation	  in	  follicular	  lymphoma	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(Jager	   et	   al.,	   2000;	   Tsujimoto	   et	   al.,	   1985),	   the	   t(3;14)	   BCL6/IgH	   translocation	   in	  diffuse	   large	   B	   cell	   lymphoma	   (Baron	   et	   al.,	   1993;	   Ye	   et	   al.,	   1993),	   the	   t(11;14)	  CCND1/IgH	  translocation	   in	  multiple	  myeloma	  (Avet-­‐Loiseau	  et	  al.,	  1998;	  Gabrea	  et	  al.,	   1999)	   and	   the	   t(8;14)	   c-­‐MYC/IgH	   translocation	   in	   Burkitt	   lymphoma	   (Dalla-­‐Favera	  et	  al.,	  1982;	  Taub	  et	  al.,	  1982).	  	  The	   genes	   target	   of	   recurrent	   chromosomal	   translocations	   and	   point	   mutations	   in	  NHL	  affect	   in	  most	  cases	  the	  survival,	  proliferation	  and	  differentiation	  of	  GC	  B	  cells.	  As	   a	   result	   of	   the	   interference	  with	   the	   physiology	   of	   the	  GC	   reaction,	  malignant	   B	  cells	  are	   	   “frozen”	   in	  a	  stage	   that	   favours	   the	  acquisition	  of	  additional	  mutations	  by	  AID,	   possibly	   contributing	   to	   tumor	   progression	   and	   ultimately	   to	   render	   these	  cancers	  often	  incurable.	  	  	  	  
	  
Figure	  8:	  Most	  Non-­‐Hodgkin	  B-­‐cell	  lymphomas	  derive	  from	  GC	  B	  cells	  
Schematic	  representation	  of	  the	  main	  types	  of	  NHL,	  highlighting	  the	  molecular	  hallmark	  and	  derivation	  from	  B	  cells	  at	  defined	  stages	  of	  their	  transit	  though	  the	  GC	  reaction.	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5.3.3 Burkitt	  Lymphoma	  Burkitt	   lymphoma	  (BL)	  was	   first	  described	   in	  Uganda	   in	  1958,	  when	  it	  was	   initially	  diagnosed	  as	  a	  sarcoma	  of	  the	  jaw	  (Burkitt,	  1958).	  	  Shortly	  after,	  it	  was	  recognized	  as	  a	   distinct	   form	   of	   NHL	   (Burkitt,	   1962).	   With	   a	   worldwide	   dissemination,	   BL	   is	   a	  hematopoietic	   tumor,	  affecting	   in	  particular	   the	   lymphoid	  system.	  There	  exist	   three	  forms	  of	  BL:	  (1)	  the	  endemic	  form,	  mainly	  distributed	  in	  subequatorial	  Africa,	  (2)	  the	  sporadic	   form,	   mainly	   occurring	   in	   the	   Western	   world	   and	   (3)	   a	   form	   affecting	  immuno-­‐compromised	  patients	  (Blum	  et	  al.,	  2004).	  	  The	   endemic	   form	   of	   BL	   is	   clinically	   characterized	   by	   jaw	   or	   kidneys	   involvement,	  whereas	   abdomen	   localizations	   are	   typical	   of	   the	   sporadic	   and	   immunodeficiency-­‐associated	   forms.	   Symptoms	   include	   abdominal	   pain,	   nausea,	   vomiting,	   bowel	  obstruction	  and	  gastrointestinal	  bleeding.	  Over	  95	  percent	  of	  endemic	  BL	  cases	  are	  associated	  with	  Epstein-­‐Barr	   virus	   (EBV)	   infection.	   In	   contrast,	   between	  15	   and	  70	  percent	  of	  sporadic	  BL	  cases	  display	  the	  presence	  of	  EBV	  in	  the	  tumor	  cells,	  with	  an	  incidence	  influenced	  by	  the	  socio-­‐economic	  status	  and	  the	  age	  at	  which	  patients	  get	  infected	   with	   the	   virus	   (Jaffe	   and	   Pittaluga,	   2011).	   Despite	   several	   studies	   have	  proposed	  an	  active	   role	  of	  EBV	   in	  BL	  pathogenesis,	   it	   remains	  still	  unclear	  how	  the	  virus	   contributes	   to	   the	   onset	   of	   this	   malignancy	   (Casola	   et	   al.,	   2004;	   Kelly	   et	   al.,	  2009;	  Rowe	  et	  al.,	  2009;	  Vereide	  and	  Sugden,	  2011).	  	  The	  genetic	  hallmark	  shared	  by	  all	  forms	  of	  BL	  is	  represented	  by	  the	  occurrence	  of	  a	  reciprocal	   chromosomal	   translocation	   that	   juxtaposes	   the	   c-­‐MYC	   oncogene	   on	  chromosome	  8,	  to	  the	  IgH	  locus	  on	  chromosome	  14	  (most	  cases),	  or,	  in	  20	  percent	  of	  the	  cases,	  to	  the	  Igκ or	  Igλ	   loci	  on	  chromosome	  2	  and	  22,	  respectively	  (Dalla-­‐Favera	  et	  al.,	  1982;	  Hecht	  and	  Aster,	  2000b;	  Taub	  et	  al.,	  1982).	  Interestingly,	  the	  analysis	  of	  chromosomal	  breakpoints	  observed	   in	  endemic	  and	  sporadic	  BL	  cases	   revealed	   the	  involvement	  of	  either	  the	  IgH	  JH	  region	  or	  the	  IgH	  switch	  region.	  These	  data	  point	  to	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alternative	  mechanisms	  responsible	  for	  the	  occurrence	  of	  double	  strand	  breaks	  at	  Ig	  loci,	  including	  SHM	  and	  CSR,	  that	  are	  responsible	  for	  the	  t(8;14)	  translocation	  (Hecht	  and	  Aster,	  2000a;	  Pelicci	  et	  al.,	  1986).	  At	   the	   histological	   level,	   BL	   appears	   as	   a	   tumor	   composed	   of	   largely	   uniform	   cells	  with	  minimal	   cytological	   variation.	   The	   cells	   are	   of	   medium/large	   size	   with	   round	  nuclei,	   moderately	   clumped	   chromatin,	   and	  multiple	   (2-­‐5)	   basophilic	   nucleoli.	   The	  cytoplasm	  is	  deeply	  basophilic.	  BL	  cells	  contain	  cytoplasmic	  lipid	  vacuoles,	  which	  are	  probably	  a	  manifestation	  of	   the	  high	  rate	  of	  proliferation	  (as	  shown	  by	  positivity	  to	  the	   Ki67	   proliferation	   marker)	   and	   of	   spontaneous	   cell	   death.	   A	   “starry	   sky”	  appearance	  is	  a	  typical	  feature	  of	  BL	  and	  reflects	  the	  numerous	  benign	  macrophages	  that	  have	   infiltrated	   the	   tumor	   to	  engulfe	  apoptotic	   tumor	  cells	   (Jaffe	  and	  Pittaluga,	  2011).	  BL	  tumor	  cells	  display	  a	  mature	  B-­‐cell	  immunophenotype,	  expressing	  surface	  IgM,	  CD10,	  CD20,	  CD22	  as	  well	  as	  CD43	  in	  nearly	  all	  cases	  (Jaffe	  and	  Pittaluga,	  2011).	  The	  absence	  of	  BCL-­‐2	  expression	  is	  helpful	  in	  ruling	  out	  “double-­‐hit”	  lymphomas	  with	  dual	  translocations	  affecting	  MYC	  and	  BCL2	  (Blum	  et	  al.,	  2004).	  Importantly,	  BL	  cells	  carry	   somatically	   mutated	   Ig	   genes,	   frequently	   associated	   to	   intra-­‐clonal	  heterogeneity,	  pointing	  to	  a	  germinal	  center	  origin	  and	  to	  ongoing	  AID	  activity	  in	  the	  tumor	  cells	  (Chapman	  et	  al.,	  1996;	  Klein	  et	  al.,	  1995).	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  Histological	   appearance	   of	   human	   BL.	   	   Hematoxylin-­‐eosin	   staining	   was	   performed	   on	   a	   lymph	   node	   section.	  Diffusely	   infiltrated	   lymphoid	   cells	   with	   small	   round	   nuclei	   and	   distinct	   nucleoli	   are	   visible.	   Numerous	   benign	  macrophages	   containing	   ingested	   apoptotic	   tumor	   cells	   generate	   the	   typical	   “starry	   sky”	   pattern.	   Insets:	  immunohistochemical	   analysis	   for	   the	   indicated	   markers	   in	   BL	   cells.	   Translocation	   involving	   c-­‐MYC	   and	  immunoglobulin	  heavy	  chain	  genes	  can	  be	  visualized	  by	  FISH	  analysis	  with	  probes	  for	  IgH	  (green)	  and	  MYC	  (red).	  t(8;14)(q24;q32)	  are	  indicated	  by	  yellow	  arrows.	  (Adapted	  from	  Blum	  et	  al.,	  2004)	  
5.3.4 Management	  and	  outcome	  of	  BL	  BL	   is	  a	  very	  aggressive	  malignancy	  due	   to	   the	  high	  proliferative	  rate.	  This	  property	  renders	   however	   BL	   particularly	   sensitive	   to	   cytostatic	   drugs	   including	  cyclophosphamide,	  vincristine,	  prednisolone,	  or	  doxorubicin,	  that	  are	  given	  at	  doses	  that	  are	  proportional	  to	  the	  stage	  of	  the	  disease.	  The	  use	  of	  rituximab	  (anti-­‐CD20)	  (or	  improved	  variants	  of	  anti-­‐CD20	  antibodies,	   such	  as	  Veltuzumab	  or	  Ofatumumab)	   in	  primary	  therapy	  has	  been	  assessed	  with	  encouraging	  results	  (Foon	  et	  al.,	  2012).	  With	  the	  current	   therapeutic	  protocols,	   the	  outcome	   for	  sporadic	  BL	   is	  excellent,	  with	  an	  overall	   cure	   rate	   of	   roughly	   90%.	   However,	   treatment	   has	   pronounced	  haematological	   toxic	   effects	   and	  mucositis,	   as	  well	   as	  high	   risk	  of	   severe	   infections.	  Moreover,	  relapse	  of	  BL,	  even	  though	  not	  very	  common,	  occurs	  on	  average	  6	  months	  after	  the	  end	  of	  the	  treatment,	  and	  has	  a	  very	  poor	  prognosis,	  probably	  because	  of	  the	  selection	  of	  particularly	  aggressive	  chemoresistant	  clones	  (Molyneux	  et	  al.,	  2012).	  	  
Figure	  9:	  Typical	  morphology	  of	  a	  lymph	  node	  in	  BL	  	  
	   37	  
5.3.5 λ-­‐MYC:	  a	  mouse	  model	  of	  Burkitt	  lymphoma	  The	   translocation	   of	   c-­‐MYC	   into	   Ig	   loci,	   leading	   to	   aberrant	   over	   expression	   of	   the	  proto-­‐oncogene	  in	  B	  cells,	  represents	  the	  molecular	  hallmark	  of	  BL.	  Several	  attempts	  have	   been	   made	   in	   the	   past	   30	   years	   to	   reconstruct	   BL	   in	   the	   mouse	   model,	   all	  centered	   on	   B-­‐cell	   specific	   over-­‐expression	   of	   the	   c-­‐MYC	   proto-­‐oncogene.	   The	   first	  mouse	  transgenic	  line	  with	  targeted	  MYC	  over-­‐expression	  to	  B	  cells	  was	  established	  by	  Adams,	  Cory	  and	  colleagues	   in	  1985.	   	   In	   this	   line	   (Eµ-­‐MYC),	  expression	  of	   the	  c-­‐MYC	  gene	  was	  placed	  under	   the	  control	  of	   the	   IgH	   intronic	  enhancer	   (Adams	  et	  al.,	  1985).	  The	  main	  limitation	  of	  this	  strain	  is	  represented	  by	  the	  premature	  expression	  of	  c-­‐MYC	  in	  B-­‐cell	  progenitors.	  Indeed,	  the	  majority	  of	  tumors	  arising	  in	  Eµ-­‐MYC	  mice	  represent	  aggressive	  IgM-­‐	  proB/preB	  lymphoblastic	   lymphomas.	  In	  2000,	  the	  Morse	  lab	   described	   the	   λ-­‐MYC	   strain	   carrying	   the	   human	   c-­‐MYC	   gene	   and	   its	   promoter	  sequence	   (cloned	   from	   a	   human	   BL-­‐cell	   line)	   under	   the	   control	   of	   Igλ	   light	   chain	  regulatory	   sequences	   (λ−MYC	   strain,	   Kovalchuk	   et	   al.,	   2000).	   This	   strategy	   was	  predicted	   to	   post-­‐pone	   onset	   of	   c-­‐MYC	   expression	   to	  mature	  B	   cells	   expressing	   IgL	  chains.	  Indeed,	  λ−MYC	  transgenic	  mice	  develop	  in	  most	  cases	  aggressive	  IgM+	  B	  cell	  lymphomas	   with	   immunophenotypical	   features	   shared	   with	   human	   BL	  (IgM+CD19+B220+CD43+	   CD5-­‐CD23-­‐).	   Moreover,	   histological	   analysis	   of	   lymphoid	  organs	   infiltrated	  with	  λ-­‐MYC	  tumor	  cells	  revealed	  a	   typical	  starry	  sky	  pattern.	  The	  main	   difference	   between	   hBL and  λ-­‐MYC	   lymphomas	   is	   represented	   by	   the	  accumulation	  in	  the	  latter	  tumors	  of	  the	  required	  combination	  of	  genetic	  mutations,	  before	  the	  entry	  of	  transgenic	  B	  cells	   in	  the	  GC	  reaction.	   Indeed	  in	  most	  cases,	   Ig	  V-­‐gene	   rearrangements	   cloned	   from	   λ-­‐MYC	   lymphomas	   lack	   signs	   of	   SHM.	   This	  limitation	  has	  been	  very	  recently	  overcome	  in	  a	  novel	  mouse	  BL	  model	  established	  by	  the	  Rajewsky	  group,	   in	  which	  expression	  of	  c-­‐MYC	  was	  specifically	   induced	   in	  GC	  B	  cells	   (Sander	   et	   al.,	   2012).	   Importantly,	   deregulated	   c-­‐MYC	   expression	   was	   not	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sufficient	  to	  initiate	  BL,	  as	  tumors	  appeared	  only	  upon	  concomitant	  activation	  of	  the	  Phosphoinositide	  3-­‐kinase	  pathway.	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5.4 The	  c-­‐MYC	  proto-­‐oncogene	  c-­‐MYC	   is	   a	   highly	   pleiotropic	   transcription	   factor	   that	   controls	   cell	   proliferation,	  metabolism,	  differentiation	  and	  apoptosis	  (Albihn	  et	  al.,	  2010;	  Nasi	  et	  al.,	  2001).	  It	  is	  therefore	  not	  surprising	  that	  its	  expression	  is	  commonly	  altered	  in	  variety	  of	  human	  tumors.	  
5.4.1 c-­‐MYC:	  structure	  and	  function	  The	  c-­‐MYC	  gene	  maps	  on	  human	  chromosome	  8	  and	  consists	  of	  3	  exons.	  Translation	  of	  the	  c-­‐MYC	   transcript	  can	  be	  initiated	  at	  3	  different	  sites:	  i)	  the	  AUG	  in	  the	  second	  exon,	  giving	  rise	  to	  the	  canonical	  64kDa	  MYC	  protein;	  ii)	  a	  non-­‐AUG	  codon	  (CAG)	  near	  the	  3′	  end	  of	  exon	  1,	  generating	  a	  longer	  c-­‐MYC	  isoform	  (p67)	  (Hann	  et	  al.,	  1988),	  and	  iii)	   an	   internal	   AUG	   codon	   in	   exon	   2,	   downstream	   the	   first	   AUG,	   resulting	   in	   the	  expression	   of	   a	   shorter	   protein	   called	   MYCS	   (Blackwood	   et	   al.,	   1994).	   The	   MYC	  protein,	   translated	   from	   the	   canonical	  AUG,	   consists	  of	   a	  N-­‐terminal	   transcriptional	  regulatory	  domain,	  followed	  by	  a	  nuclear	  localization	  signal	  and	  a	  C-­‐terminal	  region	  with	  a	  basic	  DNA-­‐binding	  domain	  tethered	  to	  a	  helix-­‐loop-­‐helix-­‐leucine	  zipper	  (HLH-­‐Zip)	  dimerization	  motif.	  To	  bind	  DNA,	  MYC	  dimerizes	  with	  Max,	  identified	  in	  1991	  as	  a	   c-­‐MYC	  obligate	  partner	  protein	   (Amati	   et	   al.,	   1993;	  Amati	   et	   al.,	   1992).	  The	  MYC-­‐Max	  heterodimer	  locks	  onto	  and	  bends	  DNA	  through	  binding	  motifs	  (5’-­‐	  CACGTG	  -­‐3’)	  termed	   E	   boxes	   (Park	   et	   al.,	   2004),	   where	   it	   mainly	   acts	   as	   inducer	   of	   gene	  transcription.	  Although	  the	  mechanism	  of	  MYC-­‐induced	  transcription	  is	  progressively	  emerging	   (Lin	   et	   al.,	   2012;	   Nie	   et	   al.,	   2012),	   its	   contribution	   to	   transcriptional	  repression	   is	   still	   unclear.	   Several	   observations	   indicate	   that	   MYC	   inhibits	   gene	  expression	   through	   different	  modalities	   that	   are	  mainly	   linked	   to	   regulatory	   loops.	  For	   example,	   it	   has	   been	   proposed	   that	   the	   inhibitory	   effect	   of	   MYC	   on	   gene	  transcription	  is	  the	  result	  of	  the	  induction	  of	  repressive	  factors,	  and/or	  the	  regulation	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of	   specific	   micro-­‐RNAs	   (miRNA)	   (Chang	   et	   al.,	   2008).	   An	   interaction	   with	   other	  transcription	  factors	  to	  repress	  gene	  expression	  has	  been	  also	  proposed	  (Eilers	  and	  Eisenman,	  2008).	  	  Finally,	  several	  studies	  have	  provided	  a	  link	  between	  MYC	  and	  genomic	  instability	  as	  an	   indirect	   consequence	   of	   its	   transcriptional	   activity	   (Wade	   and	   Wahl,	   2006).	  However,	   evidence	   proposed	   by	  Domininguez-­‐Sola	   and	   colleagues	   indicated	   a	   non-­‐transcriptional	  role	   for	  MYC	   in	   the	   initiation	  of	  DNA	  replication	  (Dominguez-­‐Sola	  et	  al.,	  2007).	  In	  fact,	  despite	  its	  conventional	  definition	  as	  transcription	  factor,	  MYC	  can	  interact	  with	  components	  of	  the	  pre-­‐replicative	  complex,	  and	  localizes	  at	  early	  sites	  of	  DNA	   replication.	   These	   observations	   indicated	   that	  MYC	  might	   directly	   control	   the	  initiation	  of	  DNA	  synthesis	  and	  progression	  through	  S	  phase.	  Moreover,	  MYC-­‐related	  genomic	  instability	  might	  result	  from	  the	  induction	  of	  DNA	  replication	  stress,	  rather	  than	  being	  dependent	  on	   the	   transcriptional	   activation	  of	   S-­‐phase	  promoting	  genes	  (Cole	  and	  Cowling,	  2008).	  
5.4.2 MYC	  regulation	  Lying	  at	  the	  crossroad	  of	  many	  different	  pathways	  including	  proliferation,	  apoptosis,	  differentiation	  and	  metabolism,	  MYC	  expression	   is	   tightly	  regulated	  by	  a	  number	  of	  transcriptional	   and	   post-­‐transcriptional	   mechanisms	   (Brooks	   and	   Hurley,	   2010;	  Hurley	  et	  al.,	  2006;	  Levens,	  2010).	  The	  MYC	  mRNA	   is	   short	   lived.	   It	   is	   targeted	  by	   several	  miRNAs	   (let-­‐7,	  miR-­‐34,	   and	  miR-­‐145)	  resulting	  in	  translational	  repression	  (Christoffersen	  et	  al.,	  2010;	  Kress	  et	  al.,	  2011).	   The	   MYC	   protein	   undergoes	   poliubiquitination	   and	   degradation	   by	   the	  proteosome,	  with	  a	  half-­‐life	  in	  the	  order	  of	  15–20	  minutes	  (Gregory	  and	  Hann,	  2000).	  Phosphorylation	  of	  2	  specific	  residues	  of	  the	  MYC	  protein	  influences	  MYC	  activation	  or	  degradation.	  Mitogen-­‐activated	  signalling	  pathways	  (inducing	  the	  activation	  of	  the	  Ras/MAPK	   pathway)	   lead	   to	   phosphorylation	   of	   MYC	   at	   Serine	   62	   (Ser62),	   which	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results	  in	  the	  stabilization	  of	  the	  protein.	  By	  contrast,	  phosphorylation	  at	  Threonine	  58	   (Thr58)	   destabilizes	   MYC	   and	   facilitates	   Ser62	   de-­‐phosphorylation.	   Thr58	   is	  phosphorylated	  by	  glycogen	   synthase	  kinase-­‐3	  beta	   (GSK3β)	   (Gregory	  et	   al.,	   2003),	  which,	  in	  turn	  is	  inhibited	  by	  the	  PI3K	  pathway.	  GSK3β	  can	  phosphorylate	  MYC	  Thr58	  only	  if	  Ser62	  is	  already	  phosphorylated	  (“primed	  phosphorylation”).	  Phosphorylation	  of	  MYC	  in	  Thr58	  promotes	  its	  recognition	  by	  the	  prolyl-­‐isomerase	  PIN1,	  which	  in	  turn	  leads	   to	   the	   isomerization	   of	   MYC	   Proline-­‐59	   (Pro59)	   thus	   enabling	   protein	  phosphatase-­‐2A	  (PP2A)	  to	  remove	  the	  phosphate	  residue	  from	  Ser62.	  The	  ubiquitin	  E3	   ligase	   SCFFWB7	   (FBW7)	   poly-­‐ubiquitylates	   MYC	   in	   a	   Thr58-­‐phosphorylation-­‐dependent	  manner,	  and	  targets	  it	  for	  proteasomal	  degradation	  (Welcker	  et	  al.,	  2004a;	  Welcker	  et	  al.,	  2004b;	  Yada	  et	  al.,	  2004)	  (Figure	  10	  adapted	  from	  Adhikary	  and	  Eilers,	  2005).	  	  
	  
Figure	  10:	  Post-­‐translational	  modification	  of	  c-­‐MYC	  in	  response	  to	  upstream	  signalling	  events	  
MYC	   Phosphorylation	   on	   serine-­‐62	   (S62),	   in	   response	   to	   Ras	   signalling,	   provides	   the	   docking	   site	   for	  GSK3β, which	   in	   turn	  phosphorylates	  MYC	  threonine-­‐58	  (T58).	  Phosphorylated	  MYC	   is	  recognized	  by	   the	  prolyl	  isomerase	  PIN1	  that	  leads	  to	  isomerization	  of	  Proline-­‐59	  and	  thereby	  enables	  PP2A-­‐mediated	  dephosphorylation	  of	  MYC	   S62.	   This	   allows	   the	   E3	   ligase	   to	   recognize	   and	   poly-­‐ubiquitylate	   T58-­‐phosphorylated	  MYC,	   promoting	  ultimately	  its	  degradation	  by	  the	  proteasome	  machinery.	  	  	  The	   selection	   for	   MYC	   Thr58	   point	   mutations	   preventing	   its	   phosphorylation	   and	  thus	  degradation	  can	  be	  observed	  in	  human	  BL	  (Bahram	  et	  al.,	  2000).	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Whereas	   high	   MYC	   protein	   levels	   represent	   a	   common	   feature	   of	   several	   human	  neoplasms,	   deregulation	   of	   MYC	   activity	   throughout	   the	   cell	   cycle	   may	   represent	  another	   important	   mechanisms	   leading	   to	   altered	   MYC	   function	   in	   tumor	   cells	  (Adhikary	  and	  Eilers,	  2005).	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5.5 The	  BCR	  in	  B	  cell	  lymphomas	  The	   expression	   of	   a	   functional,	   non	   auto-­‐reactive	   BCR	   on	   the	   surface	   of	   B	   cells	  represents	   a	   prerequisite	   to	   ensure	   a	   successful	   progression	   throughout	   B	   cell	  development.	  In	  early	  B	  cell	  development,	  the	  expression	  of	  the	  pre-­‐BCR	  first,	  and	  the	  BCR	   later,	   represents	   a	   critical	   checkpoint	   to	   promote	   further	  B-­‐cell	   differentiation	  (Kitamura	   et	   al.,	   1992;	   Kitamura	   et	   al.,	   1991;	   Torres	   et	   al.,	   1996).	   In	   secondary	  lymphoid	  organs,	  the	  survival	  of	  mature	  B	  cells	  is	  strictly	  dependent	  on	  surface	  BCR	  expression,	   as	   conditional	   ablation	   of	   the	   BCR,	   or	   its	   signaling	   component	   Igα,	   in	  genetically	   modified	   animals,	   have	   revealed	   a	   strict	   dependence	   on	   these	  determinants	  for	  B-­‐cell	  survival	  (Kraus	  et	  al.,	  2004;	  Lam	  et	  al.,	  1997;	  Srinivasan	  et	  al.,	  2009).	  	  Given	   that	  most	  mature	   B	   cell	   lymphomas	   retain	   BCR	   expression,	   it	   has	   been	   long	  suggested	   that	   the	   immunoglobulin	   receptor	   contributes	   to	   the	   survival	   and/or	  proliferation	   of	   malignant	   B	   cells,	   and	   the	   following	   evidences	   support	   this	  hypothesis.	  	  First,	  in	  BL,	  the	  MYC	  translocation	  affects	  always	  specifically	  the	  Ig	  locus	  in	  germline	  configuration,	   or	   at	   most	   carrying	   a	   non-­‐functional	   V	   gene	   rearrangement.	   This	  condition	  preserves	  in	  the	  tumor	  cells	  the	  ability	  to	  express	  a	  functional	  BCR	  and	  thus	  suggests	  the	  requirement	  of	   lymphoma	  cells	   for	  signals	  emanating	  from	  the	  antigen	  receptor	  both	  during	  tumor	  initiation	  and	  maintenance	  (Kuppers,	  2005;	  Kuppers	  and	  Dalla-­‐Favera,	  2001).	  	  Second,	   treatment	  of	   follicular	   lymphoma	  patients	  with	  anti-­‐idiotypic	  antibodies	   led	  to	  an	  efficient	   treatment	  of	   the	  disease.	  Patients	  showing	   tumor	  relapses	  developed	  FL	   consisting	   of	   malignant	   B-­‐cell	   clones	   that	   retained	   BCR	   expression	   but	   had	   a	  different	   BCR-­‐specificity,	   thus	   eluding	   the	   anti-­‐idiotypic	   treatment	   (Cleary	   et	   al.,	  1986;	  Meeker	  et	  al.,	  1985).	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Finally,	   except	   for	   classical	   Hodgkin	   disease,	   most	   GC-­‐derived	   B	   cell	   lymphomas	  (including	   the	   most	   common	   BL,	   FL	   and	   DLBCL	   types)	   with	   signs	   of	   ongoing	   Ig	  somatic	   hypermutation	   display	   a	   strong	   selective	   pressure	   to	   retain	   the	   structural	  integrity	  of	  the	  BCR,	  accumulating	  mutations	  in	  the	  CDR	  regions	  (Braeuninger	  et	  al.,	  1997;	  Lossos	  et	  al.,	  2000).	  	  
5.6 Objectives	  of	  the	  study	  As	  previously	  described,	  numerous	  observations	  pointing	   to	   the	  requirement	  of	   the	  BCR	   for	   lymphoma	   cell	   survival	   and\or	   proliferation	   are	   currently	   available.	  Nevertheless,	   the	   direct	   contribution	   of	   the	   immunoglobulin	   receptor	   to	   the	  maintenance	   of	  B	   cell	   tumors	   has	   not	   been	   specifically	   addressed.	   In	   this	   view,	   the	  aim	   of	   the	   present	   work	   is	   to	   determine	   the	   role	   of	   the	   BCR	   to	   survival	   and	  proliferation	  of	  c-­‐MYC	  transformed	  mature	  B	  cells	  in	  a	  mouse	  model	  of	  BL.	  	  For	  this	  purpose,	  cell	  proliferation	  and	  survival	  of	  transformed	  B	  cells	  were	  evaluated	  both	   in	   vitro	   and	   in	   vivo,	   upon	   conditional	   deletion	   of	   the	   BCR	   by	   TAT-­‐Cre	  transduction	   of	   primary	   lymphomas.	   Moreover,	   the	   molecular	   mechanisms	  underlying	   the	   requirement	   of	   the	   BCR	   for	   survival	   of	   lymphoma	   B	   cells	   will	   be	  addressed.	   Finally,	   the	   identification	   of	   molecules	   and\or	   signalling	   pathways,	   as	  crucial	  determinants	  for	  lymphoma	  survival,	  will	  provide	  novel	  therapeutic	  targets	  to	  be	  introduced	  in	  the	  treatment	  of	  MYC-­‐driven	  mature	  B	  cell	  tumors.	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6 Materials	  &	  Methods	  
6.1 Mice	  C57BL/6	  and	  C57BL/6	  x	  BALB/c	  F1	  (CB6F1)	  animals	  were	  purchased	  from	  Charles	  River	   or	   Jackson	   Laboratories.	   λ-­‐myc	   and	   B1-­‐8f	   mice	   were	   previously	   described	  (Kovalchuk	   et	   al.,	   2000;	   Lam	   et	   al.,	   1997).	   All	   animals	   were	   kept	   under	   specific	  pathogen	   free	   conditions.	   Mouse	   experimentations	   were	   performed	   under	   the	  protocol	   number	   approved	   by	   the	   Italian	   Ministry	   of	   Health	   and	   the	   IFOM	   IACUC	  Committee.	  
6.1.1.1 Histology	  Tissue	   samples	   were	   fixed	   in	   PBS/1%	   formalin	   and	   embedded	   in	   paraffin.	  Haematoxylin	   and	   eosin	   stainings	   were	   performed	   in	   collaboration	   with	   Dr.	   C.	  Doglioni	  and	  M.	  Ponzoni	   (Department	  of	  Pathology,	  San	  Raffaele	  Scientific	   Institute,	  Milan,	  Italy)	  according	  to	  standard	  procedures.	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6.2 Molecular	  Biology	  Techniques	  
6.2.1 Genomic	  DNA	  extraction	  from	  tail	  biopsy	  Mouse	  tissue	  or	  cells	  were	  lysed	  o/n	  at	  56°C	  in	  400	  µl	  lysis	  buffer	  (100	  mM	  Tris-­‐HCl	  pH	  8;	  5	  mM	  EDTA;	  200	  mM	  NaCl;	  0.2%	  SDS;	  100µg/ml	  Proteinase	  K),	  shaking	  at	  850	  rpm,	  overnight	  in	  Thermomixer	  compact.	  Undissolved	  debris	  were	  pelleted	  and	  DNA	  in	  the	  supernatant	  was	  precipitated	  with	  1	  ml	  of	  isopropanol.	  The	  DNA	  was	  pelleted	  by	  centrifugation,	  air-­‐dried	  and	  resuspended	  in	  400	  μl	  of	  milliQ	  water	  by	  incubation	  at	  50˚C	  for	  20	  min.	  	  
6.2.2 Genotyping	  strategy	  The	  genotypes	  of	  all	  mice	  offsprings	  were	  analyzed	  by	  polymerase	  chain	  reaction	  (PCR)	  performed	  on	  genomic	  DNA	  extracted	  from	  tail.	  For	  amplification,	  primers	  summarized	  in	  Table	  1	  and	  PCR	  reagents	  in	  Table	  2	  were	  used.	  PCR	  conditions	  are	  summarized	  in	  	  Table	   3.	   PCRs	   were	   run	   in	   automatic	   thermocycler	   GeneAmp	   PCR	   System9700	  (Applied	  Biosystems).	  
6.2.3 Agarose	  gel	  electrophoresis	  and	  DNA	  gel	  extraction	  Separation	  of	  DNA	  fragments	  by	  size	  was	  achieved	  by	  electrophoresis	  in	  agarose	  gels	  (0.7%	   -­‐	   2.5%;	  1x	  TAE	   (Sambrook	   and	  Russell,	   2001);	   1x	  GelRedTM,	  BIOTIUM).	  As	   a	  size	  marker	  for	  agarose	  gel	  electrophoresis	  1kb	  plus	  ladder	  (NEB,	  USA)	  was	  used.	  
6.2.4 RNA	  and	  DNA	  extraction	  	  Total	   RNA	   was	   extracted	   from	   106	   cells,	   using	   QIAGEN	   RNeasy	   kit	   following	   the	  manufacturer’s	  protocol.	  A	  DNAse	  (QIAGEN)	  digestion	  step	  was	  added	  before	  elution	  to	  ensure	  the	  complete	  elimination	  of	  contaminant	  DNA.	  	  
	   47	  
6.2.5 cDNA	  synthesis	  	  Complementary	   DNA	   (cDNA)	   was	   produced	   using	   SuperScript®	   VILO™	   cDNA	  Synthesis	  Kit	  (Invitrogen)	  following	  the	  manufacturer’s	  protocol.	  Specifically,	  master	  mix	  (containing	  5X	  VILOTM	  Reaction	  Mix,	  10X	  SuperScript®	  Enzyme	  Mix,	  water	  and	  RNA)	  was	  incubated	  for	  10	  min	  at	  RT.	  For	  increased	  yields	  of	  cDNA	  incubation	  time	  was	  prolonged	  to	  120	  min	  at	  42°C.	  Reaction	  was	  terminated	  by	  5	  min	  incubation	  at	  85°C.	  25	  ng	  of	  cDNA	  were	  used	  for	  real	  time	  PCR	  reaction.	  	  
6.2.6 Real-­‐time	  quantitative	  PCR	  (RT-­‐qPCR)	  For	  gene	  expression	  analysis	  RT-­‐QPCR	  was	  performed	  using	  25	  ng	  of	  cDNA,	  500	  nM	  primers	  mix	  and	  10	  μl	  of	  LightCycler	  480	  SYBR	  Green	  I	  Master,	  containing	  Hot-­‐start	  polymerase	  (Roche)	  in	  a	  final	  volume	  of	  20	  µl	  per	  reaction	  in	  96-­‐well	  format.	  Reaction	  conditions	  were:	  95°C	  for	  10	  min,	  45	  cycles	  of	  95°C	  for	  1	  sec,	  60°C	  for	  10	  sec,	  72°C	  for	  1	  sec.	  Accumulation	  of	  fluorescent	  products	  was	  monitored	  using	  a	  LightCycler®	  480	  Real-­‐Time	   PCR	   System	   (Roche).	   Specificity	   of	   PCR	   reaction	   was	   controlled	   by	   the	  melting-­‐temperature	   profiles	   of	   final	   products	   (dissociation	   curve).	   Ribosomal	  protein	   large	   p0	   (Rplp0)	   gene	   was	   used	   as	   a	   control	   housekeeping	   gene	   for	  normalization	   (Akamine	   et	   al.,	   2007;	   Laborda,	   1991).	   Primers	   are	   listed	   in	  Table	  4.	  Transcript	   fold	   enrichment	  was	   calculated	   by	  ΔΔct	  method	   (Livak	   and	   Schmittgen,	  2001).	  
6.2.7 Microarray	  analysis	  	  Affymetrix	   GeneChip®	   Arrays	   were	   performed	   at	   GeneChip®	   Mouse	   Gene	   1.1	   ST	  Array	  platform.	  The	  GeneChip®	  Mouse	  Gene	  1.1	   ST	  Array	  with	  more	   than	  750,000	  unique	   25-­‐mer	   oligonucleotides	   covers	   the	   whole	   genome	   transcript.	   Each	   of	   the	  28,853	  covered	  genes	  is	  represented	  on	  the	  array	  by	  approximately	  27	  probes	  spread	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across	   the	   full	   length	   of	   the	   gene.	   Data	   analysis	   is	   described	   in	   Statistical	   analysis	  section.	  
Table	  1:	  Genotyping	  primers,	  annealing	  temperatures	  and	  amplicons	  
Primers	   	   TA	   Product	  
Human	  c-­‐MYC	  	   	   	   Amplicon	   size	  5’-­‐GAGGCAGGCTCCTGGCAAAAGGTCA-­‐3’	   hMYC	  Fw	   58°C	   tg	   400	  bp	  5’-­‐GAAATGAGCTTTTGCTCCTCTGCTTG-­‐3’	   hMYC	  Rv	   	   	  
B1-­‐8F	  vs	  IgH	  	   	   	   	   	  5’-­‐CCAAAGTCCAGGCTGAGCAAAAC-­‐3’	   B1-­‐8f	  vs	  IgH	  Fw	   56°C	   wt	   300	  bp	  5’-­‐GATCATGAACAAAGTCACTGTAAATG-­‐3’	   B1-­‐8f	  vs	  IgH	  rv	   	   fl	   340	  bp	  
Cdkn2a\p19	   	   	   	   	  5’-­‐TTAACAGCGGAGCTTCGTACA-­‐3’	   Ink4a/Arf	  Fw	   60°C	   tg	   150	  bp	  5’-­‐CTGCACCGTAGTTGAGCAGAA-­‐3’	   Ink4a/Arf	  Rv	   	   	   	  
Trp53	   	   	   	   	  5’-­‐GGATGGTGGTATACTCAGAGCC-­‐3’	   Trp53	  Fw	   58°C	   wt	   450	  bp	  5’-­‐AGCGTGGTGGTACCTTATGAGC-­‐3’	   Trp53	  Rv	   	   	   	  
VkJk	  	   	   	   	   	  5’–GCGAAGCTTCCCTGATCGCTTCACAGG-­‐3’	   Vk	  Fw	  1	   	   VkJk1	   800bp	  5’-­‐GCGAAGCTTCCCWGCTCGCTTCAGTGG-­‐3’	   Vk	  Fw	  2	   	   VkJk2	   550bp	  5’-­‐GCGAAGCTTCCCAKMCAGGTTCAGTGG-­‐3’	   Vk	  Fw	  3	   	   VkJk3	   250bp	  5’-­‐CTCAGAGCTCTAGGCCCCTCTTTGAT-­‐3’	   Jk5	  Rv	   55°C	   VkJk5	   100bp	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Table	  2:	  Master	  mix	  used	  for	  PCR	  genotype	  
PCR	  master	  mix	   µl	  H2O	   14.4	  5x	  flexi	  buffer	   5	  MgCl2	  25	  mM	  	   2	  dNTPs	  2.5	  mM	   2	  primer	  Fw	  50	  µM	   0.2	  primer	  Rv	  50	  µM	   0.2	  GO	  Taq	   0.2	  DNA	   1	  total	   25	  	  
Table	  3:	  Conditions	  used	  for	  PCR	  genotype	  
	  	  	   	  X35	  	  
	  
Table	  4:	  Primer	  sequences	  for	  quantitative	  PCR	  analysis	  
Primers	   Sequence	   Target	  Rplp0	  Fw	   5’-­‐TTCATTGTGGGAGCAGAC-­‐3’	   RNA	  Rplp0	  Rv	   5’-­‐CAGCAGTTTCTCCAGAGC-­‐3’	   RNA	  	   	   	  B1-­‐8-­‐Cm	  Fw	   5’-­‐CTGCGGTCTATTATTGTGCAAG-­‐3’	   RNA	  B1-­‐8-­‐Cm	  Rv	   5’-­‐GGAAGACATTTGGGAAGGAC-­‐3’	   RNA	  	  
PCR	  cycle	   	  Temperature(°C)	   Time	  (min)	  94	   2:30	  94	   0:30	  TA	   0:30	  72	   0:30	  72	   5:00	  4-­‐15	   hold	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6.3 Lymphoma	  Cell	  Culture	  
6.3.1 Preparation	  of	  cell	  suspension	  from	  lymphoid	  organs	  Single-­‐cell	  suspensions	  were	  obtained	  by	  grinding	  spleens	  and	  lymph	  nodes	  between	  slide	   glasses	   followed	  by	   filtering	   through	  70	  µm	  nylon	  meshes	   (Becton	  Dickinson,	  USA).	   Femurs	   were	   flushed	   using	   a	   syringe	   containing	   5-­‐10	   ml	   of	   B-­‐cell	   medium	  (DMEM	   supplemented	   with	   10%	   heat-­‐inactivated	   fetal	   bovine	   serum,	   0.1mM	   non-­‐essential	  amino	  acids,	  1	  mM	  sodium	  pyruvate,	  50µM	  β-­‐mercaptoethanol	  and	  2mM	  L-­‐glutamine;	  Invitrogen)	  to	  obtain	  bone	  marrow	  cells.	  	  Erythrocytes	   lysis	   from	   spleen	   and	   bone	   marrow	   preparations	   was	   achieved	  incubating	  cell	  suspensions	  in	  1	  ml	  of	  a	  9:1	  (v/v)	  solution	  of	  0.15M	  NH4Cl	  and	  0.17M	  Tris-­‐HCl	   pH	   7.65	   for	   3	  min	   on	   ice.	   Red	   blood	   cell	   lysis	   was	   interrupted	   adding	   10	  volumes	  of	  B-­‐cell	  medium.	  Cells	  were	  centrifuged	  at	  1200	  rounds	  per	  minute	  (rpm)	  at	  4°C	  and	  re-­‐suspended	  in	  B-­‐cell	  medium	  before	  counting.	  Live	  cells	  were	  counted	  using	  Trypan	  blue	  dye	  to	  distinguish	  live	  and	  dead	  cells.	  	  
6.3.2 B	  cell	  activation	  Primary	  B	  cells	  were	   isolated	   from	  spleen	  of	  C57	  BL6/J	  mice	  by	  magnetic	  activated	  cell	   sorting	   (MACS)	   purification	   (see	   below,	   6.4.2,	   Magnetic	   Cell	   sorting).	   	   Briefly,	  spleen	  was	  processed	  as	  previously	  described	  (6.3.1,	  Preparation	  of	  cell	  suspension	  from	   lymphoid	   organs)	   and	   single	   cell	   suspension	   was	   labelled	   using	   anti-­‐CD19	  conjugated	   micro-­‐beads,	   according	   to	   manufacturer’s	   protocol	   (Milenyi	   Biotech,	  Germany).	  CD19+	  B	  cells	  were	  purified	  using	  LS	  columns	  (Milenyi	  Biotech,	  Germany)	  and	   activated	   by	   by	  cross-­‐linking	  the	   BCR	  using	   polyclonal	   goat	   anti-­‐mouse	  IgM	  bivalent	  antibody	  (F(ab’)2,	  20	  µg/ml,	  Jackson	  Immuno-­‐Research),	  3	  to	  5	  minutes	  at	   37°C.	   Cells	  were	  washed	   twice	  with	   ice	   cold	   PBS,	   by	   centrifuging	   for	   5	  minutes,	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2000	   rpm	  at	  4°C.	  Cells	  were	   lysed	  as	  described	  below	   (6.5.1,	   Immunoblot	   analysis)	  and	  used	  for	  western	  blot	  analysis.	  
6.3.3 Establishment	  of	  cell	  lines	  from λ−MYC	  lymphomas	  	  Primary	   lymphomas	   obtained	   from	   diseased	   animals	   were	   cultivated	   with	   B	   cell	  medium	  in	  25	  mm2	  or	  75	  mm2	  cell	  culture	  flasks	  at	  37°C	  in	  a	  humid	  atmosphere	  with	  5%	  CO2.	  Cell	  density	  was	  adjusted	  to	  2x105	  cells/ml	  and	  medium	  was	  refreshed	  every	  48	   hours.	   On	   average	   two	   weeks	   after	   initial	   seeding,	   over	   50%	   of	   primary	  lymphomas	  gave	  rise	  to	  tumor	  cell	  lines	  adapted	  to	  grow	  under	  in	  vitro	  experimental	  conditions.	  
6.3.4 TAT-­‐Cre	  transduction	  of	  primary	  lymphoma	  cells	  Lymphoma	   cells	   were	   washed	   three	   times,	   re-­‐suspended	   in	   serum-­‐free	   media	  (Hyclone,	  USA)	  at	  a	  density	  of	  5x106	  cells/ml	  and	  incubated	  for	  45	  min	  at	  37°C	  with	  37.5	  µg/ml	  (final	  concentration)	  of	  recombinant	  TAT-­‐Cre.	  Transduction	  was	  stopped	  diluting	   samples	   with	   10	   volumes	   of	   B-­‐cell	   medium,	   cells	   were	   spun	   down,	   re-­‐suspended	   in	  B-­‐cell	  medium	  and	   cultured	  at	   a	  density	  of	  2	   x	  105	   cells/ml.	  Deletion	  efficiency	  was	  evaluated	  24-­‐48	  hours	  later	  by	  flow	  cytometry.	  
6.3.5 Isolation	  of	  BCR-­‐	  lymphoma	  cells	  by	  limiting	  dilution	  	  Upon	  Tat-­‐Cre	  transduction,	  mixture	  of	  BCR+	  and	  BCR-­‐	  lymphoma	  cells	  were	  seeded	  at	  a	  density	  of	  0.3	   cells\well,	   in	  96-­‐well	  plates.	  Cells	  were	   incubated	  at	  37°C,	  5%	  CO2,	  until	  colonies	  derived	  from	  single	  cells	  were	  visible	  in	  the	  plates.	  BCR	  status	  of	  each	  colony	  was	  analysed	  by	  flow	  cytometry.	  
6.3.6 Treatment	  of	  lymphoma	  cells	  with	  small	  molecule	  inhibitors	  BCR+	  and	  BCR-­‐	  lymphoma	  cells	  were	  seeded	  at	  5x105\ml	  and	  incubated	  at	  37°C,	  5%	  CO2,	  for	  12-­‐16	  hours.	  Cells	  were	  washed	  with	  PBS	  and	  plated	  at	  a	  density	  of	  4x105\ml	  in	   B	   cell	   medium,	   in	   24-­‐well	   plate.	   1	   volume	   of	   2x	   Rapamycin	   (10nM	   final	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concentration)	  or	  CT99021	  (1µM	  final	  concentration)	  was	  added	  to	  each	  well.	  DMSO	  was	  used	  as	  vehicle	  control.	  Cells	  were	  counted	  every	  24-­‐48	  hours	  and	  analysed	  by	  flow	   cytometry	   (see	   below	   6.4.1,	   Flow	   cytometry	   and	   cell	   sorting	   analysis).	  Rapamycin	   and	   CT99021	   were	   purchased	   from	   ABCR	   (#AB253776)	   and	   Sigma-­‐Aldrich	  (#53123-­‐88-­‐9),	  respectively.	  	  
6.3.7 BCR	  complementation	  of	  tumor	  cells	  by	  retroviral	  transgenesis	  Phoenix	  packaging	  cells	  were	  transfected	  with	  either	  a	  pMIG-­‐IRES-­‐GFP	  empty	  vector	  or	  a	  pMIG-­‐IRES-­‐GFP	  vector,	  expressing	  an	  allotype	  b-­‐marked	  IgH	  chain	  carrying	  a	  B1-­‐8	  VH	  gene.	  Supernatant	  containing	  the	  viral	  particles	  was	  added	  to	  a	  BCR+	  λ-­‐MYC;B1-­‐8f	  lymphoma	  cell	  line,	  followed	  by	  three	  rounds	  of	  spin	  infection	  (2000	  rpm,	  30°C,	  45	  minutes).	   Infected	   cells	   were	   transduced	   with	   TAT-­‐Cre	   and	   sorted	   (as	   described	  below,	   6.4.1,	   Flow	   cytometry	   and	   cell	   sorting)	   respectively	   as	   GFP+IgMb+IgMa-­‐	   or	  GFP+IgMb-­‐IgMa-­‐.	   IgMb+	   and	   IgM-­‐	   sorted	   cells	   were	   mixed	   in	   equal	   numbers	   and	  cultured	  in	  vitro	  for	  9	  days	  or	  transplanted	  into	  recipient	  mice.	  	  
6.3.8 Adoptive	  transfer	  of	  λ-­‐MYC	  lymphomas	  Primary	  lymphomas	  were	  obtained	  as	  single	  cell	  suspensions	  from	  SPL,	  BM	  or	  MLN	  of	  12	  to	  16	  weeks-­‐old	  diseased	  mice.	  After	  red	  blood	  cell	  lysis,	  tumor	  cells	  were	  counted	  and	   cultured	   for	   the	   following	   one	   to	   two	  weeks	   in	   B	   cell	   medium	   at	   a	   density	   of	  2x105	   cells\ml.	   Before	   transplantation	   into	   secondary	   recipients,	   lymphoma	   cells	  were	   washed	   twice	   in	   PBS,	   re-­‐suspended	   at	   3x107	   cells/ml	   and	   100	   µl	   of	   cell	  suspension	   was	   injected	   into	   the	   tail	   vein	   of	   16-­‐20-­‐weeks	   old	   immunoproficient	  CB6F1	  mice.	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6.4 Flow	  cytometry	  
6.4.1 Flow	  cytometry	  and	  cell	  sorting	  analysis	  For	   flow	  cytometric	  analysis	  aliquots	  of	  1x106	  cells	  were	  stained	   for	  20	  minutes	  on	  ice	  in	  50	  µl	  FACS	  buffer	  (1%	  PBS,	  1%	  BSA,	  0.01%	  Sodium	  Azide	  (N3)	  containing	  the	  appropriate	  mixture	  of	  fluorescently	  labeled	  antibodies	  (Abs).	  Two-­‐step	  staining	  was	  performed	   when	   biotinylated	   Abs	   were	   detected	   using	   fluorescently-­‐labeled	  streptavidin	   as	   secondary	   reagent.	   Stained	   cells	   resuspendend	   in	   FACS	  buffer	  were	  acquired	   on	   a	   FACSCalibur	   (BD	   Pharmingen,	   USA)	   and	   data	   were	   analyzed	   using	  Flowjo	   software	   (Tree	   Star,	   USA).	   Dead	   cells	   were	   excluded	   from	   the	   analysis	   by	  labeling	  with	  propidium	  iodide	  or	  based	  on	  forward	  and	  side	  scatter	  parameters.	  	  Sorting	   of	   labeled	   cells	   was	   performed	   with	   a	   FACS	   Vantage	   or	   FACS	   Aria	   (BD	  Pharmingen,	   USA).	   Monoclonal	   Abs	   were	   purchased	   from	   eBioscience.	   	   Anti-­‐IgM	  monoclonal	   Abs	   R331.12	   and	   R3324.12	  were	   produced	   in	   house.	  Monovalent	   anti-­‐IgM	  Fab	  polyclonal	  Abs	  were	  purchased	  from	  Jackson	  Immunoresearch.	  	  List	  of	  Abs	  as	  well	  as	  working	  dilutions	  are	  listed	  in	  Table	  5	  
6.4.2 Magnetic	  cell	  sorting	  For	  B	   cell	  purification,	   splenic	   cells	  were	  magnetically	   labeled	  by	  using	  MicroBeads	  conjugated	  Abs	  anti-­‐CD19,	  following	  manufacturer’s	  protocol	  (MACS;	  Milenyi	  Biotech,	  Germany).	   This	   procedure	   allows	   the	   isolation	   of	   resting	   B	   cells	   from	   single	   cell	  suspensions	  of	   lymphoid	  tissues.	  For	  purification	  of	  BCR-­‐	  tumors,	  cells	  were	  stained	  with	   biotinylated	   anti-­‐IgM	   (cl.	   R331.12)	   for	   20	   min	   on	   ice,	   washed	   twice	   with	  PBS/0.5%	  BSA/N3	  (FACS	  Buffer),	  and	  subsequently	   labeled	  by	  incubation	  with	  anti-­‐biotin	   microbeads,	   for	   30	  min	   at	   4°C.	   Finally,	   cells	   were	   applied	   onto	   LD	   columns	  under	   a	   magnetic	   field	   (Miltenyi	   et	   al.,	   1990).	   	   Flow-­‐through	   IgM-­‐	   lymphoma	   cells	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were	   spun	   down,	   re-­‐suspended	   in	   B-­‐cell	  medium	   and	   cultured	   at	   37°C	   in	   a	   humid	  atmosphere	  with	  5%	  CO2	  	  
Table	  5:	  List	  of	  antibodies	  used	  for	  flow	  cytometry	  
Antibodies	  and	  antigen	  (clone)	   Source	   Dilution	  factor	  Monoclonal	  Rat–anti	  mouse	  CD5	  (53-­‐7.3)	   eBiosciences	   1/200	  Anti	  mouse	  IgM	  (R331.12	  )	   Home-­‐made	   1/400	  Anti	  mouse	  Kappa	  (R331.18)	   Home-­‐made	   1/800	  Monoclonal	  Rat-­‐anti	  mouse	  CD138	  (281-­‐2)	  	   eBiosciences	   1/200	  Monoclonal	  Rat-­‐anti	  mouse	  CD19	  (eBio1D3)	  	   eBiosciences	   1/400	  Monoclonal	  Rat-­‐anti	  mouse	  CD21/CD35	  (eBioD89)	  	   eBiosciences	   1/1000	  Monoclonal	  Rat-­‐anti	  mouse	  CD23	  (B3B4)	  	   eBiosciences	   1/100	  Monoclonal	  Rat-­‐anti	  mouse	  CD25	  (PC61.5)	   eBiosciences	   1/200	  Monoclonal	  Rat-­‐anti	  mouse	  CD38	  (90)	  	   eBiosciences	   1/600	  Monoclonal	  Rat-­‐anti	  mouse	  CD43	  (eBioR2/60)	  	   eBiosciences	   1/100	  Monoclonal	  Rat-­‐anti	  mouse/human	  CD45R	  (B220)	  (RA3-­‐6B2)	  	   eBiosciences	   1/400	  Monoclonal	  Rat-­‐anti	  mouse	  CD69	  (H1.2F3)	  	   eBiosciences	   1/200	  Monoclonal	  Rat-­‐anti	  mouse	  BP-­‐1	  (6C3)	  	   eBiosciences	   1/100	  Monoclonal	  mouse-­‐anti	  BrdU	  (PBR-­‐1)	  	   BD	   1/5	  Monoclonal	  mouse	  anti-­‐human	  IgM	  (G20-­‐127)	  	   BD	   1/1000	  Streptavidin	  (APC)	   eBiosciences	   1/800	  Streptavidin	  (FITC)	   eBiosciences	   1/400	  	  
6.4.3 CFSE	  labeling	  	  Single-­‐cell	  suspensions	  of	  primary	  λ-­‐MYC	  lymphoma	  cells	  or	  their	  cell	  line	  derivatives	  were	  washed	  three	  times	  in	  PBS	  followed	  by	  labeling	  for	  10	  min	  at	  37°C	  with	  serum-­‐free	   RPMI	   media	   containing	   0.5	   µM	   (final	   concentration)	   5-­‐(and-­‐6)-­‐carboxyfluorescein	   diacetate,	   succinimidyl	   ester	   (CFDA);	   Molecular	   Probes,	   USA)	  (Lyons	   and	   Parish,	   1994).	   The	   labeling	   reaction	   was	   stopped	   adding	   10	   ml	  DMEM/10%	  FBS.	  Subsequently,	  labeled	  cells	  were	  washed	  once	  in	  B-­‐cell	  medium	  and	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seeded	   at	   a	   density	   of	   1x106	   cells/ml.	   20	   million	   tumor	   cells	   were	   injected	   into	  syngeneic	  recipients	  after	  CFSE-­‐labeling	  for	  in	  vivo	  homing	  experiments.	  
6.4.4 Measurement	  of	  glucose	  uptake	  Highly	  purified	  BCR+	  and	  BCR-­‐	  lymphoma	  cells	  were	  grown	  under	  normal	  conditions,	  plated	   at	   5x105/ml	   and	   incubated	  O/N	  at	   37°C,	   5%	  CO2.	  For	   glucose	  uptake	   assays,	  100	   μM	   2-­‐NBDG	   (Invitrogen)	  was	   added	   to	   the	  media	   for	   2	   hr.	   Cells	  were	  washed	  with	  PBS,	  counted	  and	  BCR+	  and	  BCR-­‐	  cells	  were	  mixed	  in	  equal	  amount	  and	  stained	  for	  IgM	  expression	  as	  described	  above.	  Fluorescence	  was	  measured	  in	  a	  FACSCalibur	  Analyzer	  (BD).	  
6.4.5 Cell	  cycle	  analysis	  BCR+	  and	  BCR-­‐	   lymphoma	  cells	  were	  plated	  at	  a	  density	  of	  5x105\ml	  and	   incubated	  O/N	  at	  37°C,	  5%	  CO2.	  BCR+	  and	  BCR-­‐	   cells	  were	  mixed	   in	  equal	  amount	  and	  pulsed	  with	  33	  µMf	  BrdU	  (Sigma),	  for	  5	  minutes,	  at	  37°C,	  5%	  CO2.	  Cells	  were	  washed	  3	  times	  with	  cold	  PBS	  and	  surface	  stained	  for	  IgM	  was	  performed.	  	  1x106	  cells	  were	  stained	  in	  50	  µl	  of	  FACS	  buffer,	  for	  20	  min	  at	  4˚C	  in	  dark	  and	  subsequently	  washed	  twice	  with	  200	   µl	   of	   FACS	   buffer.	   Surface	   stained	   cells	   were	   fixed	   in	   BD	   Cytofix/Cytoperm™	  buffer	  for	  20	  min	  at	  room	  temperature	  (RT)	  in	  U	  bottom	  96	  well	  microplate,	  washed	  by	  Perm/Wash™	  Buffer	  (P/W)	  and	  re-­‐fixed	  in	  BD	  Cytofix/Cytoperm™	  Plus	  buffer	  for	  10	   minutes,	   at	   RT,	   light	   protected.	   Cells	   were	   washed	   with	   P/W	   and	   incubated	   5	  minutes	  with	  BD	  Cytofix/Cytoperm™	  buffer,	  at	  RT,	  light	  protected,	  and	  washed	  again	  with	  P/W.	  Fixed	  cells	  were	  treated	  with	  300	  µg/ml	  DNAse	  for	  at	  least	  1	  hour,	  at	  37°C,	  washed	  with	  P/W,	  and	  stained	  with	  anti-­‐BrdU-­‐FITC	  conjugated	  antibody,	  30	  minutes,	  RT.	  Stained	  cells	  were	  washed	  two	  times,	  re-­‐suspended	  in	  1	  ml	  of	  cold	  PBS	  containing	  propidium	  iodide	  (50	  µg/ml,	  Sigma)	  and	  RNase	  (250	  µg/ml),	  and	  incubated	  overnight	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at	   4°C.	   Samples	   were	   acquired	   by	   FACSCalibur	   (BD)	   and	   analyzed	   using	   FlowJo	  software.	  	  
6.4.6 Apoptosis	  analysis	  For	  detection	  of	  apoptotic	  cells	  CaspGLOWTM	  Fluorescein	  Active	  Caspase	  Staining	  Kit	  (Biovision)	  was	   used,	  with	   specific	  modifications	   in	   protocol.	   In	  vitro	   cultured	   cells	  were	   incubated	   in	   100	   µl	   of	   B	   cell	   medium	   containing	   1	   µl	   of	   FITC-­‐VAD-­‐FMK	  (carbobenzoxy-­‐valyl-­‐alanyl-­‐aspartyl-­‐[O-­‐methyl]-­‐	   fluoromethylketone),	   a	   cell-­‐permeable	  pan	  caspase	  inhibitor	  that	  irreversibly	  binds	  to	  the	  catalytic	  site	  of	  caspase	  proteases,	  for	  1	  h	  at	  37°C	  and	  5%	  CO2.	  Cells	  were	  collected	  by	  centrifugation	  (280	  g	  for	   5	   min)	   and	   washed	   with	   200	   µl	   of	   wash	   buffer.	   If	   required	   cells	   were	   stained	  following	   the	   protocol	   of	   chapter	   6.4.1	   (Flow	   cytometry	   and	   cell	   sorting	   analysis),	  acquired	  by	  FACSCalibur	  (BD)	  and	  analyzed	  using	  FlowJo	  software.	  	  
6.4.7 Phospho	  flow	  cytometric	  analysis	  	  106	  cells	  BCR+	  and	  BCR-­‐	  were	  fixed	  in	  2%	  paraformaldehyde,	  washed	  in	  PBS,	  and	  re-­‐suspended	   in	   90%	   ice-­‐cold	  methanol	   at	   -­‐20°C for	   at	   least	   30	  min.	   Cells	  were	   then	  washed	  three	  times	  in	  PBS/2%	  FCS	  before	  incubation	  with	  antibodies	  against	  surface	  markers	  as	  well	  as	  with	  a	  specific	  Rabbit	  anti-­‐mouse	  phospho-­‐GSK3β,	   for	  30	  min,	  at	  RT.	  Unconjugated	  phospho-­‐GSK3β	   antibody	  was	  detected	  by	  subsequent	   incubation	  with	   Cy5-­‐conjugated	   goat	   anti–rabbit	   antibody	   (30	   minutes,	   RT).	   Cells	   were	   then	  washed	  twice	  and	  analyzed	  by	  flow	  cytometry	  using	  FACSCalibur	  (BD).	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6.5 Biochemical	  techniques	  
6.5.1 Immunoblotting	  analysis	  Cells	  were	  harvested	  by	  centrifugation	  for	  5	  min	  at	  280	  g	  and	  washed	  in	  cold	  PBS.	  For	  protein	  extraction	  cell	  pellet	  was	  resuspended	  in	  8	  M	  Urea	  lysis	  buffer	  (8	  M	  Urea,	  0.1	  M	  NaH2PO4,	  0.01	  M	  Tris	  pH	  8.0)	  or	  RIPA	  buffer	  (10	  mM	  Tris-­‐HCl,	  pH	  8.0,	  1%	  Triton,	  0.1%	  SDS,	  0.1%	  Deoxycholate,	  140	  mM	  NaCl,	  1	  mM	  EDTA,	  1	  mM	  DTT,	  1	  mM	  PMSF	  and	  protease	  inhibitor	  cocktail	  Set	  III	  (EDTA-­‐free,	  Calbiochem,),	  and	  incubated	  1	  hour	  on	   ice.	   Sonication	   was	   performed	   in	   2-­‐3	   cycles	   of	   10	   sec	   each.	   Lysates	   were	  centrifuged	  at	  maximum	  speed	  for	  10	  min	  to	  remove	  debris.	  Lysates	  were	  quantified	  with	   a	   protein	   assay	   reagent	   (Bio-­‐Rad	   Laboratories).	   20	   -­‐	   50	   µg	   of	   proteins,	   in	  Laemmli	   loading	   buffer	   (62.5	   mM	   Tris-­‐HCl	   pH	   6.8,	   2	   %	   (w/v)	   SDS,	   5	   %	   (v/v)	   2-­‐mercaptoethanol	  and	  10	  %	  (v/v)	  glycerol)	  and	  10	  µl	  of	  NOVEX	  ®	  Sharp	  Pre	  Stained	  protein	   standard	   (Invitrogen)	   were	   run	   onto	   10%	   SDS-­‐polyacrylamide	   gel	  electrophoresis	   and	   transferred	   by	   dry	   iBlot®	   Dry	   Blotting	   Device	   (Invitrogen)	   to	  nitrocellulose	   membranes	   (iBlot®	   Transfer	   Stack,	   Invitrogen)	   in	   6	   minutes.	   After	  blotting,	   the	   membranes	   were	   stained	   with	   Ponceau	   S	   staining	   solution	   (0.1	   %	  Ponceau	   S	   (w/v)	   and	   5%	   acetic	   acid	   (w/v)	   to	   verify	   equal	   loading	   and	   transfer.	  Membranes	   were	   briefly	   washed	   in	   water	   and	   blocked	   for	   1	   h	   at	   RT	   in	   blocking	  solution	  5%	  BSA,	  or	  5%	  milk,	  in	  TBS-­‐T	  (20	  mM	  Tris	  HCl	  pH	  7.4,	  500	  mM	  NaCl,	  0,1	  %	  Tween).	   After	   blocking,	   filters	   were	   incubated	   with	   primary	   antibodies	   (Table	   6),	  diluted	   in	   blocking	   solution,	   for	   1-­‐2	   hours	   at	   RT	   or	   overnight	   at	   4°C.	   After	   three	  washes,	   of	   5	  min	   each	   in	   TBS-­‐T,	  membranes	  were	   incubated	  with	   the	   appropriate	  horseradish	   peroxidase	   (HRP)	   conjugated	   secondary	   antibody	   diluted	   in	   blocking	  solution	  (Table	  6),	  for	  30	  min,	  at	  room	  temperature.	  Membranes	  were	  washed	  three	  times	  for	  5	  min	  in	  TBS-­‐T	  and	  the	  bound	  secondary	  antibody	  was	  revealed	  using	  the	  ECL	  (Enhanced	  Chemiluminescence)	  plus	  method	  (Amersham).	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Table	  6:	  Antibodies	  used	  for	  immunoblot	  protein	  detection	  
Primary	  Abs	   Residue	   Clone	   Dilution	  factor	   Source	  Rabbit	  α	  p-­‐Syk	   Tyr	  525/526	   Polyclonal	   1/1000	  (BSA)	   Cell	  signaling	  Rabbit	  α-­‐Syk	   	   Polyclonal	   1/1000	  (BSA)	   Cell	  signaling	  Rat	  α	  phosho-­‐tyrosine	   	   4G10	   1/1000	  (BSA)	   Millipore	  Rabbit	  α-­‐phospho-­‐MYC	  	   Thr	  58	   Polyclonal	   1/500	  (BSA)	   Santa	  Cruz	  Mouse	  α-­‐Vinculin	   	   hVIN-­‐1	   1/20000	  (MILK)	   Sigma	  Mouse	  α-­‐TP53	   	   Polyclonal	   1/1000	   Santa	  Cruz	  
Secondary	  Abs	   	   	   	   	  Goat	  α	  mouse	  Ig	   Polyclonal	   170-­‐6516	   1/20000	   BioRad	  Goat	  α	  rabbit	  Ig	   Policlonal	   170-­‐6515	   1/20000	   BioRad	  	  
6.5.2 Mitochondrial	  respiration	  BCR+	   and	   BCR-­‐	   lymphoma	   cells	   were	   cultured	   at	   2x105\ml	   for	   24	   hours.	   Equal	  numbers	   of	   BCR+	   or	  BCR-­‐	   cells	  were	   loaded	   into	   an	   oxygraph	   chamber	   and	   oxygen	  consumption	  was	  measured.	   	   Baseline	   respiration	  was	  measured	   in	   the	   absence	   of	  exogenous	   substrates;	   cells	   were	   then	   stimulated	   with	   the	   protonophore	  carbonylcyanide-­‐4-­‐(trifluoromethoxy)-­‐phenylhydrazone	   (FCCP;	   0.05	   mM)	   	   and	  uncoupled	   respiration	   was	   measured.	   Finally,	   antimycin	   A	   (2.5	   μM)	   was	   used	   to	  inhibit	   cytochrome	   bc1	  complex	   (complex	   III),	   thus	   allowing	   non-­‐mitochondrial	  respiration	  to	  be	  measured.	  Respiration rates were measured for each condition by an 
average value of the oxygen flux within a region of stable, consistent oxygen 
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6.5.3 Measurement	  of	  Lactate	  dehydrogenase	  activity	  	  LDH	   activity	   in	   lymphoma	   cells	   was	   defined	   by	   measurement	   of	   NADH	   levels	   in	  supernatant	   of	   cultured	   cells.	   BCR+	   or	   BCR-­‐	   cells	   were	   seeded	   at	   2x105\ml	   and	  supernatant	   was	   collected	   48	   hours	   later.	   NADH	   levels	   were	   determined	   using	  Lactate	   Dehydrogenase	   Activity	   Assay	   Kit	   (BioVision),	   according	   to	  manufacturer’s	  protocol.	  NADH	  binding	  to	  a	  specific	  probes	  results	  in	  a	  colorimetric	  reaction	  (λmax=	  450	  nm),	  and	  optical	  density	  (OD)	  was	  measured	  using	  a	  microplate	  reader	  (WALLAC	  VICTOR3,	   PerkinElmer)	   at	   time	   zero	   (A1),	   and	   after	   incubating	   the	   reaction,	   light	  protected,	   at	   37°C	   for	   30	   min	   (A2)	   (or	   longer	   if	   the	   LDH	   activity	   was	   low).	   The	  difference	   between	   the	   two	   reads	   (∆A450	   nm	   =	   A2	   -­‐	   A1)	   was	   then	   calculated.	  Background	  values	  were	  subtracted	   from	  all	   readings.	  ∆A450nm	  of	   the	  sample	  was	  applied	  to	  a	  NADH	  standard	  curve	  to	  get	  “B”	  (the	  NADH	  amount	  that	  was	  generated	  between	  T1	  and	  T2).	  LDH	  Activity	  was	  then	  calculated	  as	  following:	  
!"#  !"#$%$#& = !!2− !1 ∗ ! ∗ !"#$%&  !"#$%"&' =   !"#$/!"#/!"   =   !"/!"	  Where:	  	  	  
• B	  is	  the	  NADH	  amount	  that	  was	  generated	  between	  t1	  and	  t2	  (in	  nmol).	  
• 	  t1	  is	  the	  time	  of	  first	  reading	  (A1)	  (in	  min).	  	  
• t2	  is	  the	  time	  of	  second	  reading	  (A2)	  (in	  min).	  	  
• V	  is	  the	  pre-­‐treated	  sample	  volume	  added	  into	  the	  reaction	  well	  (in	  ml).	  Unit	   definition:	  One	  unit	   of	   LDH	   is	   the	   amount	   of	   enzyme	   that	   generates	  1.0	   	   µmol	  NADH	  per	  minute	  at	  37°C	  in	  the	  provided	  buffer	  system.	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6.6 Stable	  Isotope	  Labelling	  Aminoacid	  in	  Cell	  Culture	  (SILAC)	  	  
6.6.1 Aminoacid	  Labeling	  of	  lymphoma	  B	  cells	  BCR+	  and	  BCR-­‐	   lymphoma	  cells	  were	  grown	   in	  SILAC	  media,	  prepared	  as	  described	  previously	   (Ong	   et	   al.,	   2002).	   Briefly,	   cells	  were	   grown	   in	   lysine-­‐	   and	   arginine-­‐free	  DMEM/Ham’s	  F12	  (1:1),	  supplemented	  with	  10%	  dialyzed	  fetal	  bovine	  serum	  (FBS,	  Invitrogen).	  “Heavy”	  and	  “Light”	  media	  were	  prepared	  by	  adding	  0.146	  g/L	  13C6,	  15N2	  L-­‐Lysine	  and	  0.84	  g/L	  13C6	  15N4	  L-­‐Arginine	  (Sigma)	  or	  the	  corresponding	  non-­‐labelled	  amino	   acids,	   respectively.	   Growth	   in	   SILAC	   media	   was	   carried	   out	   for	   eight	  replications,	  to	  ensure	  complete	  protein	  labelling.	  Equal	  numbers	  (12x106)	  of	  heavy	  and	  light	  labelled	  cell	  population	  were	  mixed	  and	  lysed	  in	  300	  µl	  RIPA	  buffer.	  Briefly,	  protein	   extracts	  were	   Trypsin	   digested	   in	   solution	   overnight.	   To	  maximize	   protein	  identification,	   sample	   complexity	   was	   reduced	   by	   peptide	   fractionation	   using	  isoelectric	  focusing	  (IEF)	  (See	  below,	  6.6.2	  In	  solution	  digestion	  and	  off-­‐gel	  separation	  
of	   peptide	   mixtures).	   Liquid	   chromatography	   was	   coupled	   with	   tandem	   mass	  spectrometry	   on	   a	   high-­‐resolution	   instrument	   (LTQ-­‐FT	  Ultra	   Thermo	   Scientific;	   for	  details	   see	   below	   6.6.3,	   Liquid	   chromatography	   and	   Mass	   Spectrometry).	   The	  experiment	  was	  performed	  in	  triplicate.	  
6.6.2 In	  solution	  digestion	  and	  off-­‐gel	  separation	  of	  peptide	  mixtures	  Total	  protein	  extracts	  (150	  µg)	  from	  BCR+	  and	  BCR-­‐	  lymphoma	  cells	  were	  dissolved	  in	  denaturation	   solution	   (6	   M	   urea,	   2	   M	   thiourea	   in	   20	   mM	   ammonium	   hydrogen	  carbonate)	   for	   30	   min.	   After	   complete	   denaturation,	   extracts	   were	   supplemented	  with	   1	   mM	   DTT	   and	   incubated	   for	   additional	   30	   minutes.	   Thyols	   were	  carboxymethylated	  with	  5	  mM	  IAA	  for	  20	  minutes	  and	  the	  proteins	  were	  digested	  by	  addition	   of	   1	   μg	   LysC	   for	   3	   h.	   After	   4-­‐fold	   dilution	   with	   50	   mM	   ammonium	   bi-­‐carbonate,	  1	  μg	  trypsin	  was	  added	  and	  the	  sample	  was	  incubated	  overnight	  at	  37°C.	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The	   digestion	   was	   terminated	   by	   acidifying	   the	   sample	   to	   pH<2	   with	   100%	   TFA.	  Product	   peptides	   were	   then	   separated	   according	   to	   their	   isoelectric	   point	   (pI)	   by	  isoelectrofocusing	  electrophoresis,	  using	  the	  Agilent	  3100	  OFFGEL	  Fractionation	  Kit	  (Agilent	  Technologies)	  (Hubner	  et	  al.,	  2008).	  Samples	  were	  prepared	  and	  separated	  according	  to	  the	  manufacturer’s	  protocol.	  After	  separation,	  peptides	  mixtures	  focused	  at	   different	   pH	  were	   reconstituted	  with	   1%	  TFA	   and	   desalted	   and	   purified	   on	   C18	  STAGE	  tips	  (Rappsilber	  et	  al.,	  2007).	  
6.6.3 Liquid	  chromatography	  and	  Mass	  Spectrometry	  Peptides	   eluted	   from	  C18	  Stage-­‐tips	  were	  analyzed	  by	  nano-­‐liquid	   chromatography	  using	   an	   Agilent	   1100	   Series	   nano-­‐flow	   LC	   system	   (Agilent	   Technologies),	   directly	  interfaced	   to	   a	   LTQ-­‐FT	  Ultra	  mass	   spectrometer	   (ThermoFisher	   Scientific,	   Bremen,	  Germany).	  The	  nano-­‐liter	   flow	  LC	  was	  operated	   in	  one	  column	  set-­‐up	  with	  a	  15	  cm	  analytical	   column	   (75	   lm	   inner	   diameter,	   350	   lm	  outer	   diameter)	   packed	  with	   C18	  resin	  (ReproSil,	  Pur	  C18AQ	  3	   lm,	  Dr.	  Maisch,	  Germany).	  Solvent	  A	  was	  0.1%	  FA	  and	  5%	   ACN	   in	   ddH2O	   and	   19	   solvent	   B	   was	   95%	   ACN	   with	   0.1%	   FA.	   Samples	   were	  injected	  in	  an	  aqueous	  0.1%	  TFA	  solution	  at	  a	  flow	  rate	  of	  500	  nl/min.	  We	  used	  140	  min	  gradient	  from	  2%	  to	  60%	  acetonitrile	  in	  0.5%	  acetic	  acid.	  Nanoelectrospray	  ion	  source	  (Proxeon,	  Odense,	  Denmark)	  was	  used	  with	  a	  spray	  voltage	  of	  1.5–2.0	  kV.	  No	  sheath,	   sweep	  and	  auxiliary	  gasses	  were	  used	  and	  capillary	   temperature	  was	  set	   to	  180°C.	   The	   mass	   spectrometer	   was	   operated	   in	   a	   data-­‐dependent	   mode	   to	  automatically	   switch	   between	  MS	   and	  MS/MS	   acquisition.	   In	   the	   LTQ-­‐FT	  Ultra,	   full	  scan	   MS	   spectra	   were	   acquired	   at	   a	   target	   value	   of	   2,000,000	   ions	   and	   with	   a	  resolution	  of	  100,000	  (FWHM)	  at	  400	  m/z.	  In	  the	  LTQ	  MS/MS,	  spectra	  were	  acquired	  using	  a	  target	  value	  of	  5,000	  ions	  and	  the	  five	  most	  intense	  ions	  were	  isolated	  for	  CID-­‐fragmentation.	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6.6.4 Analysis	  of	  proteomics	  data	  	  Identification	   and	   quantification	   of	   proteins	   was	   carried	   out	   using	   the	   MaxQuant	  software	   package	   v.	   1.2.2.5	   (Cox	   and	  Mann,	   2008;	   Cox	   et	   al.,	   2011).	   The	   integrated	  Andromeda	  algorithm	  was	  used	  to	  search	  the	   IPI	  Mouse	  protein	  sequence	  database	  (v.3.87,	  Sep	  2011).	  A	  maximum	  of	  two	  missed	  cleavages	  were	  permitted.	  Oxidation	  of	  Methionine	   and	   acetylation	   of	   the	   protein	   N-­‐terminus	   were	   used	   as	   variable	  modifications.	  Carbamidomethylation	  of	  cysteine	  was	  used	  as	  a	  fixed	  modification.	  A	  minimum	   peptide	   length	   of	   6	   residues	   was	   required	   and	   the	   maximum	   false	  discovery	  rates	  were	  set	  to	  1%	  at	  both	  the	  protein	  and	  peptide	  levels.	  To	  determine	  at	  high	   confidence	   a	   qualitative	   proteome,	   each	   MaxQuant-­‐defined	   proteinGroup	  required	   a	  minimum	   of	   three	   peptide	  matches,	   of	   which	   at	   least	   two	  were	   unique	  from	   all	   peptides	   identified.	   Therefore,	   to	   determine	   an	   accurate	   quantitative	  proteome,	  a	  minimum	  of	  three	  ratio	  counts	  (RC>2)	  was	  considered.	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6.7 Statistical	  analysis	  
6.7.1 Student’s	  t-­‐test	  Statistical	  analysis	  of	  normally	  distributed	  values	  (Gaussian)	  was	  performed	  by	  two-­‐tailed	   unpaired	   Student’s	   t-­‐test.	   Differences	   were	   considered	   significant	   at	   p-­‐
value<0.05.	  
6.7.2 2-­‐way	  ANOVA	  Statistical	   analysis	   to	   compare	   two	   independent	   variables	   in	   grouped	   samples	  was	  performed	   using	   2-­‐way	   ANOVA	   test.	   Differences	   were	   considered	   significant	   at	   p-­‐
value<0.05.	  
6.7.3 Chi-­‐square	  with	  Yates	  correction	  Statistical	  analysis	   to	   test	   independence	   in	  contingency	   tables	  was	  performed	  using	  chi-­‐squared	   test	   with	   Yates	   correction.	   Differences	   were	   considered	   significant	   at	  
p<0.05	  
6.7.4 Statistical	  analysis	  of	  the	  microarray	  data	  	  Microarray	   analysis	   was	   performed	   on	   Affymetrix	  Mouse	   Gene	   1.1	   ST	   arrays.	   Raw	  data	   (CEL	   files)	   were	   filtered	   and	   normalized	   with	   Affymetrix	   Power	   Tools	   (APT)	  Software	   Package,	   using	   the	   rma-­‐sketch	   algorithm	   to	   generate	   Log2	   transformed	  intensity	   values.	   Log2	   transformed	   data	   were	   annotated	   and	   analyzed	   using	   the	  annotation	   “pd.mogene.1.1.st.v1”	   (Benilton	   Carvalho,	   Platform	   Design	   Info	   for	  Affymetrix	   MoGene-­‐1_1-­‐st-­‐v1;	   R	   package	   version	   3.6.0),	   “mogene11stprobeset.db”	  (Arthur	  Li,	  Affymetrix	  Mouse	  Gene	  1.1	  -­‐	  ST	  Array	  Probeset	  Revision	  4	  annotation	  data	  (chip	   mogene11stprobeset);	   R	   package	   version	   4.0.1.),	  “mogene11sttranscriptcluster.db”	   (Arthur	   Li,	   Affymetrix	   Mouse	   Gene	   1.1-­‐ST	   Array	  Transcriptcluster	  Revision	  4	   annotation	  data	   (chip	  mogene11sttranscriptcluster);	  R	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package	   version	   4.0.1.)	   and	   the	   “affy”	   (Gautier	   et	   al.,	   2004)	   package	   of	   R	   software	  version	   2.16.0	   (http://www.r-­‐project.org).	   Genes	   with	   a	   cut-­‐off	   of	   1.5-­‐fold	   change	  over	  the	  baseline,	  in	  at	  least	  two	  independent	  tumors,	  were	  defined	  as	  differentially	  expressed	  and	  were	  included	  in	  the	  gene	  ontology	  analysis.	  
6.7.5 Gene	  Ontology	  analysis	  Gene	  Set	  Enrichment	  analysis	  was	  performed	  accessing	  the	  Gene	  Set	  Analysis	  Tool	  kit	  V2	   (Zhang	   et	   al.,	   2005)	   (http://bioinfo.vanderbilt.edu/webgestalt/)	   on	   September	  2012.	  A	  hypergeometric	  test	  was	  run	  to	  identify	  ten	  overrepresented	  Gene	  Ontology	  categories	   among	   Biological	   Process,	  Molecular	   Functions	   and	   Cellular	   Component.	  	  	  Adjusted	   p	   values	   were	   calculated	   applying	   Benjamini	   &	   Hochberg	   multiple	   test.	  Similarly	   a	   WIKIPathways	   Enrichment	   analysis	   was	   performed	   to	   identify	  overrepresented	  signaling	  pathways.	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7 RESULTS	  
7.1 The	  λ-­‐MYC	  lymphoma	  model	  
λ-­‐MYC	   transgenic	   mouse	   strain	   (Kovalchuk	   et	   al.,	   2000)	   has	   been	   considered	   for	  several	   years	   the	   best	  mouse	  model	   for	  BL,	   given	   the	   close	   similarity	   in	   its	   genetic	  features,	   immunophenotype	   and	   histological	   appearance	   with	   the	   human	   BL.	   This	  strain	  was	  generated	  by	  cloning	  the	  c-­‐MYC	  oncogene,	  derived	  from	  a	  human-­‐BL	  cell	  line,	  under	  the	  control	  of	  the	  Ig	  λ	  light	  chain	  regulatory	  elements,	  thus	  restricting	  its	  overexpression	  in	  B	  cell	  compartment,	  and	  more	  precisely,	  from	  pre-­‐B	  cell	  stage	  on.	  
λ-­‐MYC	  model	   overcomes	   the	   limitation	   of	   the	   Eµ-­‐MYC	  mouse	  model,	  where	   c-­‐MYC	  overexpression	   in	   pro-­‐B	   cells	   resulted	   in	   the	   development	   of	   lymphoblastic	  lymphoma	  rather	  than	  BL.	  For	  this	  reason,	  the	  λ-­‐MYC	  mouse	  model	  was	  used	  in	  the	  present	  study	  to	  investigate	  the	  role	  of	  the	  BCR	  in	  BL.	  	  	  
7.2 λ-­‐MYC;	  B1-­‐8f	  mice	  develop	  clonal	  Ig+	  B	  cell	  lymphomas	  To	  delete	  the	  BCR	  in	  a	  conditional	  manner,	  λ-­‐MYC	  transgenic	  mice	  (Kovalchuk	  et	  al.,	  2000)	  were	  bred	  to	  B1-­‐8f	  knock-­‐in	  animals,	  carrying	  a	  conditional	  pre-­‐rearranged	  VH	  gene	  inserted	  into	  the	  endogenous	  IgH	  locus	  (Lam	  et	  al.,	  1997)	  (Figure	  11).	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Figure	  11:	  The	  λ−MYC;	  B1-­‐8f	  lymphoma	  model	  
λ-­‐MYC	  mice	  expressing	  a	  human	  c-­‐MYC	  gene	  under	  the	  control	  of	  Ig	  light	  (igL)	  chain	  cis	  regulatory	  elements,	  were	  bred	   to	   conditional	   B1-­‐8f	   knock-­‐in	   mice	   carrying	   a	   pre-­‐rearranged	   Ig	   heavy	   (IgH)	   chain	   variable	   region	   gene,	  flanked	  by	  loxP	  sites	  inserted	  into	  the	  IgH	  locus	  replacing	  the	  JH	  segments.	  	  	  
λ-­‐MYC;B1-­‐8f	  double	   transgenic	  mice	  showed	  a	  median	  survival	  of	  122	  days	   (Figure	  12).	  By	  this	  time,	  animals	  suffered	  of	  macroscopic	   lymphadenopathy,	  splenomegaly,	  decreased	  motility,	   shaggy	   fur	   and,	   at	   advanced	   stages	  of	   tumor,	   cachexia	   and	   limb	  paralysis.	  	  	  
	  
Figure	  12:	  Survival	  of	  λ−MYC;	  B1-­‐8f	  mice	  
Kaplan-­‐Meier’s	  plots	  representing	  the	  survival	  of	  λ-­‐MYC;	  B1-­‐8f	  mice.	  Median	  survival	  was	  122	  days	  (n=43).	  	  	  Both	  male	  and	  female	  transgenic	  mice	  were	  equally	  affected.	  Histological	  analysis	  of	  the	  spleen	  of	  λ-­‐MYC;	  B1-­‐8f	  diseased	  animals	  revealed	  an	  expanded	  white	  pulp,	  and	  an	  infiltration	  of	  the	  red	  pulp	  by	  tumor	  cells.	  Tumors	  featured	  a	  “starry	  sky”	  appearance	  similar	   to	   human	   BL	   resulting	   from	   the	   presence	   of	   tissue	   macrophages	   clearing	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apoptotic	   cell	   debris	   (Figure	   13a).	   Upon	   dissection	   of	   diseased	   animals,	   flow	  cytometric	  analysis	  revealed	  the	  dissemination	  of	  large	  (FSChi)	  CD19+	  CD43+	  tumor	  B	  cells	   in	   spleen	   (SPL),	   bone	  marrow	   (BM)	   and	   lymph	  nodes	   (LN)	  where	   tumor	   cells	  frequently	  replaced	  the	  resident	  lymphocyte	  population	  (Figure	  13b).	  
	  
Figure	   13:	  λ-­‐MYC;B1-­‐8f	  mice	   develop	   tumors	   resembling	   human	  Burkitt	   lymphoma	   by	   histological	   and	  
immunophenotypic	  appearance	  
a)	   Hematoxylin	   and	   eosin	   staining	   of	   spleen	   sections	   from	   a	   representative	   λ-­‐MYC;B1-­‐8f	   diseased	   animal,	  revealing	  expanded	  red	  pulp	  and	  infiltrated	  white	  pulp	  (middle	  panel)	  and	  a	  characteristic	  starry	  sky	  appearance,	  comprised	  of	  sheets	  of	  neoplastic	  lymphoid	  cells	  with	  round	  to	  irregular	  nuclei	  and	  multiple	  distinct	  nucleoli,	  and	  numerous	   tingible	  body	  macrophages	   (400x,	  black	  arrows).	  Upper	  panel	   shows	  a	   representative	   spleen	  section	  from	   a	   C57BL6/J	   control	  mouse.	   Upper	   and	  middle	   picture:	  magnification	   X20,	   lower	   X400;	  b)	   Representative	  FACS	  analysis	  of	  single-­‐cell	  suspensions	  from	  lymphoid	  organs	  of	  a	  representative	  λ-­‐MYC;B1-­‐8f	  diseased	  animal.	  Dot	  plots	  are	  gated	  on	  live	  B220+	  B	  cells.	  An	  aged-­‐matched	  C57BL6/J	  wild-­‐type	  (WT)	  animal	  was	  used	  as	  control.	  	  Immunophenotypic	  analysis	  of	  B	   lymphoma	  cells	  revealed	  the	  expression	  of	  surface	  markers	  shared	  with	  B-­‐cell	  progenitors	  (CD43	  and	  AA4.1),	  immature/mature	  B	  cells	  (IgM,	   CD38)	   and	   most	   importantly	   with	   human	   BL	   (such	   as	   IgM,	   CD19,	   B220	   and	  CD43).	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Figure	  14:	  Immunophenotype	  of	  λ-­‐MYC;	  B1-­‐8f	  primary	  lymphoma	  B	  cells	  
Flow	  cytometric	  determination	  of	  surface	  expression	  levels	  of	  the	  indicated	  markers	  in	  CD19+	  splenic	  wild-­‐type	  B	  cells	  (filled	  grey	  line),	  tumor	  B	  cells	  (thick	  black	  line)	  and	  CD19-­‐	  non-­‐B	  cells	  (red	  thin	  line).	  
	  
Figure	  15:	  λ−MYC;B1-­‐8f	  tumors	  are	  clonal	  	  
Analysis	   by	   genomic	   PCR	   of	   IgL	   VκJκ	   V-­‐gene	   rearrangements	   in	   control	   (C57BL/6)	   CD19+	   B	   cells	   and	   in	   10	  independent	   primary	  λ−MYC;B1-­‐8f	   lymphomas.	   The	   4	   PCR	   bands	   amplified	   in	   the	   control	   sample	   identify	   VkJk	  rearrangements	   using	   respectively,	   Jk1,	   Jk2,	   Jk3,	   and	   Jk5	   segments.	   In	   all	   tumor	   samples	   a	   single-­‐PCR	  band	  was	  visible	  confirming	  the	  clonal	  nature	  of	  lymphomas.	  The	  1Kb	  ladder	  size	  ladder	  (first	  lane)	  was	  used	  to	  determine	  the	  size	  of	  the	  PCR	  fragments.	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A	   representative	   immunophenotypic	   analysis	   of	   λ-­‐MYC;B1-­‐8f	   lymphoma	   B	   cells	   is	  shown	  in	  Figure	  14,	  and	  the	  repertoire	  of	  surface	  molecules	  expressed	  on	  λ-­‐MYC;B1-­‐8f	  tumor	  B	  cells	  pointed	  to	  an	  immature	  B	  cell	  phenotype.	  Importantly,	   analysis	   of	   VJ	   rearrangements	   on	   the	   Igκ	   locus	   from	   10	   independent	  tumors	  confirmed	  the	  monoclonal	  nature	  of	  λ-­‐MYC;B1-­‐8f	  lymphomas	  (Figure	  15).	  
7.2.1 Basal	  BCR	  signaling	  in	  λ-­‐MYC;	  B1-­‐8f	  lymphomas	  The	  survival	  of	   resting	  mature	  B-­‐cells	   is	   strictly	  dependent	  on	  a	   tonic,	   low-­‐strength	  signal	  emanating	  from	  the	  BCR,	  since	  genetic	  deletion	  of	  the	  receptor,	  or	  its	  signalling	  components,	   represents	   a	   “sentence	  of	  death”	   for	   a	   lymphocyte	   (Kraus	  et	   al.,	   2004;	  Lam	   et	   al.,	   1997).	   BCR-­‐dependent	   signalling	   is	   initiated	   by	   receptor-­‐associated	  tyrosine	  kinases	  of	  the	  Src	  family	  (Lyn,	  Fyn,	  and	  Blk)	  (Saijo	  et	  al.,	  2003)	  and	  of	  the	  Syk	  family	   (Syk	  and	  Zap-­‐70)	  (Rowley	  et	  al.,	  1995).	  Activated	  Syk	  and	  Src-­‐family	  protein	  kinases	  phosphorylated	  specific	  proteins,	  such	  as	  CD19	  or	  BCAP	  (B-­‐cell	  PI3K	  adapter	  protein)	  that	  mediate	  the	  recruitment	  of	  PI3K	  to	  the	  plasma	  membrane,	  promoting	  its	  activation	   (Okkenhaug	   and	   Vanhaesebroeck,	   2003).	   Concomitant	   depletion	   of	   BCR	  and	   activation	   of	   candidate	   signalling	   pathways	   in	   mature	   B-­‐lymphocytes	   in	   vivo	  provided	  evidence	  that	  B	  cells	  without	  BCRs	  can	  survive	  and	  accumulate	  only	  in	  the	  presence	   of	   a	   constitutively	   active	   PI3K	   (Srinivasan	   et	   al.,	   2009).	   In	   fact,	   the	  establishment	   of	   either	   a	   constitutive	   mitogen-­‐activated	   protein	   kinase	   (MAPK)	  pathway,	   a	   constitutive	   Rac1	   pathway,	   or	   a	   constitutive	   non-­‐canonical	   NF-­‐κB	  pathway,	  was	   not	   able	   to	   rescue	   B	   cells,	   devoid	   of	   BCRs,	   from	   death.	   Interestingly,	  deletion	  of	  FOXO1	  alone	  also	  rescued	  B	  cells	  without	  BCRs,	  suggesting	  that	  the	  PI3K-­‐AKT-­‐FOXO	  axis	  is	  crucial	  in	  supporting	  BCR-­‐driven	  signals	  that	  mediate	  survival	  of	  B	  cells	  (Srinivasan	  et	  al.,	  2009).	  The	  signal	  emanating	  from	  the	  BCR	  in	  resting	  B	  cells	  is	  weaker	  than	  that	  triggered	  in	  response	   to	   antigen	   recognition	   that	   leads	   to	   a	   robust	   activation	   of	   downstream	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signaling	   pathways	   such	   as	   the	   NF-­‐kB,	   PI3K	   and	   MAPK	   pathways,	   responsible	   for	  inducing	  cell	  proliferation	  and	  differentiation.	  	  The	   activation	   status	   of	   the	   BCR	   signalling	   pathway	   in	   primary	   λ-­‐MYC;B1-­‐8f	  lymphomas	   was	   assessed	   by	   immunoblot	   analysis.	   The	   levels	   of	   total	   tyrosine-­‐phosphorylated	   proteins,	   as	   well	   as	   phosphorylation	   of	   specific	   effectors	   of	   BCR-­‐signalling,	   were	   compared	   between	   primary	   lymphoma	   cells	   and	   both	   resting	   and	  BCR-­‐activated	  wild-­‐type	  splenic	  B	  cells.	  	  
	  
Figure	  16:	  λ-­‐MYC;B1-­‐8f	  lymphoma	  B	  cells	  show	  basal,	  tonic	  BCR	  signalling	  
a)	   Immunoblot	   analysis	   to	   measure	   total	   levels	   of	   phosphotyrosine	   proteins	   in	   protein	   extracts	   from	   three	  independent	  primary	  B-­‐cell	  lymphomas	  (#2567,	  #2646	  and	  #2676,	  respectively).	  Ex	  vivo	  isolated	  CD19+	  splenic	  B	  cells	   before	   (resting)	   and	   after	   (anti-­‐F(ab)2))	   BCR	   cross-­‐linking	   were	   used	   as	   reference.	   Vinculin	   levels	   were	  measured	  to	  control	  for	  protein	  input	  b)	  Immunoblot	  analysis	  of	  phosphorylated	  Syk	  (pSyk)	  in	  three	  independent	  primary	  λ-­‐MYC	  lymphomas	  (#2567,	  #2646	  and	  #2676,	  respectively)	  before	  (-­‐)	  and	  after	  (+)	  BCR	  crosslinking	  (α-­‐IgM	  F(ab)2	  ab).	  Ex	  vivo	   isolated	  CD19+	  splenic	  B	  cells	  were	  used	  as	  controls.	  Total	  Syk	   levels	  were	  measured	   to	  control	  for	   loading	  differences.	  Predicted	  Syk	  molecular	  weight	  (MW)	  is	  72	  kDa.	  Normalized	  phospho-­‐Syk	  levels	  are	   shown	   in	   the	   lower	  panel.	  Bars	   indicate	   fold	   change	   in	  phospho-­‐Syk	   levels	   compared	   to	   those	  measured	   in	  resting	  CD19+	  splenic	  B	  cells.	  
MW	   MW	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As	  shown	  in	  Figure	  16,	  the	  pattern	  of	  phospho-­‐tyrosine	  proteins	  in	  three	  independent	  lymphomas	   closely	   resembled	   that	   of	   resting	   B	   cells.	   Moreover,	   phosphorylation	  levels	   of	   the	   Syk	   tyrosine	   kinase,	   an	   essential	   proximal	   effector	   of	   BCR	   signalling,	  were	  comparable	  between	  lymphoma	  and	  wild-­‐type	  resting	  mature	  splenic	  B	  cells.	  	  	  These	   results	   indicate	   that	  λ-­‐MYC;B1-­‐8f	   tumor	   B	   cells	   receive	   a	   tonic	   low-­‐strength	  signal	  from	  their	  BCR.	  Finally,	  I	  could	  show	  that	  crosslinking	  of	  the	  BCR	  in	  lymphoma	  cells	  led	  to	  a	  robust	  increase	  in	  total	  tyrosine-­‐phosphorylated	  protein	  levels	  as	  well	  as	  Syk	  phosphorylation,	  pointing	  to	  a	  functionally	  competent	  BCR	  expressed	  by	  tumor	  B	  cells.	  
7.2.2 λ-­‐MYC;B1-­‐8f	  lymphomas	  expand	  in	  vitro	  and	  in	  vivo	  upon	  transplantation	  Single	   cell	   suspensions	   of	   primary	   λ-­‐MYC;B1-­‐8f	   lymphoma	   B	   cells	   isolated	   from	  lymphoid	   organs	   of	   diseased	   animals,	   were	   cultured	   in	   vitro	   in	   complete	   B	   cell	  medium.	   	   An	   initial	   phase	   of	   cell	   death	   was	   followed	   by	   an	   exponential	   growth	   of	  lymphoma	  B	   cells	   that	   had	   adapted	   to	   the	   in	  vitro	  culture	   conditions.	   Lymphoma	  B	  cells	   showed	   a	   doubling	   time	   ranging	   between	   12	   to	   24	   hours	   (Figure	   17).	   The	  establishment	  of	  stable	  cell	  lines	  was	  often	  associated	  with	  the	  property	  of	  lymphoma	  cells	  to	  shorten	  the	  doubling	  time.	  	  
	  
Figure	  17:	  Ex	  vivo	  isolated	  lymphoma	  cells	  grow	  in	  vitro	  
In	  vitro	  growth	  curve	  of	  purified	  λ-­‐MYC;B1-­‐8f	  primary	  lymphomas	  (#2676	  or	  #2646).	  Tumor	  cells	  were	  counted	  every	  24	  hours	  and	  diluted	  every	  second	  day.	  Each	  time	  point	  represents	  the	  average	  count	  of	  three	  replicates.	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To	  determine	  the	  ability	  of	  lymphoma	  cells	  to	  give	  rise	  to	  secondary	  tumors,	  ex	  vivo	  isolated	   λ-­‐MYC;B1-­‐8f	   tumor	   cells	   were	   transplanted	   into	   non-­‐irradiated,	  immunoproficient	  syngeneic	  recipients	  through	  tail-­‐vein	  injection.	  	  Recipient	  mice	   were	   sacrificed	   20	   days	   after	   transplantation	   and	   lymphoid	   organs	  analyzed	   for	   the	   presence	   of	   tumor	   cells.	   Lymphoma	   cells	   were	   identified	   by	   flow	  cytometry	   in	  all	   lymphoid	  organs	  on	   the	  basis	  of	   their	  size	   (FSChi)	  and	   their	  unique	  surface	   marker	   combination	   (IgM+CD43+)	   (Figure	   18).	   Histological	   analysis	  confirmed	   the	   presence	   of	   aggressive	   B-­‐cell	   lymphomas	   in	   the	   lymphoid	   organs	   of	  recipients,	   often	   associated	   to	   the	   identification	   of	   tumor	   cells	   in	   non-­‐lymphoid	  organs	  including	  lung	  and	  liver.	  	  
	  
Figure	  18:	  λ−MYC;B1-­‐8f	  lymphoma	  B	  cells	  give	  rise	  to	  secondary	  tumors	  upon	  transplantation	  	  
Representative	  flow	  cytometric	  analysis	  of	  splenic	  cell	  suspensions	  obtained	  from	  wild-­‐type	  (WT)	  CB6F1	  mice	  and	  similar	   animals	   transplanted	   three	   weeks	   earlier	   with	   3	   million	   λ−MYC;B1-­‐8f	   lymphoma	   cells	   (#1970).	  Immunophenotype	  of	  CD19-­‐gated	  B	  cells	  are	  shown.	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7.2.3 λ-­‐MYC	  lymphomas	  retain	  surface	  BCR	  expression	  after	  prolonged	  in	  vitro	  and	  in	  
vivo	  growth	  	  The	   development	   of	   clonal	   B-­‐cell	   malignancies	   in	   λ-­‐MYC	   mice	   reflects	   the	  accumulation	   of	   secondary	   genetic	   alterations	   in	   B	   cells	   expressing	   the	   λ-­‐MYC	  transgene.	  	  The	  most	  common	  alterations	  found	  in	  c-­‐MYC	  transformed	  B	  cells	  include	  the	   loss	   of	   the	   tumor	   suppressor	   loci	   Trp53	   and	   Cdkn2a	   (Schmitt	   et	   al.,	   1999).	   	   In	  accordance	   with	   published	   results,	   we	   found	   that	   the	  ?-­‐MYC;B1-­‐8f	   mice	   primary	  lymphomas	   suffered	   from	  either	  biallelic	   inactivation	  of	  Cdkn2a	  or	   accumulation	  of	  inactivating	  mutations	  affecting	  p53	  protein	   stability	  (Figure	  19	  and	   (Mezzanzanica	  et	  al.,	  2004).	  	  
Figure	   19:	   Status	   of	   Cdkn2a	   and	   Trp53	   loci	   in	  
λ−MYC;B1-­‐8f	  lymphoma	  B	  cells.	  	  
Measurement	   by	   genomic	   PCR	   of	   the	   status	   of	  Cdkn2a	  and	  Trp53	  loci	  in	  three	  independent	  λ−MYC	  lymphomas.	  For	  the	  assessment	  of	  the	  Cdkn2a	  locus,	  I	  performed	  a	  competitive	  PCR	  using	  simultaneously	  primers	   annealing	   specifically	   to	   Cdkn2a	   and,	   as	  control,	   Ezh2.	   Arrows	   indicate	   the	   amplicons	  corresponding	   to	   the	   indicated	   genes.	   DNA	   from	  C57BL/6	  wild	  type	  was	  used	  as	  control	  	  
Figure	   20:	   p53	   protein	   is	   stabilized	   in	  
λ−MYC;B1-­‐8f	  tumor	  cells.	  	  
Immunoblot	   analysis	   of	   TP53	   protein	   measured	   in	  protein	  extracts	  from	  ex	  vivo	  isolated	  resting	  B	  cells	  (CD19+	   B	   cells),	   and	   lymphoma	   cells	   derived	   from	  three	   independent	   λ−MYC;B1-­‐8f	   mice	   (#2567,	  #2646	  and	  #2676).	  Measurement	  of	  Vinculin	   levels	  was	  performed	  to	  control	  for	  protein	  input.	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  A	  previous	  report	  had	  shown	  that λ−MYC	   primary	   lymphomas	   and	   their	   cell	   line	  derivatives	   suffer	   from	   a	   high	   degree	   of	   genomic	   instability,	   including	   large-­‐scale	  chromosomal	   aberrations	   (Rockwood	   et	   al.,	   2002).	   This	   condition	  may	   lead	   to	   the	  acquisition	   over	   time	   of	   additional	   genetic	   alterations	   that	   may	   render	   lymphoma	  cells	  independent	  of	  the	  BCR,	  and	  thus	  facilitate	  the	  isolation	  of	  BCR-­‐less	  tumors.	  	  To	  test	  this	  possibility,	  ex	  vivo	  isolated	  lymphoma	  cells	  were	  cultured	  for	  prolonged	  time	  
in	   vitro	   or	   serially	   transplanted	   into	   non-­‐irradiated,	   syngeneic	   recipient	   mice,	   and	  monitored	  for	  BCR	  expression.	  	  
	  
Figure	  21:	  λ−MYC;B1-­‐8f	   lymphoma	   cells	   retain	  BCR	   expression	   even	   after	   prolonged	   in	  vitro	   culture	   or	  
serial	  transplantation	  
a)	  Flow	  cytometric	  analysis	  of	   surface	   IgM	   levels	   in	  ex	  vivo	  isolated	  primary	   lymphoma	  cells	  before	   (ex	  vivo)	  or	  after	   prolonged	   in	   vitro	  culture	   (over	   50	   passages).	   Two	   independent	   primary	   lymphomas	   #2676	   and	   #2646)	  were	   assessed;	   b)	   Representative	   flow	   cytometric	   analysis	   of	   surface	   IgM	   levels	   in	   a	   primary	   λ−MYC	   tumor	  (#50780),	   and	   in	   lymphomas	   retrieved	   from	   the	   spleen	   of	   CB6F1	   recipients	   after	   serial	   transplantations.	  Histograms	   indicated	  FSChi	  CD19+	  cells	  gated	  tumor	  cells;	  CD19-­‐	   IgM-­‐	  cells	  (filled	  grey	  histograms)	  were	  used	  as	  negative	  control.	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Extended	  growth	  both	  in	  vitro	  	  (Figure	  21a)	  and	  in	  vivo	  (Figure	  21b)	  of	  lymphoma	  cells	  was	  associated	  to	  the	  retention	  of	  surface	  Ig	  expression,	  thus	  suggesting	  a	  selective	  requirement	  for	  the	  antigen	  receptor	  to	  control	  lymphoma	  survival	  and/or	  proliferation	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7.3 Inducible	  BCR	  inactivation	  in	  λ-­‐MYC;B1-­‐8f	  lymphomas	  	  	  In	  this	  section,	  I	  will	  describe	  the	  effects	  of	  BCR	  inactivation	  on	  the	  in	  vitro	  and	  in	  vivo	  growth	  properties	  of	  λ-­‐MYC;B1-­‐8f	  B	  lymphoma	  cells.	  	  To	  ablate	  BCR	  expression	  in	  transformed	  B	  cells,	  we	  took	  advantage	  of	  the	  Cre/loxP	  recombination	   technology.	   Specifically,	   ex	   vivo	   isolated	   B	   lymphoma	   cells	   were	  subjected	   to	   a	  Tat-­‐Cre	  protein	   transduction	  protocol	   (Joshi	   et	   al.,	   2002;	   Peitz	   et	   al.,	  2002).	   Tat-­‐Cre	   is	   a	   recombinant	   protein	   consisting	   of	   Cre-­‐recombinase	   fused	   to	   a	  short	  peptide	  from	  the	  HIV	  Tat	  protein	  allowing	  passive	  diffusion	  through	  the	  plasma	  cell	   membrane	   (Schwarze	   et	   al.,	   2000).	   	   We	   developed	   a	   protocol	   that	   allowed	  efficient	   Cre-­‐mediated	   recombination	   at	   the	   B1-­‐8f	   allele,	   while	   minimizing	   the	  exposure	  time	  of	  tumor	  cells	  to	  Cre	  activity,	  preventing	  thereby	  possible	  toxic	  effects	  exerted	  by	  the	  recombinase	  (Schmidt-­‐Supprian	  and	  Rajewsky,	  2007).	  Upon	   Tat-­‐Cre	   transduction	   of	   primary	   lymphoma	   cells	   (or	   tumor	   cells	   grown	   in	  cultures	   for	   a	   limited	  number	  of	  passages),	   I	  monitored	  by	   flow	  cytometry	  analysis	  surface	   BCR	   expression	   of	   treated	   cells.	   A	   population	   of	   BCRlow	   tumor	   cells	   was	  already	  visible	  24	  hours	  after	   transduction	  and	  became	  clearly	  distinct	   from	  that	  of	  the	  BCR+	  counterparts	  in	  the	  following	  day,	  ranging	  between	  30	  and	  60	  percent	  of	  all	  tumor	  cells	  (Figure	  22a).	  	  
7.3.1 BCR	  ablation	  causes	  the	  disappearance	  of	  lymphoma	  cells	  in	  vitro	  To	  study	   the	   impact	  of	  BCR	  deletion	  on	   lymphoma	  cells,	  ex	  vivo	   isolated	  primary	  λ-­‐MYC;B1-­‐8f	  tumor	  cells	  were	  cultured	  for	  few	  days,	  TAT-­‐Cre	  transduced	  and	  BCR+	  and	  BCR-­‐	  cells	  monitored	  over	  the	  following	  days	  by	  flow	  cytometry	  analysis.	  BCR+	  tumor	  cells	   expanded	   exponentially	   in	   vitro,	   in	   contrast	   to	   their	   BCR–	   counterparts	   that	  gradually	  disappeared	  from	  the	  cultures.	  Depending	  on	  the	  initial	  ratio	  between	  BCR+	  and	  BCR-­‐	   lymphoma	   cells,	   from	  5	   to	  10	  days	   after	  Tat-­‐Cre	   transduction	   Ig-­‐negative	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tumor	   cells	  were	   hardly	   detectable	   in	   culture.	   The	   disappearance	   in	   vitro	  of	   tumor	  cells	   following	   BCR	   inactivation	   has	   been	   observed	   in	   4	   independent	   lymphomas	  (Figure	  22a).	  	  The	  loss	  of	  BCR-­‐negative	  cells	  was	  confirmed	  by	  Southern	  blot	  analysis.	  Specifically,	  the	   band	   corresponding	   to	   the	   B1-­‐8	   allele	   that	   had	   undergone	   Cre-­‐mediated	  recombination	   (B1-­‐8∆)	   was	   no	   longer	   detected	   in	   tumor	   samples	   isolated	   starting	  from	  day	  3	  of	  TAT-­‐cre	  transduction	  (Figure	  22b).	  This	   result	   excludes	   the	   possibility	   that	   the	   BCR+	   population	   contains	   tumor	   cells	  expressing	   a	   different	   BCR,	   as	   a	   result	   of	   secondary	   IgH	   gene	   rearrangements	  triggered	  by	  B1-­‐8f	  inactivation.	  	  
7.3.2 BCR	  loss	  impairs	  lymphoma	  outgrowth	  in	  vivo	  under	  competitive	  conditions	  I	  next	  assessed	  whether	  the	  loss	  of	  the	  antigen	  receptor	  interfered	  with	  the	  ability	  of	  lymphoma	   cells	   to	   grow	   in	   vivo.	   Primary	   λ−MYC;B1-­‐8f	   lymphomas	   were	   ex	   vivo	  isolated,	   expanded	   in	   culture	  and	   subjected	   to	  TAT-­‐Cre	   transduction	   to	   induce	  BCR	  inactivation.	  48	  hours	  after	  transduction,	  lymphoma	  cells	  were	  purified	  by	  magnetic	  cell	  sorting	  (MACS)	  on	  the	  basis	  of	  BCR	  expression,	  and	  allowed	  to	  grow	  for	  three	  to	  five	  days	   in	  culture.	  Finally,	  an	  equal	  number	  of	  BCR+	  and	  BCR-­‐	   tumor	  cells	  was	  co-­‐injected	  through	  the	  tail	  vein	  into	  syngeneic	  immunoproficient	  mice	  (Figure	  23	  upper	  panels).	   I	   also	   injected	   highly	   purified	   (>95%)	   BCR+	   or	   BCR-­‐-­‐only	   tumor	   cells	   in	  another	   set	   of	   recipients.	   Recipients	   were	   sacrificed	   18	   to	   21	   days	   after	  transplantation,	   when	   signs	   of	   tumor	   outgrowth	   were	   clearly	   manifest.	   Cell	  suspensions	  were	  retrieved	  from	  lymphoid	  organs	  of	  recipient	  mice	  and	  analyzed	  by	  flow	  cytometry	  (Figure	  23	  lower	  panels).	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Figure	   22:	   BCR	   ablation	   promotes	   the	   rapid	  
disappearance	  of	  λ-­‐MYC	  lymphomas	  in	  vitro	  
a)	   Flow	   cytometric	   analysis	   of	   in	   vitro	   cultures	   of	   4	  independent	  ?-­‐MYC;	  B1-­‐8f	   tumor	  B	   cells	   upon	  TAT-­‐Cre	  transduction.	   Percentage	   of	   IgM+	   and	   IgM-­‐	   lymphoma	  cells	   at	   the	   indicated	   time	   points,	   before	   and	   after	   TAT-­‐Cre	   transduction,	   are	   displayed.	   Dot	   plots	   are	   gated	   on	  live	   FSChi	   B	   cells;	   b)	   Status	   of	   the	   B1-­‐8	   allele	   in	   B	  lymphoma	   cell	   cultures	   at	   the	   indicated	   days	   after	   TAT-­‐Cre	  transduction	  revealed	  by	  Southern	  blot	  analysis.	  Size	  and	   position	   of	   bands	   corresponding	   respectively	   to	   the	  conditional	  (B1-­‐8f,)	  and	  Cre-­‐deleted	  (B1-­‐8∆)	  B1-­‐8	  allele	  and	  the	  IgH	  germline	  (GL)	  gene	  are	  indicated.	  Note	  that	  mice	  are	  heterozygous	  for	  the	  B1-­‐8f	  knock-­‐in	  gene.	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Mice	  that	  received	  only	  BCR+	  tumor	  cells	  displayed	  a	  sizeable	  fraction	  of	  tumor	  cells	  in	   primary	   and	   secondary	   lymphoid	   organs.	   	   In	   accordance	   with	   the	   in	   vitro	  data,	  lymphoma	  cells	  retrieved	  from	  mice	  transplanted	  with	  the	  mixture	  of	  BCR+	  and	  BCR-­‐	  cells	  showed	  a	  consistent	  counterselection	  of	  Ig-­‐negative	  lymphomas	  that	  were	  in	  all	  cases	   detected	   in	   very	   low	   amounts	   (tumor	   cell	   numbers	   obtained	   from	   the	  transplantation	  of	  four	  independent	  lymphomas	  is	  provided	  in	  Table	  7).	  
	  
Figure	  23:	  BCR	  ablation	  interferes	  with	  the	  tumorigenic	  potential	  of	  λ-­‐MYC	  lymphomas	  in	  vivo	  
FACS	  analysis	  of	  single	  BCR+	  and	  BCR-­‐	  primary	  lymphoma	  populations	  (#2567;	  left	  and	  right	  plots)	  or	  1:1	  mixtures	  (middle	  plot)	  derived	  from	  λ-­‐myc;B1-­‐8f	  mouse	  transduced	  in	  vitro	  with	  	  Tat-­‐Cre,	  before	  (Day	  0)	  or	  19	  days	  after	  their	  transplantation	  in	  syngeneic	  recipients.	  Cells	  in	  transplanted	  mice	  were	  retrieved	  from	  the	  spleen.	  Dot	  plots	  are	  gated	  on	  live	  FSChi	  cells.	  Numbers	  represent	  percentage	  of	  gated	  cells.	  	  Noteworthy,	   tumor	   latency	   in	  mice	   transplanted	  with	  purified	  BCR-­‐	   lymphoma	  cells	  was	  prolonged.	  This	  condition	  was	  often	  associated	  with	  reduced	  numbers	  of	  tumor	  cells	   infiltrating	  lymphoid	  organs	  of	  recipients.	  Strikingly,	   in	  most	  cases,	  tumor	  cells	  retained	   surface	   Ig	   expression,	   likely	   originating	   from	   the	   few	   contaminating	   BCR+	  tumor	   cells	   that	   remained	   in	   the	   BCR-­‐	   lymphoma	   mixture	   that	   was	   injected.	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Altogether,	   these	   results	   reveal	   a	   strict	   requirement	   for	   BCR	   expression	   for	  lymphoma	   cell	   survival/proliferation	   when	   tumors	   are	   grown	   under	   competitive	  conditions.	  	  
	  
Table	  7:	  Numbers	  of λ-­‐MYC	  lymphoma	  cells	  retrieved	  after	  transplantations	  of	  BCR+/BCR-­‐	  1:1	  mixtures.	  	  
Summary	   of	   the	   data	   relative	   to	   absolute	   numbers	   of	   BCR+	   and	   BCR-­‐	   lymphoma	   cells	   generated	   from	   four	  independent	   primary	   lymphomas,	   retrieved	   from	   the	   spleen	   of	   recipient	   animals	   after	   their	   injection	   as	   a	   1:1	  mixture.	  Each	   tumor	  competition	  was	   transplanted	   into	  3	   recipients,	  which	  were	   sacrificed	  between	  18	  and	  21	  days	   after	   transplantation.	   Average	   numbers	   of	   IgM+	   (black	   bars)	   and	   IgM-­‐	   (grey	   bars)	   tumor	   cells	   (±	   SD)	   are	  shown.	  
7.3.3 λ-­‐MYC	  lymphomas	  home	  primarily	  to	  the	  bone	  marrow	  regardless	  of	  Ig	  status	  	  	  The	   failure	   of	   BCR-­‐deficient	   lymphoma	   cells	   to	   expand	   in	   vivo	   could	   reflect	   the	  inability	  of	  the	  tumor	  cells	  to	  migrate	  to	  sites	  that	  support	  their	  growth.	  To	  test	  this	  possibility,	   two	   independent	   BCR+	   lymphomas	   (#2646	   and	   #2676)	   and	   their	   BCR-­‐	  derivatives	   (generated	  by	  TAT-­‐Cre	   transduction),	  were	   labeled	  with	   the	   fluorescent	  cell	   tracker	   5-­‐(and-­‐6)-­‐Carboxyfluorescein	   Diacetate-­‐Succinimidyl	   Ester	   (CFSE)	   and	  intravenously	   injected	   in	   equal	   amount	   into	   non-­‐irradiated	   syngeneic	  mice	   (Figure	  24a).	   Recipient	   animals	   were	   sacrificed	   respectively	   two	   and	   forty-­‐four	   hours	  following	  transplantation,	  and	  lymphoid	  organs	  were	  analyzed	  by	  flow	  cytometry	  for	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the	  presence	  of	  CFSE-­‐labeled	  cells.	  Tumor	  cells	  first	  reached	  the	  bone	  marrow	  where	  they	   represented	   0.2-­‐0.6%	   of	   all	   CD19+	   B	   cells	   two	   hours	   after	   transplantation	  (Figure	   24b	   upper	   panel).	   Importantly,	   the	   ratio	   between	   BCR+	   and	   BCR-­‐	   cells	  was	  comparable	   to	   that	   of	   the	   injected	  mixture,	   pointing	   to	   a	  normal	  migration	  of	  BCR-­‐deficient	  lymphoma	  cells	  to	  lymphoid	  sites.	  
	  	  
Figure	  24:	  Normal	  homing	  to	  the	  bone	  marrow	  of	  BCR-­‐less	  lymphoma	  cells	  	  
a)	  Flow	  cytometric	  analysis	  of	  IgM+	  and	  IgM-­‐	  lymphoma	  cells,	  obtained	  after	  Tat-­‐cre	  transduction	  of	  2	  independent	  primary	  lymphomas	  (#2646	  and	  #2676),	  stained	  with	  CFSE	  at	  the	  time	  of	  their	  transplantation	  as	  a	  1:1	  mixture	  in	  syngeneic	   recipient;	   b)	   Flow	   cytometric	   analyses	   of	   bone	   marrow	   cells	   respectively	   2	   h	   and	   44	   h	   after	  transplantation	  are	   shown.	  Dot	  plots	  are	  gated	  on	   live	  CD19+	   cells.	  Numbers	   indicate	  percentage	  of	   cells	   falling	  within	  the	  indicated	  quadrants.	  	  Strikingly,	  by	  44	  hours	  post-­‐transplantation,	  BCR+	  tumor	  cells	  from	  lymphoma	  #2676	  were	  largely	  overrepresented	  indicating	  a	  rapid	  loss	  of	  receptor-­‐negative	  lymphoma	  cells	  (note:	  a	  BCR+/-­‐	  ratio	  of	  2:1	  at	  the	  time	  of	  injection	  increased	  to	  6:1,	  44	  hours	  after	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transplantation;	   Figure	  24b,	   lower	  panel).	   These	   results	   reveal	   a	   rapid	   clearance	  of	  BCR-­‐negative	  tumor	  cells	  after	  reaching	  their	  niche.	  
7.3.4 Ig-­‐deficient	  lymphomas	  gain	  growth	  competence	  upon	  BCR	  restoration	  High	   levels	  of	  Cre	  expression	  can	  exert	   toxic	  effects	  on	  mammalian	  cells	  (Higashi	  et	  al.,	  2009;	  Schmidt-­‐Supprian	  and	  Rajewsky,	  2007;	  Silver	  and	  Livingston,	  2001).	  To	  test	  whether	  the	  disappearance	  of	  BCR-­‐deficient	  lymphoma	  cells	  was	  due	  to	  a	  toxic	  effect	  exerted	  by	  Cre	  recombinase,	  we	  generated	  a	  retroviral	  vector	  allowing	  the	  expression	  of	   a	   functional	   IgH	   chain	   consisting	   of	   the	   variable	   region	   encoded	   by	   the	   VH186.2	  (B1-­‐8)	   gene	   that	   could	   be	   distinguished	   by	   flow	   cytometry	   using	   allotype-­‐specific	  antibodies.	   Specifically,	   λ−MYC;B1-­‐8f	   tumor	   cells	   (IgHa+)	   were	   infected	   with	   the	  retrovirus	   expressing	   IgHb	   to	   become	   IgHa+IgHb+	   double-­‐positives.	   The	   latter	   were	  subsequently	   transduced	   with	   TAT-­‐Cre	   to	   inactivate	   the	   B1-­‐8f/IgHa	   gene	   (Figure	  25a).	  Cre-­‐transduced,	  IgHb-­‐expressing	  tumor	  cells	  were	  mixed	  in	  equal	  amounts	  with	  BCR-­‐	   tumor	   cells	   infected	  with	   a	   control	   virus	   and	   allowed	   to	   grow	   in	   competition	  both	  in	  vitro,	  and	  in	  vivo.	  If	   BCR-­‐	   cells	   suffered	   from	   genetic	   aberrations	   caused	   by	   Cre	   recombinase,	  complementation	  with	  a	  novel	  IgH	  chain	  will	  not	  improve	  their	  ability	  to	  outcompete	  IgM-­‐	   tumor	   cells.	   Instead,	   IgH-­‐complemented	   tumor	   cells	   reacquired	   the	   ability	   to	  outcompete	   their	   receptor-­‐less	   counterparts	   over	   a	   short	   period	   of	   in	   vitro	  culture	  (Figure	   25b,	   upper	   panel).	   Moreover,	   transplantation	   of	   mixtures	   of	   IgH-­‐complemented	   and	   BCR-­‐	   lymphoma	   cells	   led	   after	   three	   weeks	   to	   the	   preferential	  expansion	   of	   IgH-­‐complemented	   cells	   both	   in	   the	   spleen	   and	   bone	   marrow	   of	  recipients	  (Figure	  25b	   lower	  panel).	  These	  experiments	  rule	  out	   the	  possibility	   that	  the	   disappearance	   of	   BCR-­‐	   tumor	   cells	   depend	   on	   a	   toxic	   effect	   exerted	   by	   Cre	  recombinase.	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Figure	   25:	   Expression	   of	   a	   novel	   IgH	  
rescues	  BCR-­‐deficient λ-­‐MYC	  cells	  
a)	  Primary	  λ-­‐MYC;B1-­‐8f	  (IgMa+)	  lymphoma	  cells	   were	   infected	   with	   a	   retrovirus	  expressing	   allotype-­‐b	   IgM	   (IgMb)	   in	  combination	  with	   the	  GFP	   reporter	   (green	  stars).	   	   IgMa;IgMb	   double	   positive	   (GFP+)	  cells	  were	  Tat-­‐Cre	  transduced	  to	  induce	  the	  loss	   of	   IgMa.	   	   IgMa-­‐IgMb+	   cells	   were	   finally	  mixed	   in	   equal	   amounts	   with	   BCR-­‐	   GFP+	  lymphoma	   cells	   (infected	   with	   a	   GFP	  control	   virus)	   and	   cultured	   in	   vitro	   for	   9	  days	  or	  transplanted	   in	  vivo	   into	  syngeneic	  mice.	   b)	   Summary	   table	   representing	   the	  average	  fraction	  of	  GFP+	  tumor	  B	  cells	  with	  the	   indicated	   surface	   Ig	   phenotype	  retrieved	  from	  bone	  marrow	  (BM)	  and	  spleen	  (SPL)	  of	  two	  transplanted	  mice	  before	  and	  27	  days	  after	  injection.	  A	  similar	  analysis	  was	  performed	  for	  tumor	  cells	  grown	  as	  1:1	  mixtures	  in	  vitro	  for	  9	  days.	  	  	  
7.3.5 BCR-­‐	  lymphoma	  cells	  expand	  in	  vivo	  in	  the	  absence	  of	  their	  BCR+	  counterparts	  The	   evidences	   provided	   so	   far	   indicate	   that	   the	   BCR	   is	   critical	   for	   lymphoma	   cell	  survival	   and\or	   proliferation,	   under	   conditions	   of	   competitive	   growth	   both	   in	  vitro	  and	  in	  vivo.	  In	  order	  to	  investigate	  whether	  the	  BCR	  controls	  lymphoma	  survival	  in	  a	  cell	   autonomous	   fashion,	   tumor	   B	   cells	   isolated	   from	   two	   independent	   primary	   λ-­‐
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MYC;B1-­‐8f	   mice	   (#2646	   and	   #2676)	   were	   allowed	   to	   expand	   in	   vitro	   for	   few	  passages,	  TAT-­‐Cre	  transduced,	  and	  cloned	  by	  limiting	  dilution.	  	  	  
	  
Figure	  26:	  	  Pure	  BCR-­‐	  cells	  grow	  in	  vitro	  as	  their	  BCR+	  counterparts	  	  
Growth	  curves	  of	  respectively	  BCR-­‐	  (grey	  line)	  and	  BCR+	  (black	  line)	  tumor	  cells	  grown	  alone.	  Cells	  were	  obtained	  from	  primary	  λ-­‐MYC;B1-­‐8f	  lymphoma	  #2676	  (left	  panel)	  and	  #2646	  (right).	  Cells	  were	  counted	  and	  diluted	  every	  24	  hours.	  Each	  time	  point	  represents	  the	  average	  count	  of	  three	  replicates.	  
	  Surprisingly,	   purified	   BCR–	   tumor	   cells	   grew	   to	   the	   same	   extent	   as	   their	   BCR+	  counterparts	   (Figure	   26),	   in	   striking	   contrast	   to	   their	   rapid	   disappearance	   when	  grown	  in	  competition.	  Interestingly,	  I	  identified	  few	  BCR-­‐	  tumor	  clones	  that	  were	  no	  longer	   counterselected	   by	  BCR+	   tumors,	   pointing	   to	   the	   selection	   of	   cells	   that	   have	  accumulated	  additional	  genetic	  mutations	  overcoming	  the	  need	  for	  a	  functional	  BCR	  (Figure	  27,	  left	  plots,	  #2567	  clone).	  In	  accordance	  with	   the	   in	  vitro	  data,	  BCR-­‐	  tumor	  expanded	  successfully	   in	   lymphoid	  organs	   of	   recipients	   only	   in	   the	   absence	   of	   their	   BCR+	   counterparts	   (Figure	   28a).	  However,	  whereas	   the	   injection	  of	  BCR+	   tumor	  cells	  killed	  recipients	  on	  average	  17	  days	  after	  transplantation,	  the	  same	  number	  of	  BCR-­‐deficient	  lymphomas	  showed	  an	  appreciable	   delay	   in	   causing	   lethality	   of	   injected	   animals	   	   (23	   days	   on	   average)	  (Figure	  28b).	  	  These	  data	  suggest	  that	  the	  contribution	  of	  the	  BCR	  to	  tumor	  growth	  becomes	  evident	  predominantly	  under	  conditions	  of	  inter-­‐clonal	  competition	  both	  in	  vitro	  and	  in	  vivo.	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Figure	  27:	  Prolonged	  cultures	  of	  receptor-­‐less	  lymphomas	  selects	  clones	  that	  become	  BCR-­‐independent	  	  
Flow	  cytometric	  analysis	  of	  BCR+/BCR-­‐	  tumor	  mixtures.	  BCR+	  and	  BCR-­‐	  cells	  were	  cloned	  by	  limiting	  dilution	  of	  a	  mixture	  of	  Tat-­‐Cre	  transduced	  λ-­‐myc;B1-­‐8f	   lymphoma	  cells	   from	  three	   independent	  tumors	  (#2567,	  #2646	  and	  #2676).	   IgM	   expression	   was	   evaluated	   at	   the	   indicated	   time	   points.	   Dot	   plots	   are	   gated	   on	   FSChi	   live	   cells.	  Numbers	  represent	  percentage	  of	  displayed	  cells.	  Note	  the	  loss	  of	  BCR	  dependency	  of	  lymphoma	  #2567.	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Figure	  28:	  Pure	  BCR–	  lymphomas	  generate	  secondary	  tumors	  with	  longer	  latency	  
a)	   Flow	   cytometric	   analysis	   of	   BCR-­‐	   tumor	   cells	   cloned	   by	   limiting	   dilution	   from	   primary	   cultures	   of	   Tat-­‐Cre	  transduced	  #2676	  λ-­‐MYC;B1-­‐8f	   lymphoma	  cells.	  Cells	  were	   transplanted	  as	  such	  or	  as	  a	  1:1	  mixture	  with	  BCR+	  counterparts.	  Upper	  dot	  plots	  show	  frequency	  of	  BCR+	  and	  BCR-­‐	  at	  the	  time	  of	  transplantation.	  Lower	  plots	  display	  FACS	   analysis	   of	   tumor	   cell	   suspensions	   obtained	   from	   spleen	   of	   transplanted	   mice,	   sacrificed	   20	   days	   after	  transplantation.	  Dot	  plots	  are	  gated	  on	  FSChi	  live	  cells.	  Numbers	  represent	  percentage	  of	  cells;	  b)	  Cloned	  BCR-­‐	  and	  BCR+	  tumor	  cells	  obtained	  after	  transduction	  of	  lymphomas	  #2676	  or	  #2567	  were	  transplanted	  into	  independent	  recipient	   mice.	   Survival	   of	   mice	   (n=3)	   receiving	   either	   BCR+	   (black	   curve)	   or	   BCR-­‐	   (grey	   curve)	   tumors	   was	  compared.	  	  	  
7.3.6 BCR	  regulates	  G1-­‐to-­‐S	  transition	  in	  c-­‐MYC	  transformed	  B	  cells	  	  To	   elucidate	   the	   basis	   of	   the	   competitive	   disadvantage	   of	   BCR–	   tumor	   cells,	   I	  compared	  the	  cell-­‐cycle	  status	  of	  these	  cells	  to	  that	  of	  their	  BCR+	  counterparts.	  BCR+	  and	   BCR-­‐	   cells	   from	   four	   independent	   lymphomas	   were	   allowed	   to	   transiently	  incorporate	   the	   thymidine	   analogue,	   5-­‐bromodeoxyuridine	   (BrdU)	   followed	   by	  staining	  of	   the	  cells	  with	  Propidium	  Iodide	   (PI).	  This	  approach	  allows	   through	   flow	  cytometry	   analysis,	   the	   precise	   determination	   of	   the	   fraction	   of	   cells	   falling	   in	   the	  various	  stages	  of	   the	  cell	  cycle,	   including	  those	  actively	  undergoing	  DNA	  replication	  (Miltenburger	   et	   al.,	   1987;	   Sasaki	   et	   al.,	   1989;	   Vanderlaan	   and	   Thomas,	   1985).	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Primary	  lymphoma	  cells	  were	  Tat-­‐Cre	  transduced	  and	  BCR+	  and	  BCR-­‐	  lymphoma	  cells	  were	   cultured	   as	   1:1	   mixtures.	   At	   the	   stage	   when	   BCR-­‐	   cells	   were	   getting	   counter	  selected,	  the	  mixed	  tumor	  culture	  was	  pulsed	  with	  BrdU	  for	  5	  minutes.	  Staining	  of	  the	  cells	  with	  PI	  was	  coupled	   to	   incubation	  with	   fluorescent-­‐labeled	  anti-­‐BrdU	  and	   IgM	  staining.	   Three-­‐color	   flow	   cytometric	   analysis	   revealed	   that	   lymphoma	   cells	   were	  mainly	  distributed	  between	  the	  Go/G1	  and	  the	  S-­‐phase,	  regardless	  of	  surface	  Ig	  status.	  	  On	  average,	  cultures	  contained	  10%	  of	  cells	  in	  the	  G2/M	  phases	  of	  the	  cell	  cycle.	  The	  comparison	  between	  BCR+	  and	  BCR-­‐	  cells	   revealed	  significant	  differences	   in	   the	  cell	  cycle	  profiles.	  Indeed,	  BCR-­‐deficient	  tumors	  cells	  showed	  a	  higher	  fraction	  of	  cells	  in	  G0/G1	  compared	  to	  their	  BCR+	  counterparts	  (Figure	  29a).	  Conversely,	  the	  percentage	  of	   BCR-­‐	   lymphoma	   cells	   undergoing	   active	  DNA	   replication	   (BrdU+)	   in	   S-­‐phase	  was	  lower	  compared	  to	  that	  of	  the	  BCR+	  competitors.	  These	  results	  indicate	  that	  the	  BCR	  controls	  G1-­‐to-­‐S	  transition	  in	  c-­‐MYC	  transformed	  B-­‐cell	  lymphomas	  (Figure	  29a).	  	  We	   next	   asked	   whether	   the	   cell	   cycle	   alterations	   observed	   in	   BCR-­‐	   tumor	   cells	   in	  competition	   assays	   was	   dependent	   on	   the	   presence	   of	   their	   BCR+	   counterparts.	  Therefore,	  BCR+	  and	  BCR-­‐	   lymphoma	  cells	  (obtained	  by	  subcloning,	  or	  as	  a	  result	  of	  cell	   sorting)	   were	   cultured	   separately	   for	   several	   days	   before	   performing	   BrdU/PI	  cell-­‐cycle	   analysis.	   Interestingly,	   I	   failed	   to	   observe	   significant	   differences	   between	  the	  cell-­‐cycle	  profiles	  of	  BCR+	  and	  BCR-­‐	  lymphomas	  	  (Figure	  29b).	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Figure	  29:	  BCR	  regulates	  G1-­‐to-­‐S	  transition	  in	  λ-­‐MYC	  lymphoma	  B	  cells	  
a)	   Cell	   cycle	   analysis	   of	   BCR+	   and	   BCR-­‐	   lymphoma	   cells	   stained	   for	   BrdU	   incorporation	   and	   DNA	   content	  (propidium	  iodide,	  PI)	  were	  analyzed	  4	  days	  after	  a	  1:1	  in	  vitro	  competition	  assay	  (right	  panel).	  Summary	  of	  the	  data	   is	   shown	   on	   the	   left.	   The	   experiment	   was	   performed	   with	   lymphoma	   cells	   derived	   from	   4	   independent	  tumors	  (#2646,	  n=4;	  #2676	  n=6;	  #2564,	  n=5;	  #2487,	  n=6);	  b)	  Flow	  cytometric	  analysis	  of	  BrdU	  incorporation	  in	  highly	  enriched	  cultures	  of	  BCR+	  and	  BCR-­‐	  tumors.	  Summary	  of	  the	  data	  obtained	  from	  4	  independent	  lymphomas	  is	   shown	   in	   the	   left	   panel	   (#2646,	   n=6;	   #2676	  n=4;	   #2564,	   n=3;	   #2487,	   n=3).	  Numbers	   above	   each	   histogram	  indicate	  the	  ratio	  of	  the	  average	  percentage	  of	  BCR-­‐	  and	  BCR+	  tumor	  cells	  (±	  SD),	  in	  the	  indicated	  phases	  of	  the	  cell	  cycle.	  Cell	  doublets	  were	  excluded	  from	  the	  analysis.	  Numbers	  indicate	  percentage	  of	  cells.	  	  This	  result	  points	  to	  a	  critical	  contribution	  exerted	  by	  the	  BCR+	  tumor	  population	  to	  the	  cell-­‐cycle	  delay	  at	  the	  G1-­‐to-­‐S	  transition	  suffered	  by	  BCR-­‐	  negative	  lymphomas.	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7.3.7 Counter	  selection	  of	  BCR–	  tumor	  cells	  is	  associated	  with	  increased	  apoptosis	  I	   next	   tested	  whether	   aberrant	   cell	   death	   contributed	   to	   the	  disappearance	  of	  BCR-­‐	  lymphomas	   grown	   in	   the	   presence	   of	   the	   BCR+	   counterparts.	   Flow	   cytometric	  determination	  of	  DNA	  content	  using	  PI	  staining	  revealed	  a	  substantial	  percentage	  of	  BCR-­‐	   lymphoma	   cells	   with	   a	   hypodiploid	   (<2n)	   DNA	   content,	   representing	   cells	  undergoing	  apotosis	  (Figure	  30a	  and	  b).	  	  
	  
Figure	  30:	  The	  BCR	  protects	  lymphoma	  cells	  from	  apoptosis	  
a)	   Representative	   flow	   cytometric	   analysis	   of	   IgM+	   and	   IgM-­‐	   lymphoma	   B	   cells	   (#2487)	   5	   days	   after	   in	   vitro	  competition.	  Numbers	  in	  the	  histograms	  indicate	  frequencies	  of	  sub-­‐G1	  apoptotic	  cells	  b)	  Frequencies	  of	  apoptotic	  BCR+	  (black	  bars)	  and	  BCR-­‐	  (grey	  bars)	  lymphoma	  B	  cells,	  measured	  by	  flow	  cytometry	  according	  to	  DNA	  content	  (sub-­‐G1),	   at	   5	   days	   of	   in	   vitro	   competition.	   Tumor	   cells	   were	   from	   4	   independent	   lymphomas	   (#2646,	   #2676,	  #2564	  and	  #2487).	  Bars	  represent	  the	  average	  of	  3	  replicates	  (±	  SD)	  (t-­‐test:	  	  **p<0.001	  or	  *p<0.05).	  	  To	  confirm	  this	  result,	  the	  fraction	  of	  apoptotic	  cells	  was	  determined	  comparing	  the	  status	  of	  caspase	  activation	  in	  BCR+	  and	  BCR-­‐	  lymphomas.	  Activation	   of	   programmed	   cell-­‐death	   is	   associated	  with	   the	   proteolytic	   cleavage	   of	  pro-­‐caspases	   and	   the	   generation	   of	   active	   caspases	   (Durrieu	   et	   al.,	   1998).	   The	  fluorescent-­‐labeled	   pan-­‐caspase	   inhibitor	   peptide	   VAD-­‐FMK	   (carbobenzoxy-­‐valyl-­‐alanyl-­‐aspartyl-­‐[O-­‐methyl]-­‐fluoromethylketone)	   binds	   with	   varying	   affinity	   to	   a	  spectrum	   of	   active	   caspases	   (caspase-­‐1,	   -­‐3,	   -­‐4,	   -­‐5,	   -­‐7,	   -­‐8	   and	   -­‐9)	   (Smolewski	   et	   al.,	  2002),	  representing	  therefore	  a	  suitable	  tool	  to	  assess	  by	  flow	  cytometry	  the	  fraction	  
	   90	  
of	  cells	  undergoing	  apoptosis.	  Flow	  cytometric	  analysis	  of	  4	  independent	  λMYC;B1-­‐8f	  lymphomas	  transduced	  with	  Tat-­‐Cre,	  revealed	  a	  two	  to	  three	  fold	  higher	  percentage	  of	  apoptotic	  cells	  within	  the	  population	  of	  BCR–	  lymphomas	  as	  compared	  to	  the	  BCR+	  counterparts	  present	  in	  the	  same	  in	  vitro	  culture	  (Figure	  31a	  and	  b).	  	  
	  
Figure	  31:	  BCR	  inactivation	  triggers	  activation	  of	  caspases	  in	  λ-­‐MYC	  lymphomas	  
a)	  Representative	   flow	   cytometric	   analysis	   of	   IgM+	   and	   IgM-­‐	  B	   lymphoma	   cells	   (#2676)	   after	   5	   days	   of	   in	  vitro	  competition.	  Numbers	  within	  histogram	  plots	  indicate	  frequencies	  of	  apoptotic	  lymphoma	  cells	  expressing	  active	  caspases	  revealed	  through	  the	  staining	  with	  the	  caspase	  inhibitor	  VAD-­‐FMK;	  b)	  Frequencies	  of	  BCR+	  (black	  bars)	  and	  BCR-­‐	  (grey	  bars)	  lymphoma	  B	  cells	  expressing	  active	  caspase(s),	  measured	  by	  flow	  cytometry	  after	  5	  days	  of	  competition.	  Tumor	  cells	  were	  derived	  from	  4	  independent	  tumors	  (#2646,	  #2676,	  #2564	  and	  #2487).	  Columns	  represent	  fold	  change	  over	  BCR+	  caspase+	  tumor	  cells.	  	  These	  data,	  together	  with	  those	  on	  cell	  cycle	  analysis,	  are	  compatible	  with	  a	  scenario	  in	  which	  the	  competitive	  loss	  of	  BCR–	  tumor	  B	  cells	  is	  the	  result	  of	  a	  combination	  of	  impaired	  proliferation	  and	  increased	  programmed	  cell	  death.	  
7.3.8 Human	  Burkitt	  lymphoma	  RAMOS	  cells	  require	  BCR	  for	  in	  vitro	  growth	  To	   extend	   our	   findings	   to	   human	   BL,	   I	   analyzed	   the	   RAMOS	   BL	   cell	   line	   (Sale	   and	  Neuberger,	  1998).	  RAMOS	  cells	  carry	  the	  t(8;14)	  translocation	  	  juxtaposing	  c-­‐MYC	  	  to	  the	  IgH	  locus	  and,	  importantly,	   	  display	  ongoing	  Ig	  somatic	  hypermutation	  (Zhang	  et	  al.,	   2001).	  As	   a	   consequence	   of	   the	   latter,	   crippling	  mutations	   at	   IgH	   and/or	   IgL	  V-­‐genes	  cause	  the	  continuous	  generation	  of	  a	  minute	  fraction	  (less	  than	  0.1%)	  of	  BCR-­‐	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tumor	   cells,	   never	   expanding	   in	   vitro.	   I	   tested	  whether	   the	   failure	   of	   BCR-­‐deficient	  RAMOS	   cells	   to	   overgrow	   in	   vitro	  was	   the	   result	   of	   a	   competitive	   disadvantage	   of	  these	  cells	  when	  cultured	  in	  the	  presence	  of	  their	  BCR+	  counterparts.	  To	  address	  this	  possibility,	  spontaneously	  generated	  BCR-­‐	  RAMOS	  cells	  were	  purified	  by	  cell	  sorting	  and	  cloned	  by	   limiting	  dilution	  (Figure	  32a).	  BCR+	  and	  BCR-­‐	  RAMOS	  cells	  were	  then	  mixed	   in	   equal	   numbers	   and	   followed	   over	   time.	   By	   8-­‐12	   days	   of	   culture,	   flow	  cytometry	   analysis	   revealed	   an	   over	   representation	   of	   RAMOS	   cells	   expressing	   a	  functional	  BCR	  (Figure	  32b).	  
	  
Figure	  32:	  BCR	  provides	  a	  competitive	  advantage	  to	  the	  RAMOS	  human	  Burkitt	  lymphoma	  cell	  line	  
a)	   RAMOS	   cells	   were	   sorted	   according	   to	   surface	   IgM	   expression	   (upper	   left).	   Ig-­‐negative	   tumor	   cells	   were	  enriched	  after	  cell	  sorting	  (upper	  right).	  Sorted	  cells	  were	  cloned	  by	  limiting	  dilution.	  We	  identified	  both	  BCR+	  and	  BCR-­‐	  RAMOS	  clones	  (lower	  plots);	  b)	  Representative	  dot	  plot	  showing	  1:1	  mixtures	  of	  BCR+/-­‐	  RAMOS	  cells	  at	  the	  start	   of	   the	   competition	   (Day	   0)	   or	   12	   days	   later.	   Dot	   Plots	   are	   gated	   on	   FSChi	   live	   cells.	   Numbers	   represent	  percentage	  of	  cells	  in	  the	  corresponding	  quadrants.	  The	  lower	  part	  of	  the	  panel	  shows	  a	  summary	  of	  the	  data	  of	  three	  independent	   in	  vitro	  competition	  assays.	  Average	  ratios	  of	  BCR+/BCR-­‐	   lymphoma	  cells	   from	  3	  experiments	  are	  represented	  (±SD).	  	  	  	  I	  next	  asked	  whether	  the	  BCR	  facilitates	  G1-­‐to-­‐S	  transition	  and	  prevents	  apoptosis	  in	  human	  Burkitt	  lymphoma	  cells,	  as	  observed	  in	  the	  murine	  BL	  model.	  Therefore,	  BCR+	  and	  BCR-­‐	  Ramos	  cells	  were	  cultured	  as	  independent	  populations	  or	  in	  competition	  for	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8-­‐12	   days,	   and	   BrdU	   incorporation,	   as	   well	   as	   caspase	   activation,	   were	   studied.	  Interestingly,	   upon	   8	   days	   of	   competition	   I	   could	   score	   a	   partial	   increase	   in	   the	  percentage	  of	  BCR-­‐	   lymphoma	   cells	   in	  G1	  phase,	   as	   compared	   to	   the	  BCR-­‐proficient	  counterpart	  (Figure	  33).	  	  
	  
Figure	  33:	  The	  BCR	  influences	  G1-­‐to-­‐S	  transition	  in	  RAMOS	  cells	  in	  competition	  	  	  
a)	  Flow	  cytometric	  analysis	  of	  BrdU	  incorporation	  in	  BCR+	  and	  BCR-­‐	  BL	  RAMOS	  cells,	  cultured	  as	  pure	  populations	  (left	  plots	  and	  histograms),	  or	  for	  8	  days	  in	  competition	  (right	  plots	  and	  histograms).	  Average	  ratio	  of	  frequencies	  of	   BCR-­‐	   over	   BCR+	   cells	   in	   the	   indicated	   stages	   of	   the	   cell	   cycle	   (±SD)	   is	   shown	   in	   the	   lower	   histograms.	   Cell	  doublets	  were	  excluded	  from	  the	  analysis.	  Cells	   in	  dot	  plots	  were	  gated	  on	  the	  basis	  IgM	  status.	  Numbers	  in	  dot	  plots	  represent	  percentage	  of	  cells.	  	  Indeed,	   the	   increased	  population	   at	   the	  G1	   stage	  was	   associated	  with	   a	   comparable	  reduction	   in	   the	   fraction	   of	   BCR-­‐	   cells	   in	   S-­‐phase.	   Similarly	   to	   the	   results	   from	   the	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mouse	  model,	   the	   same	   increment	  was	   not	   observed	  when	   IgM-­‐	   Ramos	   cells	   were	  cultured	   independently	   from	   the	   BCR+	   counterparts,	   thus	   suggesting	   a	   non	   cell-­‐autonomous	  defect.	  Moreover,	  Caspase-­‐glow	  staning	  identified	  a	  significantly	  higher	  fraction	  of	  apoptotic	  cells	  mainly	  in	  the	  BCR-­‐deficient	  population.	  However,	   programmed	   cell	   death	   appeared	   to	   be	   a	   cell	   autonomous	   defect	   in	   IgM-­‐	  RAMOS	  cells,	  as	  no	  detectable	  difference	  were	  present	  between	  the	  competition	  and	  the	  independent	  cultures	  (Figure	  34).	  These	  results	  confirm	  the	  importance	  of	  the	  BCR	  in	  sustaining	  the	  growth	  of	  human	  BL	   and	   support	   a	   scenario	   where	   the	   continuous	   presence	   in	   the	   tumor	   of	   BCR-­‐expressing	   tumor	   cells	   represents	   a	   limiting	   factor	   for	   the	   outgrowth	   of	   lymphoma	  cells	  loosing	  the	  BCR	  as	  a	  consequence	  of	  ongoing	  Ig	  SHM.	  	  
	  
Figure	  34:	  The	  BCR	  protects	  human	  Burkitt	  lymphoma	  from	  programmed	  cell	  death	  
Representative	  flow	  cytometric	  analysis	  of	  IgM+	  and	  IgM-­‐	  RAMOS	  cells,	  cultured	  as	  single/pure	  populations,	  or	  for	  8	  days	  in	  competition.	  Numbers	  indicate	  frequencies	  of	  apoptotic	  cells	  among	  respectively	  IgM+	  (black	  numbers	  above	  the	  gate)	  or	  IgM-­‐	  (grey	  numbers	  below	  the	  gate)	  BL	  cells,	  detected	  with	  caspase-­‐glow	  staining;	  Frequencies	  of	   active	   caspase(s)+	  BCR+	   (black	  bars)	   and	  BCR-­‐	   (grey	  bars)	   lymphoma	  B	   cells	  measured	   in	  pure	   cultures	   (left	  panels),	  or	  in	  competition	  for	  8	  days	  (right	  panels)	  are	  shown.	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7.4 Mechanisms	  causing	  the	  loss	  of	  BCR-­‐	  lymphomas	  In	   this	   section	   I	   will	   describe	   a	   series	   of	   experiments	   that	   were	   performed	   in	   the	  attempt	   to	   dissect	   the	   molecular	   mechanism(s)	   responsible	   for	   the	   increased	  apoptosis	  and	  the	  impaired	  proliferation	  of	  tumor	  cells	  undergoing	  acute	  ablation	  of	  the	  BCR.	  	  
7.4.1 Quantitative	  proteome	  analysis	  of	  BCR+	  and	  BCR-­‐	  lymphomas	  	  To	   identify	   the	   pathways	   influenced	   by	   BCR	   deletion	   in	   lymphoma	   cells,	   in	  collaboration	   with	   the	   group	   of	   Tiziana	   Bonaldi	   (European	   Institute	   of	   Oncology,	  Milan)	  we	  established	  a	  quantitative	  proteome	  profile	  of	  B	  lymphoma	  cells	  before	  and	  after	   acute	   loss	   of	   the	   BCR,	   using	   Stable	   Isotope	   Labeling	   with	   Aminoacid	   in	   Cell	  culture	  (SILAC).	  This	  technology	  relies	  on	  the	  incorporation	  of	  isotope-­‐labeled	  amino	  acids	  (like	  L-­‐arginine	  containing	  six	  atoms	  of	  13C),	  in	  proteins	  synthesized	  by	  cells	  in	  exponential	   growth	   (Ong	  et	   al.,	   2002;	  Ong	   and	  Mann,	   2007).	   In	  particular,	   cells	   are	  cultured	   in	  either	  “light”	  medium	  with	  amino	  acids	  of	  natural	   isotope	  abundance	  or	  “heavy”	  medium	  containing	  the	  labeled	  amino	  acid	  of	  choice.	  When	  proteins	  extracted	  from	   cells	   grown	   respectively	   in	   light	   or	   heavy	   medium	   are	   analyzed	   by	   mass	  spectrometry,	   pairs	   of	   chemically	   identical	   peptides	   of	   different	   stable-­‐isotope	  composition	  can	  be	  differentiated	  owing	  to	  their	  mass	  difference	  (Figure	  35).	  	  BCR+	   and	  BCR-­‐	   lymphoma	   cells,	   obtained	   after	   Tat-­‐Cre	   transduction	   of	   the	   primary	  
λ−MYC;B1-­‐8f	   tumor	  #2567,	  were	   cultured	   in	  medium	   containing	   L-­‐arginine	   and	   L-­‐lysine,	  marked	  with	   either	   light	  or	  heavy	   isotopes.	   Cells	  were	   cultured	   for	  4-­‐5	  days	  (corresponding	  to	  8-­‐10	  generations)	  to	  allow	  efficient	  incorporation	  of	  labeled	  amino	  acids.	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Figure	  35:	  Schematic	  representation	  of	  SILAC	  methodology	  applied	  to	  BCR+	  and	  BCR-­‐	  λ-­‐MYC	  lymphomas	  
BCR+	  or	  BCR-­‐	   lymphoma	  cells	  were	  cultured	   in	  medium	  containing	   labeled	  (“heavy”	  or	  “light”)	  aminoacids	   for	  7	  days.	  Cells	  were	  harvested	  and	  BCR+	  cells	  labeled	  with	  heavy	  aminoacids	  were	  mixed	  in	  equal	  amounts	  with	  their	  BCR-­‐	  counterparts	  labeled	  with	  light	  aminoacids	  (the	  reciprocal	  experiment	  was	  also	  performed).	  Protein	  extracts	  were	  then	  processed	  for	  LC-­‐MS/MS	  analysis.	  With	  this	  approach,	  the	  same	  protein	  derived	  from	  different	  samples	  can	  be	  differentiated	  according	  to	  the	  difference	  of	  the	  mass	  of	  its	  peptide	  composition.	  b)	  Representative	  example	  of	   protein	   quantification	   in	   BCR-­‐	   and	   BCR+	   cells	   (left	   panels),	   labeled	   with	   light	   and	   heavy	   aminoacids,	  respectively.	  Ig	  heavy	  chain	  (Igh-­‐6)	  and	  microtubule-­‐actin	  crosslinking	  factor	  1	  are	  shown.	  As	  internal	  control,	  a	  comparison	   between	   BCR+	   cells	   labeled	   respectively	   with	   heavy	   and	   light	   aminoacids	   labeled	   is	   shown	   (right	  panels).	  	  The	   particular	   cell	   culture	   medium	   used	   for	   these	   experiments	   did	   not	   affect	  significantly	   the	   growth	   rate	   of	   both	   BCR+	   and	   BCR-­‐	   cells	   (data	   not	   shown).	   	   Cells	  incorporating	  heavy	  or	   light	  amino	  acids	   into	   their	  proteins	  were	  mixed	  together	   in	  equal	  amount.	  Cytosolic,	  nuclear	  and	  insoluble	  protein	  fractions	  were	  extracted	  from	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each	   sample	   and	   processed	   for	   liquid	   chromatography	   (LC)-­‐mass-­‐spectrometry	  (MS)/MS	  analysis.	  We	  quantified	  with	  a	  high	  confidence	  over	  4000	  proteins	   in	  both	  BCR+	  and	  BCR-­‐	  tumor	  cells	  (ratio	  counts>2).	  Importantly,	  5%	  of	  cellular	  proteins	  were	  significantly	  regulated	  by	  BCR	  expression	  in	  lymphoma	  cells	  (p<0.01)	  (Figure	  36).	  	  
	  
Figure	  36:	  Quantification	  of	  proteins	  regulated	  by	  the	  BCR	  in	  λ-­‐MYC	  lymphomas	  	  
Pie	  chart	  representation	  of	  proteins	  quantified	  with	  a	  good	  confidence	  (ratio	  counts>2)	  through	  SILAC	  technology.	  Percentage	  (and	  absolute	  number)	  of	  quantified	  proteins	  controlled	  by	  the	  BCR	  is	  indicated	  in	  pink	  (responders;	  
p<0.01).	  Differentially	  expressed	  proteins	  between	  BCR+	  and	  BCR-­‐	  lymphoma	  cells	  are	  divided	  in	  up-­‐	  (purple)	  and	  down	  (green)-­‐regulated	  in	  BCR-­‐	  cells.	  	  	  
7.4.2 BCR	  regulates	  metabolism	  of	  λ-­‐MYC;B1-­‐8f	  lymphomas	  	  The	   comparison	   of	   proteomes	   of	   BCR+	   and	   BCR-­‐	   lymphoma	   cells	   revealed	   200	  proteins	  differentially	  expressed	  between	  the	  two	  tumor	  subsets.	  This	  group	  of	  genes	  was	   further	  divided	   into	   two	  subgroups	   consisting	  of	   genes	   respectively	  up-­‐	   (48%)	  and	   down-­‐	   (52%)	   regulated	   in	   BCR-­‐deficient	   lymphomas	   (Figure	   36).	   Ingenuity	  Pathway	   enrichment	   Analysis	   (IPA)	   performed	   on	   statistically	   significant	   (p<0.01)	  down-­‐regulated	  responders	   in	  BCR-­‐deficient	  tumors,	   identified	  enzymes	  involved	  in	  key	   metabolic	   processes	   including	   glycolysis,	   gluconeogenesis,	   pyruvate	   and	  galactose	   metabolism	   (Figure	   37).	   Interestingly,	   several	   enzymes	   of	   the	   same	  metabolic	   pathway	   such	   as	   glycolysis	   were	   at	   the	   same	   time	   down	   regulated	   in	   a	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modest,	  yet	  significant,	   fashion	  in	  response	  to	  BCR	  inactivation.	  This	  result	  suggests	  an	   influence	   of	   the	   BCR	   on	   the	   efficiency	   of	   lymphoma	   cells	   to	   exploit	   glucose	  breakdown	   for	   both	   energetic	   and	   anabolic	   processes.	   Loss	   of	   the	   antigen	   receptor	  had	  also	  consequences	  on	  steady	  state	  levels	  of	  key	  BCR	  signalling	  effectors,	  including	  Cd79a,	  PLCγ2	  and	  Vav1,	   suggesting	  a	  positive	   feedback	  mechanism	  supporting	  BCR	  function	   in	   lymphoma	   cells	   (Figure	   38).	   Interestingly,	   among	   the	   proteins	   whose	  expression	   increased	   in	   response	   to	  BCR	   inactivation,	  we	   found	   components	   of	   the	  NRF2-­‐mediated	   oxidative	   stress	   response	   and	   signaling	   pathways	   associated	   to	  mitochondrial	   dysfunction.	   These	   results	   warrant	   further	   validation	   to	   determine	  whether	  they	  contribute	  to	  the	  loss	  of	  BCR-­‐negative	  lymphomas.	  	  
	  
Figure	  37:	  The	  BCR	  influences	  metabolism	  and	  its	  own	  signalling	  of	  c-­‐MYC	  transformed	  B	  cells	  
Ingenuity	  pathway	  enrichment	  analysis	  on	  proteins	  respectively	  down-­‐	  (left	  panel)	  and	  up-­‐	  (right	  panel)	  regulated	  in	   BCR-­‐	   lymphoma	   cells	   (#2567).	   Only	   significantly	   enriched	   pathways	   are	   shown	   (p<0.01,	   red	   dashed	   line	  indicates	  threshold	  of	  significance)	  	  	  	  	  	  	  
-­‐log(adj	  p	  value)	   -­‐log(adj	  p	  value)	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   Normalized	  H/L	  ratio	  	   Ratio	  H/L	  (count)	   Ratio	  H/L	  (significance)	  
Glycolysis	   	   	   	  Phosphoglucomutase-­‐1	   1,18	   50	   8.62E-­‐06	  Hexokinase-­‐1	   1,78	   6	   1.27E-­‐08	  6-­‐phosphofructokinase	   1.4	   9	   1.14E-­‐06	  Fructose-­‐bisphosphate	  aldolase	   1.15	   421	   2.58E-­‐05	  Triosephosphate	  isomerase	   1.13	   225	   0.00036058	  Glyceraldehyde-­‐3-­‐phosphate	  dehydrogenase	   1.17	   15	   0.0023722	  Phosphoglycerate	  kinase	  1	   1.18	   596	   5.94E-­‐07	  Phosphoglycerate	  kinase	  2	   1.22	   14	   1.60E-­‐07	  
β-­‐enolase	   1.51	   116	   1.22E-­‐33	  Pyruvate	  kinase	  (Isoform	  M2)	   1.15	   1151	   2.01E-­‐05	  L-­‐lactate	  dehydrogenase	  A	  chain	   1.1	   937	   0.0061961	  
Glucose	  uptake	   	   	   	  Phosphoinositide	  3-­‐Kinase-­‐C2-­‐α	   1.61	   84	   7.17E-­‐22	  
Galactose	  metabolism	   	   	   	  Galactokinase	  1	   1.13	   178	   0.00028304	  Galactokinase	  2	   1.62	   8	   4.12E-­‐08	  
BCR	  signalling	   	   	   	  Phospholipase	  C-­‐gamma-­‐2	   1.14	   177	   0.00010835	  Vav1	   1.15	   66	   0.0019863	  Hcls1	   1.14	   20	   0.00023631	  Rac2	   1,094	   69	   0.0083523	  CD79a	  antigen	   1.62	   24	   6.22E-­‐18	  Igκ	  constant	  region	   1.21	   51	   3.54E-­‐07	  IgH	  constant	  region	   8.4	   70	   8.71E-­‐252	  
	  
Table	  8:	  The	  BCR	  modulates	  sugar	  metabolism	  and	  its	  own	  signalling	  effectors	  in	  lymphoma	  cells	  
Main	  pathways	  down	  regulated	  in	  response	  to	  BCR	  ablation	  as	  revealed	  through	  Ingenuity	  Pathway	  enrichment	  Analysis.	   Normalized	   H/L	   ratio	   indicates	   the	   degree	   of	   down	   regulation	   of	   the	   indicated	   proteins	   upon	   BCR	  ablation	   (for	  example,	   levels	  of	  Hexokinase-­‐1	  are	  78%	  down	  regulated	   in	  BCR-­‐	  cells).	  Ratio	  H/L	  count	   indicates	  number	  of	  times	  each	  protein	  was	  counted.	  Significance	  of	  the	  data	  is	  shown	  in	  the	  last	  column.	  	  
7.4.3 BCR	  protects	  lymphoma	  cells	  from	  starvation	  	  To	   investigate	  whether	  BCR	  expression	   influenced	   the	   growth	   of	   tumor	   cells	   under	  conditions	  of	  limited	  nutrient	  supply,	  BCR+	  and	  BCR-­‐	  lymphoma	  cells	  generated	  upon	  Tat-­‐Cre	   transduction	   of	   independent	   primary	   tumors	   were	   co-­‐cultured	   in	   medium	  containing	  limiting	  amounts	  of	  fetal	  bovine	  serum	  (FBS),	  a	  major	  source	  of	  nutrients	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and	  growth	  factors.	  1:1	  mixtures	  of	  BCR+	  and	  BCR-­‐	   lymphomas	  were	  cultured	  under	  serum-­‐restricted	  conditions	  for	  24	  hours.	  BCR-­‐deficient	  lymphomas	  showed	  a	  higher	  sensitivity	  to	  nutrient	  deprivation	  than	  their	  BCR+	  counterparts,	  as	  confirmed	  by	  the	  acceleration	  in	  the	  counter-­‐selection	  when	  mixtures	  of	   tumor	  cells	  were	  cultured	  in	  low	  serum	  (0.1%	  FBS)	  (Figure	  38).	  
	  
Figure	  38:	  BCR-­‐	  lymphoma	  cells	  are	  preferentially	  counter	  selected	  in	  response	  to	  serum	  deprivation	  
Flow	  cytometric	  analysis	  of	  BCR+	  and	  BCR–	   tumor	  cells	   cultured	   in	   competition,	   for	  24	  hours,	   in	  B-­‐cell	  medium	  complemented	   with	   the	   indicated	   percentage	   of	   fetal	   bovine	   serum	   (FBS).	   Dot	   plots	   are	   gated	   on	   live	   FSChi	  lymphocytes.	   Numbers	   indicate	   percentage	   of	   BCR+	   and	   BCR-­‐	   tumor	   cells.	   Tumor	   cells	   derived	   from	   two	  independent	  lymphomas	  (#2646	  and	  #2676)	  are	  shown.	  	  To	   further	   address	   the	   involvement	   of	   the	   BCR	   in	   the	   regulation	   of	   lymphoma	  anabolic	   metabolism,	   BCR+	   and	   BCR-­‐	   tumors	   were	   cultured	   in	   competition	   in	   the	  presence	   of	   Rapamycin,	   a	   specific	   inhibitor	   of	   the	   mTOR	   (mammalian	   Target	   Of	  Rapamycin)	   kinase,	   which	   is	   an	   essential	   regulator	   of	   nutrient	   uptake	   (Peng	   et	   al.,	  2002).	   Strikingly,	   treatment	   with	   Rapamycin	   of	   1:1	   mixtures	   of	   BCR+	   and	   BCR-­‐	  
	   100	  
transformed	  B	  cells	  (from	  two	  independent	  lymphomas)	  led	  to	  a	  significant	  (3-­‐fold)	  acceleration	  in	  the	  counter	  selection	  of	  receptor-­‐negative	  tumors	  in	  vitro	  (Figure	  39a-­‐c).	  	  
	  
Figure	  39:	  BCR-­‐	  lymphoma	  cells	  are	  more	  sensitive	  to	  Rapamycin	  treatment	  than	  their	  BCR+	  counterparts	  
a)	  Representative	   flow	  cytometric	  analysis	  of	  BCR+	  and	  BCR–	   tumor	  cells	  co-­‐cultured	   for	  4	  days	   in	   the	  presence	  (RM)	  or	  absence	  (CTRL)	  of	  10nM	  Rapamycin.	  Dot	  plots	  are	  gated	  on	  live	  FSChi	   lymphocytes.	  Numbers	  represent	  percentage	  of	  BCR+\–	  tumor	  cells.	  Tumor	  cells	  derived	  from	  two	  independent	  lymphomas	  (#2646	  and	  #2676)	  are	  shown;	   b)	   Growth	   curves	   of	   BCR+	   (black	   lines)	   and	   BCR-­‐	   cells	   (grey	   lines),	   derived	   from	   lymphoma	   #2646,	  cultured	  in	  competition	  for	  2	  days	  in	  the	  presence	  (triangles)	  or	  absence	  (rectangles)	  of	  10nM	  Rapamycin	  (RM);	  c)	  Summary	  of	   competition	  assays	  between	  BCR+	  and	  BCR-­‐	   lymphoma	  cells	  derived	   from	   two	   independent	  λ-­‐MYC	  lymphomas	   (#2646	   and	   #2676),	   cultured	   in	   presence	   (RM,	   red	   symbols)	   or	   absence	   (CTRL,	   black	   symbols)	   of	  10nM	   Rapamycin.	   Ratio	   of	   BCR+/BCR-­‐	   cells	   at	   the	   indicated	   time	   points	   of	   the	   competition	   are	   shown.	   Bars	  represent	  average	  of	  4	  and	  3	  replicates,	  in	  #2646	  and	  #2676	  tumors,	  respectively	  (2way-­‐Anova:	  *p<0.05).	  	  	  Moreover,	   cell	   cycle	   analysis	   of	   Rapamycin	   treated	   cells	   showed	   an	   increase	   in	  apoptotic	   cells	   (with	   a	   hypodiploid	   (<2n)	   DNA	   content)	   mainly	   in	   the	   BCR-­‐	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compartment,	   whereas	   cell	   cycle	   of	   both	   BCR+	   and	   BCR-­‐	   populations	   was	   slightly	  affected	  (Figure	  40).	  	  
	  
Figure	  40:	  Rapamycin	  induces	  cell	  death	  preferentially	  in	  BCR-­‐deficient	  lymphoma	  cells	  
Cell-­‐cycle	   analysis	   (BrdU/PI)	   of	   BCR+	   and	  BCR-­‐	   lymphoma	   cells	   (#2564	  λ−MYC;B1-­‐8f	   tumor),	   co-­‐cultured	   for	   3	  days	  in	  the	  presence	  (RM,	  yellow	  histograms)	  or	  absence	  (CTRL,	  red	  histograms)	  of	  10nM	  Rapamycin.	  Numbers	  above	  each	  histogram	  represent	  ratios	  of	  frequencies	  of	  BCR-­‐	  and	  BCR+	  lymphoma	  cells	  at	  the	  indicated	  	  stage	  of	  the	   cell	   cycle.	   Apoptotic	   cells	   (in	   either	   IgM+	   or	   IgM-­‐	   gates)	   were	   detected	   according	   to	   DNA	   content	   (PI),	   as	  hypodiploid	  (<2n)	  cells.	  	  Interestingly,	  Rapamycin	  treatment	  of	  independent	  cultures	  of	  BCR+	  and	  BCR-­‐	  tumors	  resulted	   in	   a	   significant	   difference	   in	   cell	   numbers	   between	   the	   two	   populations	  (Figure	  41).	  In	  particular,	  cell	  viability	  of	  both	  BCR+	  and	  BCR-­‐	  tumors	  was	  affected,	  as	  shown	  by	   a	   reduction	   in	   cell	   number	   regardless	   of	   BCR	   expression,	   after	   2	   days	   of	  treatment;	   nevertheless,	   Rapamycin-­‐induced	   toxicity	   was	   significantly	   more	  pronounced	  in	  BCR-­‐	  lymphoma	  cells	  (p<0.001)	  (Figure	  41).	  	  Altogether,	   these	   results	   reveal	   a	   higher	   sensitivity	   of	   lymphoma	   cells	   loosing	   BCR	  expression	   to	   undergo	   cell	   death	  when	   grown	   under	   condition	   of	   limiting	   nutrient	  supply,	  as	  well	  as	  upon	  Rapamycin	  treatment.	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Figure	  41:	  The	  BCR	  exerts	  a	  mild	  protective	  effect	  against	  Rapamycin-­‐induced	  cell	  death	  
Numbers	   of	   BCR+	   (black	   and	   red	   bars)	   and	   BCR-­‐	   (grey	   and	   yellow	   bars)	   lymphoma	   cells	   (#2646	  λ−MYC;B1-­‐8f	  tumor)	   grown	   in	   separate	   cultures,	   in	   the	   presence	   (red	   and	   yellow	   bars)	   or	   absence	   (black	   and	   grey	   bars)	   of	  10nM	  Rapamycin	  (RM)	  for	  2	  days.	  Histograms	  represent	  average	  of	  triplicates	  for	  the	  indicated	  time	  points	  (±SD)	  (2way-­‐Anova:	  **p-­‐value<0.001).	  ns=	  not	  significant.	  	  
7.4.4 Contribution	  of	  the	  BCR	  to	  energy	  metabolism	  in	  c-­‐MYC	  transformed	  B	  cells	  	  One	  of	  the	  hallmarks	  of	  tumor	  cells	  is	  the	  shift	  in	  glucose	  metabolism	  from	  oxidative	  phosphorylation	   to	   aerobic	   glycolysis,	   also	   known	  as	   the	  Warburg	   effect	   (Warburg,	  1956).	  The	  shift	  to	  a	  more	  inefficient	  glucose	  metabolism	  (catabolism	  of	  one	  glucose	  molecule	  leads	  to	  only	  two	  ATP	  molecules	  instead	  of	  38	  molecules	  obtained	  through	  oxidative	  phosphorylation)	  is	  counteracted	  by	  the	  increase	  in	  anabolic	  processes	  that	  rely	   on	   glycolysis	   intermediates	   to	   support	   the	   rapid	   growth	   of	   tumor	   cells.	   I	  therefore	  tested	  whether	  BCR	  expression	  influenced	  glucose	  metabolism	  and	  thereby	  lymphoma	  growth.	  	  
7.4.4.1 Normal	  glucose	  uptake	  in	  λ-­‐MYC	  lymphomas	  lacking	  BCR	  expression	  To	   test	   whether	   the	   antigen	   receptor	   influenced	   the	   uptake	   of	   glucose	   in	   λ-­‐MYC	  lymphomas,	   BCR+	   and	   BCR-­‐	   tumor	   cells	   generated	   by	   TAT-­‐cre	   transduction	   of	   3	  independent	   primary	   tumors,	   were	   grown	   in	   vitro	   under	   competitive	   conditions.	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Glucose	   uptake	  was	  measured	   at	   the	   single	   cell	   level	   using	   the	   fluorescent	   labeled	  glucose	   analog	   2-­‐NBDG	   (2-­‐(N-­‐(7-­‐Nitrobenz-­‐2-­‐oxa-­‐1,3-­‐diazol-­‐4-­‐yl)Amino)-­‐2-­‐Deoxyglucose)	  (Zhong	  et	  al.,	  2010).	  At	   the	  earliest	   time	  when	  counter	  selection	  of	  BCR-­‐	  cells	  was	  observed	  (Figure	  42a,	  upper	   right	  plot),	   glucose	  uptake	  was	  not	   significantly	   affected	  by	  BCR	   inactivation	  (Figure	  42a,	  left	  histograms).	  	  
	  
Figure	  42:	  BCR	  does	  not	  influence	  glucose	  uptake	  in	  lymphoma	  B	  cells	  
a)	  Representative	  example	  of	  uptake	  of	  the	  glucose	  analog	  NBDG	  in	  BCR+	  (black	  thick	  histogram)	  and	  BCR-­‐	  (grey	  filled	  histograms)	  lymphoma	  cells	  (#2487)	  upon	  24	  hours	  of	  competition.	  Unlabeled	  cells	  were	  used	  as	  negative	  control	  (grey	  thin	  line).	  Numbers	  indicate	  percentages	  of	  BCR+	  (black)	  and	  BCR-­‐	  (grey)	  lymphomas	  that	  have	  up	  taken	  2-­‐NBDG	  at	   the	   indicated	   time	  points.	  Histograms	   refer	   to	   live	  FSChi	   lymphoma	  cells.	  Mixture	  of	  BCR+	  and	  BCR-­‐	  cells	  used	  for	  the	  analysis	  were	  analyzed	  by	  flow	  cytometry	  at	  the	  onset	  of	  competition	  and	  24	  h	  later.	  Note	  the	   over	   2-­‐fold	   increase	   in	   the	   fraction	   of	   BCR+	   tumor	   cells,	   1-­‐day	   after	   the	   beginning	   of	   the	   competition.	   b)	  Percentages	   of	   2-­‐NBDG-­‐positive	   BCR+	   (black	   lines)	   and	   BCR-­‐	   cells,	   derived	   from	   three	   independent	   tumors	  (#2646,	   #2564	   and	   #2487),	  measured	   by	   flow	   cytometry	   at	   the	   indicated	   time	   points.	   Uptake	   of	   2-­‐NBDG	  was	  measured	  after	  24	  hours	  of	  competition.	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In	  particular,	  the	  percentage	  of	  BCR+	  and	  BCR-­‐	  lymphoma	  cells	  internalizing	  2-­‐NBDG	  was	  comparable,	  with	  saturation	  of	  the	  signal	  occurring	  between	  30	  and	  60	  minutes	  after	  the	  start	  of	  the	  labelling	  (Figure	  42).	  In	  a	  similar	  fashion,	  no	  major	  differences	  in	  glucose	   uptake	   were	   scored	   at	   early	   time	   points,	   (between	   1	   and	   15	   minutes	   of	  labelling	  with	  2-­‐NBDG)	  (Figure	  42b).	  These	  results	  exclude	  a	  role	  of	   the	  BCR	   in	   the	  control	  of	  glucose	  uptake	  in	  c-­‐MYC	  transformed	  B	  cells.	  	  
7.4.4.2 Normal	  pyruvate	  to	  lactate	  conversion	  in	  BCR-­‐deficient	  lymphoma	  cells	  Pyruvic	  acid	  represents	  a	  central	  node	   in	  glucose	  metabolism.	  Pyruvic	  acid	  supplies	  energy	   to	   living	  cells	   through	   the	  citric	  acid	  cycle	  (also	  known	  as	   the	  Krebs	  cycle	  or	  TCA	   cycle)	   under	   conditions	   of	   normoxia	   (aerobic	   respiration).	   Alternatively	   it	   is	  reduced	  to	  lactic	  acid	  under	  anaerobic	  conditions	  or	  as	  a	  consequence	  of	  the	  Warburg	  effect.	  To	   determine	  whether	  BCR	   controlled	   the	   reduction	   of	   pyruvate	   to	   lactate,	   Lactate	  De-­‐Hydrogenase	   (LDH)	   activity	  was	  measured	   in	   tumor	   cells,	   before	   and	   after	  BCR	  inactivation.	   I	   quantified	  NADH	   levels	   in	   the	   conditioned	  media	   of	   tumor	   cells	   as	   a	  read-­‐out	  of	  LDH	  activity.	  BCR+	  and	  BCR-­‐	  lymphoma	  cells	  were	  isolated	  upon	  Tat-­‐Cre	  transduction	  of	  2	   independent	   tumors	   (#2567,	  #2646),	   grown	   in	  vitro	  for	  24	  hours	  and	  conditioned	  medium	  collected	  for	  NADH	  measurements.	  As	  shown	  in	  Figure	  43	  NADH	  levels	  were	  not	  significantly	  different	  between	  cultures	  of	  BCR-­‐proficient	  and-­‐deficient	   cells.	   This	   result	   suggests	   that	   conversion	   of	   pyruvate	   into	   lactate	   is	   not	  altered	   in	   BCR-­‐negative	   lymphomas	   at	   least	   when	   cells	   are	   grown	   under	   non-­‐competitive	  conditions.	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Figure	  43:	  LDH	  activity	  is	  not	  significantly	  altered	  in	  response	  to	  BCR	  ablation	  
Colorimetric	   measurement	   of	   NADH	   production	   in	   supernatants	   collected	   from	   in	   vitro	   cultures	   of	   pure	   BCR+	  (black	  bars)	  and	  BCR-­‐	  (grey	  bars)	  lymphoma	  cells	  derived	  from	  2	  independent	  tumors	  (#2567	  and	  #2646).	  LDH	  activity	  normalized	  to	  BCR+	  lymphoma	  cells	  (±	  SD)	  is	  shown.	  
7.4.4.3 Analysis	  of	  mitochondrial	  function	  in	  λ-­‐MYC	  B-­‐cell	  lymphomas	  	  Measurement	   of	   oxygen	   consumption	   has	   long	   been	   used	   to	   assess	   mitochondrial	  function	   (Chance	   and	  Williams,	   1956).	   To	   investigate	   whether	   BCR	   influenced	   the	  consumption	  of	  oxygen	  through	  oxidative	  phosphorylation,	  I	  measured	  mitochondrial	  respiration	  in	  BCR+	  and	  BCR-­‐	  tumor	  cells.	  To	  this	  aim,	  highly	  purified	  populations	  of	  BCR+	  and	  BCR-­‐	   lymphoma	  cells	  generated	   from	  3	   independent	  λ−MYC;B1-­‐8f	   tumors	  (#2567,	  #2646	  and	  #2676),	  were	  expanded	  shortly	  in	  vitro	  and	  oxygen	  consumption	  of	   the	   purified	   cells	   was	   measured	   in	   collaboration	   with	   dr	   M.	   Giorgio	   (European	  Institute	   of	   Oncology,	   Milan).	   Both	   basal	  and	  uncoupled	   respiration	   was	  measured	  (Figure	  44).	  Basal	   respiration	   is	   controlled	  by	   the	  ATP	   turnover	  of	   the	   cell	   (Brown,	  1992),	  whereas	  uncoupled	  respiration	  represents	  the	  maximum	  respiration	  rate	  of	  a	  cell.	  The	  latter	  can	  be	  measured	  by	  addition	  of	  carbonylcyanide-­‐4-­‐trifluoromethoxy-­‐phenylhydrazone	  (FCCP)	  and	  evaluates	  the	  integrity	  of	  the	  electron	  transport	  chain.	  Respiration	   rates	   were	   normalized	   to	   total	   protein	   amounts,	   limiting	   thereby	   the	  impact	  of	  differences	   in	   the	   amount	  of	   cells	  measured	   in	   the	  oxygraph	   chamber.	  λ-­‐
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MYC	  lymphomas	  showed	  a	  considerable	  degree	  of	  oxygen	  consumption	  under	  basal	  conditions	  thus	  highlighting	  robust	  oxidative	  phosphorylation.	  Importantly,	  BCR+	  and	  BCR-­‐	   lymphoma	   cells	   showed	   similar	   uncoupled-­‐to-­‐basal	   respiration	   ratios,	   thus	  excluding	  major	  mitochondrial	  alterations	  resulting	  from	  BCR	  loss.	  	  These	   data	   suggest	   that	   the	   BCR	   neither	   influences	   glucose	   uptake,	   nor	   the	  conversion	   of	   pyruvate	   to	   lactate	   or	   mitochondrial	   respiration	   in	   lymphomas	  provided	   with	   an	   excess	   in	   sugar	   substrates	   and	   in	   the	   presence	   of	   normal/high	  partial	  pressure	  of	  oxygen.	  	  
	  
Figure	  44:	  O2	  consumption	  is	  independent	  of	  BCR	  expression	  in	  λ-­‐MYC	  lymphomas	  	  
Mitochondrial	  respiration	  measured	  in	  BCR+	  (black	  bars)	  and	  BCR-­‐	  (grey	  bars)	  lymphoma	  cells	  derived	  from	  three	  independent	  tumors	  (#2567,	  #2646	  and	  #2676).	  Respiration	  rate	  is	  expressed	  as	  uncoupled	  to	  basal	  respiration	  ratio.	  Samples	  are	  normalized	  according	  to	  protein	  content.	  
7.4.5 BCR	  controls	  GSK3β 	  activity	  in	  lymphoma	  cells	  A	   series	   of	   studies	   have	   identified	   in	   the	   recent	   years	   a	   number	   of	   BCR	   effectors	  controlling	   the	   survival	   of	   resting	  mature	   B	   cells	   and	   their	   contribution	   to	   Burkitt	  lymphomagenesis	   (Refaeli	   et	   al.,	   2008;	   Sander	   et	   al.,	   2012;	   Schmitz	   et	   al.,	   2012;	  Srinivasan	   et	   al.,	   2009;	   Werner	   et	   al.,	   2010).	   In	   particular,	   the	   PI3K	   pathway	   was	  shown	  to	  play	  a	  central	  role	  in	  sustaining	  the	  survival	  signal	  emanating	  from	  the	  BCR	  in	  resting	  mature	  B	  cells	  (Srinivasan	  et	  al.,	  2009).	  	  More	  recently,	  it	  was	  demonstrated	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that	   constitutive	   activation	   of	   the	   PI3K	   pathway	   was	   necessary	   to	   support	   c-­‐MYC-­‐dependent	  transformation	  of	  germinal	  center	  B	  cells	  leading	  ultimately	  to	  BL	  (Sander	  et	   al.,	   2012).	  Glycogen	   Synthase	  Kinase	  3	  beta	   (GSK3β)	   is	   an	   essential	   downstream	  effector	  of	  the	  PI3	  kinase	  signalling	  pathway.	  It	  is	  phosphorylated	  on	  serine-­‐9	  by	  the	  AKT	   kinase	   causing	   its	   inactivation.	   I	   tested	   whether	   BCR	   could	   influence	   the	  phosphorylation	  of	  GSK3β	   in	  λ-­‐MYC	   lymphomas.	  To	   this	  aim,	  mixtures	  of	  BCR+	  and	  BCR-­‐	   lymphoma	   cells,	   obtained	   upon	   Tat-­‐Cre	   transduction	   of	   four	   independent	  primary	  tumors	  (#2646,	  #2676,	  #2564	  and	  #2487),	  were	  cultured	   for	   few	  days.	  As	  soon	   as	   the	   counter	   selection	   of	   BCR-­‐deficient	   tumor	   cells	   became	   apparent,	   I	  measured	   by	   phosphoflow	   the	   levels	   of	   phosphorylated	   GSK3β	   (Ser9),	   in	   the	  individual	  tumor	  populations.	  The	  levels	  of	  phosphorylated	  GSK3β	  were	  significantly	  reduced	  in	  lymphoma	  cells	  that	  had	  undergone	  BCR	  loss	  (Figure	  45a).	  	  
Figure	   45:	   Reduced	   GSK3β	   phosphorylation	   in	   λ-­‐
MYC	  lymphomas	  loosing	  BCR	  expression	  
a)	   Representative	   flow	   cytometric	   analysis	   of	   Ser9	  phosphorylated	   GSK3?	   levels	   in	   BCR+	   and	   BCR-­‐	   cells	  upon	   in	  vitro	   competition.	   In	   the	   left	   plot,	   percentages	  of	   BCR+	   and	   BCR-­‐	   cells	   are	   shown.	   In	   the	   right	   panel	  median	   fluorescent	   intensity	   (MFI)	   of	   phosphorylated	  GSK3β	   (pGSK3β)	   in	   BCR+	   (black	   thick	   line)	   and	   BCR-­‐	  (grey	   filled	   line)	   lymphoma	   cells	   is	   shown.	   Dot	   plots	  show	   FSChi	   live	   lymphoma	   B	   cells.	   Tumor	   cells	   were	  derived	   from	   λ-­‐MYC;B1-­‐8f	   lymphoma	   #2564;	   b)	  Median	   fluorescence	   intensity	   of	   phopshorylated	  GSK3β	   in	  BCR+	   (black	   circles)	   	   and	  BCR-­‐	   (red	   squares)	  tumor	   B	   cells	   grown	   under	   competition.	   The	   analysis	  was	   performed	   on	   cells	   derived	   from	   4	   independent	  lymphomas	  (#2564,	  #2646,	  #2676	  and	  #2487).	  (t-­‐test:	  *p<0.05	  or	  **p<0.01).	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These	   results	  highlight	   the	   central	   role	   exerted	  by	   the	  BCR	   in	   the	   control	  of	  GSK3β	  activity	  in	  c-­‐MYC	  transformed	  B	  cells.	  
7.4.6 BCR-­‐dependent	  inhibition	  of	  GSK3β 	  sustains	  growth	  of	  λ-­‐MYC	  lymphomas	  Reduced	  serine-­‐9	  phosphorylation	   is	  expected	  to	   increase	  GSK3β	  activity	  (reviewed	  in	  Cohen	  and	  Frame,	  2001).	  To	  determine	  whether	   the	   increased	  activity	  of	  GSK3β	  was	  responsible	  for	  the	  counter	  selection	  of	  BCR-­‐less	  lymphoma	  cells,	  we	  treated	  1:1	  mixtures	   of	   BCR+/BCR-­‐	   tumor	   cells	   with	   the	   GSK3β-­‐specific	   inhibitor	   CT99021	  (Meijer	   et	   al.,	   2004).	   I	   first	   titrated	   the	   drug	   on	   purified	  BCR+	   and	  BCR-­‐	   lymphoma	  cells,	  addressing	  cell	  viability	  at	  different	  doses	  of	  CT99021	  after	  respectively	  1-­‐	  and	  2-­‐days	  of	  treatment	  (Figure	  46).	  The	  inhibitor	  caused	  a	  mild	  reduction	  in	  the	  growth	  of	   BCR+	   and	   BCR-­‐	   cells,	   with	   an	   extension	   of	   their	   doubling	   time	   when	   cells	   were	  exposed	   at	   the	   highest	   dose.	   The	   specificity	   of	   the	   inhibition	  was	   confirmed	  by	   the	  reduction	   in	   both	   BCR+	   and	   BCR-­‐	   lymphoma	   cells	   of	   c-­‐MYC	   phosphorylation	   on	  threonine-­‐58	  (Thr58),	  a	  known	  target	  of	  GSK3β	  (Adhikary	  and	  Eilers,	  2005)	  (Figure	  47).	  Finally,	   four	   independent	   lymphomas	  (#2646,	  #2676,	  #2564	  and	  #2487)	  were	  transduced	  with	  Tat-­‐Cre,	  and	  1:1	  mixtures	  of	  BCR+	  and	  BCR-­‐	  lymphomas	  were	  grown	  in	   the	  presence	  of	   1µM	  CT99021.	   Strikingly,	   inhibition	  of	  GSK3β	   activity	  prevented	  the	   counter	   selection	   of	   BCR-­‐	   lymphoma	   cells	   and	   in	   few	   instances	   favored	   the	  expansion	  of	  the	  BCR-­‐	  population	  (Figure	  48a	  and	  b).	   	   Importantly,	   the	   inhibition	  of	  GSK3β	   upon	   CT99021	   treatment	   was	   reversible	   as	   its	   withdrawal	   led	   to	   the	  preferential	   expansion	   of	   BCR-­‐proficient	   lymphomas	   (Figure	   48a).	   	   These	   results	  reveal	   the	   essential	   function	   of	   the	   BCR	   to	   control/limit	   the	   activity	   of	   GSK3β,	  necessary	  to	  sustain	  the	  growth	  of	  λ-­‐MYC	  lymphomas.	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Figure	   46:	   Effects	   of	   the	   GSK3β 	   inhibitor	  
CT99021	   on	   in	   vitro	   growth	   of	   λ-­‐MYC	  
lymphomas	  






Figure	   47:	   GSK3β 	   inhibition	   through	   CT99021	  
blocks	   Threonine	   58	   c-­‐MYC	   phosphorylation	   in	  λ-­‐
MYC	  B-­‐lymphoma	  cells	  
Immunoblot	   analysis	   to	  measure	  Threonine	  58	   c-­‐MYC	  phosphorylation	  (Thr58),	  in	  BCR+	  and	  BCR-­‐	  lymphoma	  B	   cells	   (#2646),	   cultured	   in	   the	   presence	   of	   1µM	  CT99021,	  or	  DMSO,	   for	  48	  hours.	  Vinculin	   levels	  were	  quantified	  to	  control	  for	  protein	  input.	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Figure	  48:	  Modulation	  of	  GSK3β	  activity	  influences	  counter	  selection	  of	  BCR-­‐	  lymphoma	  cells	  
Representative	  flow	  cytometric	  analysis	  of	  1:1	  mixtures	  of	  BCR+	  and	  BCR–	  tumor	  cells	  cultured	  for	  20	  days	  in	  the	  presence	   (CT)	   or	   absence	   (DMSO)	   of	   1	  µM	  CT99021.	   Lower	   dot	   plots	   (CTèDMEM)	   represent	   flow	   cytometric	  analyses	  of	  BCR+/-­‐	   competitions	  10	  days	   after	   removal	  of	   the	  GSK3β	   inhibitor.	  Dot	  plots	   are	   gated	  on	   live	  FSChi	  lymphocytes.	  Numbers	  indicate	  percentage	  of	  BCR+\–	  tumor	  cells.	  Tumor	  cells	  were	  derived	  from	  two	  independent	  
λ-­‐MYC;B1-­‐8f	  lymphomas	  (#2646	  and	  #2676);	  b)	  Summary	  of	  the	  data	  relative	  to	  in	  vitro	  competitions	  of	  BCR+	  and	  BCR-­‐	   lymphoma	   cells,	   obtained	   from	   three	   independent	   λ-­‐MYC;B1-­‐8f	   lymphomas	   (#2646,	   #2676	   and	   #2487),	  cultured	   in	   the	  presence	   (CT,	   red	   symbols)	   or	   absence	   (CTRL,	   black	   symbols)	   of	   1µM	  CT99021.	  Ratios	   of	  BCR+	  over	  BCR-­‐	  cells	  are	  shown	  before	  (t0)	  and	  6	  days	  after	  competition.	  Bars	  represent	  average	  of	  4,	  3	  and	  2	  replicates	  of	  	  #2646,	  #2676	  and	  #2487	  tumors,	  respectively	  (t-­‐test:	  *p<0.05	  or	  **p<0.01).	  Each	  symbol	  represents	  average	  of	  technical	  triplicates.	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7.4.7 GSK3β 	  inhibition	  restores	  normal	  cell-­‐cycle	  progression	  in	  BCR-­‐	  lymphomas	  	  Loss	   of	   the	   BCR	   promotes	   a	   delay	   in	   cell	   cycle	   progression	   and	   an	   increase	   in	  apoptosis	   of	  BCR-­‐deficient	   lymphomas	  when	  grown	   in	   competition	  with	   their	  BCR+	  counterparts	  (see	  paragraphs	  7.3.6	  and	  7.3.7).	  Given	  the	  ability	  of	  the	  GSK3β	  inhibitor	  CT99021	  to	  block	  counter	  selection	  of	  BCR-­‐	  lymphomas,	  I	  assessed	  its	  contribution	  to	  cell–cycle	  progression.	  	  
Ex	  vivo	   isolated	   lymphoma	  cells	  were	  Tat-­‐Cre	   transduced,	  expanded	   for	   few	  days	   in	  
vitro	  and	  BCR+	  and	  BCR-­‐	  cells	  cultured	  in	  a	  1:1	  ratio	  in	  the	  presence	  of	  1µM	  CT99021	  (or	   DMSO)	   (Figure	   49a).	   Cell	   cycle	   analysis	  was	   performed	   coupling	   BrdU	   labeling	  with	   staining	   for	   DNA	   content	   (PI)	   and	   surface	   IgM	   expression	   	   (as	   described	   in	  paragraph	  7.3.6).	   In	   the	  absence	  of	   the	   inhibitor,	   the	  percentage	  of	  BCR-­‐	   lymphoma	  cells	  in	  G0/G1	  was	  1.5-­‐2	  fold	  higher	  than	  in	  their	  BCR+	  competitors,	  in	  accordance	  with	  previous	   results.	   Noteworthy,	   the	   normalization	   of	   BCR+/BCR-­‐	   ratios	   induced	   by	  pharmacological	  inhibition	  of	  GSK3β	  (Figure	  49a)	  was	  associated	  to	  an	  increase	  in	  the	  fraction	  of	  cells	  in	  S-­‐phase	  that	  was	  particularly	  evident	  among	  BCR-­‐	  cells	  (Figure	  49b	  and	   c).	   These	   results	   highlight	   the	   control	   exerted	   by	   GSK3β	   on	   the	   entry	   of	  lymphoma	  cells	  into	  S-­‐phase.	  	  
7.4.8 GSK3β 	  inhibition	  rescues	  apoptosis	  of	  BCR-­‐	  lymphomas	  	  Experiments	  displayed	  in	  Figure	  34	  and	  have	  revealed	  the	  protective	  role	  exerted	  by	  the	   BCR	   on	   tumor	   cell	   survival.	   To	   test	   whether	   aberrant	   GSK3β	   activation	   was	  involved	  in	  the	  enhanced	  apoptosis	  of	  BCR-­‐deficient	  lymphomas,	  BCR+	  and	  BCR-­‐	  cells	  generated	   from	  ex	  vivo	  isolated	  primary	   lymphomas	  as	  a	  result	  of	  Cre	   transduction,	  were	  cultured	  as	  1:1	  mixtures	  for	  2	  days,	  in	  the	  presence	  of	  1µM	  CT99021.	  Apoptotic	  cells	  were	  identified	  according	  to	  either	  DNA	  content	  (fraction	  of	  hypodiplod	  cells),	  or	  expression	  of	  active	  forms	  of	  caspases	  (fraction	  of	  cells	  labeled	  by	  VAD-­‐FMK).	  In	  the	  absence	  of	  the	  GSK3β	  inhibitor,	  the	  fraction	  of	  apoptotic	  cells	  was	  3	  to	  5	  fold	  higher	  in	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the	   population	   of	   BCR-­‐	   cells	   as	   compared	   to	   its	   BCR+	   counterpart	   (Figure	   50a	   and	  Figure	  51a).	  	  
	  
Figure	  49:	  GSK3β	  inhibition	  facilitates	  G1-­‐to-­‐S	  transition	  mainly	  in	  BCR-­‐	  lymphoma	  cells	  	  
a)	   Representative	   flow	   cytometric	   analysis	   of	   BCR+	   and	   BCR–	   tumor	   cells	   (#2646)	   cultured	   for	   4	   days	   in	  competition,	   in	   the	   presence	   (CT)	   or	   absence	   (CTRL)	   of	   1μM	   CT99021.	   Dot	   plots	   are	   gated	   on	   live	   FSChi	  lymphocytes.	  Numbers	  indicate	  percentage	  of	  BCR+\–	  tumor	  cells;	  b)	  BrdU	  incorporation	  assays	  measured	  in	  BCR+	  and	  BCR-­‐	  cells	  after	  4	  days	  of	  competition	  in	  the	  presence	  (CT)	  or	  absence	  (CTRL)	  of	  1μM	  CT99021.	  Cell	  doublets	  were	  excluded	  from	  the	  analysis.	  Dot	  plots	  are	  gated	  on	  either	  IgM+	  (left)	  or	  IgM-­‐	  (right)	  cells.	  Numbers	  represent	  percentage	  of	  cells;	  c)	  Summary	  of	  cell	  cycle	  analyses	  of	  BCR+	  and	  BCR-­‐	  lymphoma	  cells,	  cultured	  in	  competition	  in	  the	  presence	  (CT,	  red	  symbols)	  or	  absence	  (CTRL,	  black	  symbols)	  of	  1μM	  CT99021.	  Ratio	  of	  BCR-­‐	  over	  BCR+	  cells	  is	  plotted	   separately	   for	   each	   stage	   of	   the	   cell-­‐cycle	   (2way-­‐Anova:	   *p<0.05;	   **p-­‐<0.01;	   ***	   p<0.001).	   Tumor	   cells	  derived	  from	  four	  independent	  lymphomas	  (#2646,	  #2676,	  #2564	  and	  #2487)	  were	  analyzed.	  
	   113	  
Upon	  treatment	  of	  BCR+/BCR-­‐	  tumor	  mixtures	  with	  CT99021,	  I	  observed	  a	  significant	  improvement	  in	  the	  survival	  of	  BCR-­‐	  lymphoma	  cells	  (Figure	  50	  and	  Figure	  51).	  These	  results	  indicate	  an	  essential	  contribution	  of	  the	  BCR	  to	  prevent	  tumor	  death	  through	  the	  inhibition	  of	  GSK3β	  activity.	  
	  
	  
Figure	  50:	  GSK3β	  inhibition	  improves	  the	  survival	  of	  BCR-­‐	  lymphoma	  cells	  
Representative	  flow	  cytometric	  analysis	  of	  IgM+	  and	  IgM-­‐	  B	  lymphoma	  cells	  (#2487)	  after	  2	  days	  of	  competition,	  cultured	  in	  the	  presence	  (CT)	  or	  absence	  (CTRL)	  of	  µM	  CT99021.	  Numbers	  within	  histograms	  indicate	  frequencies	  of	  apoptotic	  cells	  with	  a	  hypodiploid	  DNA	  content;	  b)	  Ratio	  of	  BCR-­‐	  over	  BCR+	  lymphoma	  B	  cells	  with	  less	  than	  2n	  DNA	   content	   measured	   by	   flow	   cytometry	   after	   2	   days	   of	   competition,	   in	   the	   presence	   (CT,	   red	   symbols)	   or	  absence	  (CTRL,	  black	  symbols)	  of	  1µM	  CT99021;	  bars	  indicate	  the	  average	  of	  3	  replicates	  (t-­‐test	  **p<0.01).	  Tumor	  cells	  were	  derived	  from	  four	  independent	  λ-­‐MYC;B1-­‐8f	  lymphomas	  (#2646,	  #2676,	  #2564	  and	  #2487).	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Figure	  51:	  GSK3β	  inhibition	  prevents	  apoptosis	  in	  BCR-­‐	  lymphoma	  cells	  
a)	  Flow	  cytometric	  analysis	  of	  IgM+	  and	  IgM-­‐	  lymphoma	  B	  cells	  after	  4	  days	  of	  in	  vitro	  competition,	  cultured	  in	  the	  presence	   (CT)	   or	   absence	   (CTRL)	   of	   1µM	   CT99021.	   Numbers	   in	   the	   representative	   histograms	   indicate	   the	  frequency	  of	  apoptotic	  cells	  (VAD-­‐FMK+)	  detected	  by	  flow	  cytometry	  among	  BCR+	  (black	  thick	  line)	  and	  BCR-­‐	  cells	  (grey	   filled	   line);	   b)	   Analysis	   of	   the	   ratio	   of	   BCR-­‐/BCR+	   tumor	   cells	   expressing	   active	   caspase(s)	   (VAD-­‐FMK+);	  Tumor	  cells	  were	  obtained	   from	  three	   independent	  λ-­‐MYC;B1-­‐8f	   lymphomas	  (#2676,	  #2564	  and	  #2487)	  (t-­‐test	  
**p<0.05).	  
7.4.9 Identification	  of	  BCR-­‐regulated	  genes	  in	  λ-­‐MYC	  lymphomas	  To	   identify	   genes	   controlled	   by	   the	   BCR	   in	   lymphoma	   cells,	   whole	   transcriptome	  analysis	   of	   BCR+	   and	   BCR-­‐	   lymphoma	   cells	   grown	   in	   competition	   was	   performed,	  respectively	  in	  the	  presence	  or	  absence	  of	  the	  GSK3β	  inhibitor	  CT99021.	  Specifically,	  BCR+	   and	   BCR-­‐	   lymphoma	   cells	   obtained	   from	   3	   independent	   primary	   tumors	  transduced	  with	  TAT-­‐Cre,	  were	  cultured	  in	  the	  presence	  of	  either	  CT99021	  or	  vehicle,	  and	  cell	  competition	  was	  monitored	  by	  FACS.	  Tumor	  cells	  were	  sorted	  on	  the	  basis	  of	  surface	   Ig	   expression,	   at	   the	   time	   when	   BCR-­‐deficient	   tumor	   cells	   started	   to	   get	  counter	  selected	  (in	  the	  absence	  of	  CT99021).	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Figure	  52:	  Purification	  of	  BCR+	  and	  BCR-­‐	  lymphoma	  cells	  from	  mixed	  cultures	  for	  transcriptome	  analyses	  
Flow	   cytometric	   analysis	   of	   BCR+	   and	   BCR-­‐	   lymphoma	   cells	   from	   three	   independent	   λ-­‐MYC;B1-­‐8f	   lymphomas	  (#2564,	  #2646	  and	  #2676),	   cultured	   in	   competition	   in	   the	  presence	   (CT)	  or	   absence	   (CTRL)	  of	   1µM	  CT99021.	  Numbers	  indicate	  percentages	  of	  live/FSChi	  cells.	  
	  
The	  identity	  of	  sorted	  cells	  was	  confirmed	  through	  a	  quantitative	  assessment	  of	  B1-­‐8f	  transcripts	  that	  were	  10-­‐	  to	  100-­‐fold	  reduced	  in	  BCR-­‐	  lymphomas	  compared	  to	  their	  BCR+	  sorted	  counterparts	  (Figure	  53).	  	  	  
	   116	  
	  
Figure	  53:	  Analysis	  of	  B1-­‐8	  mRNA	  levels	  in	  sorted	  BCR+	  and	  BCR-­‐	  λ-­‐MYC;B1-­‐8f	  lymphoma	  cells	  
Quantitative	  Real-­‐Time	  PCR	  to	  measure	  B1-­‐8	  mRNA	  levels	  in	  BCR+	  (black	  bars)	  and	  BCR-­‐	  (grey	  bars)	  tumor	  cells,	  derived	   from	   three	   independent	   lymphomas	   (#2564,	   #2646	   and	   #2676),	   sorted	   after	   2	   days	   of	   in	   vitro	  competition	   in	   the	   presence	   (CT)	   or	   absence	   (CTRL)	   of	   1µM	   CT99021.	   Columns	   represent	   average	   transcript	  levels	  of	  triplicates	  relative	  to	  BCR+	  CTRL,	  and	  normalized	  to	  the	  housekeeping	  gene	  RPLP0	  (±	  SD).	  	  	  
Figure	   54:	   BCR	   controls	   target	   gene	  
expression	   through	   GSK3β 	  
inhibition	  in	  λ-­‐MYC	  lymphoma	  cells	  
Numbers	   of	   genes	   differentially	  expressed	   between	   BCR+	   and	   BCR-­‐	  lymphoma	   cells,	   cultured	   in	  competition	  in	  the	  presence	  or	  absence	  (CTRL)	  of	   1µM	  CT99021	   inhibitor.	  Up-­‐	  (blue)	  and	  down-­‐regulated	  genes	  (red)	  in	   at	   least	   2	   independent	   tumors	   are	  displayed	  (fold	  change:	  ±1.5).	  	  Affymetrix	   gene-­‐chip	   analyses	   identified	   over	   400	   genes	   differentially	   expressed	  between	  BCR+	  and	  BCR-­‐	  tumor	   cells	   in	   at	   least	  2	  out	  of	  3	   independent	   tumors	   (fold	  change	   ±1.5).	   In	   particular,	   306	   genes	   were	   up-­‐regulated	   and	   112	   were	   down-­‐regulated	   in	   BCR-­‐	   lymphoma	   cells.	   Strikingly,	   almost	   80%	   (237	   among	   the	   up-­‐regulated	  and	  87	  among	  the	  down-­‐regulated	  genes)	  of	  differentially	  expressed	  genes	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were	   normalized	   in	  BCR-­‐	   lymphomas	   in	   response	   to	   the	   treatment	  with	   the	  GSK3β	  inhibitor	  CT99021	  (Figure	  54).	  	  These	   results	   indicate	   that	   the	   BCR	   controls	   a	   core	   subset	   of	   324	   genes	   through	  GSK3β	   inhibition	   to	   sustain	   the	   survival	   and	   proliferation	   of	   c-­‐MYC	   transformed	   B	  cells.	  
7.4.9.1 BCR	  target	  genes	  are	  enriched	  within	  particular	  categories	  of	  gene	  ontology	  	  To	  gain	  insights	  into	  the	  relevance	  of	  BCR-­‐regulated	  genes	  in	  the	  biology	  of	  λ-­‐MYC	  B	  cell	  lymphomas,	  I	  performed	  gene	  set	  enrichment	  analysis	  (GEA)	  on	  genes	  that	  were	  either	  induced	  or	  repressed	  upon	  BCR	  loss	  (fold	  change	  ±1.5).	  As	  shown	  in	  Figure	  55,	  programmed	   cell	   death	   was	   among	   the	   categories	   of	   biological	   processes	   most	  significantly	  enriched	  for	  genes	  up-­‐regulated	  in	  BCR-­‐deficient	  lymphoma	  cells	  (Figure	  55,	  upper	  panel)	  (p<0.01).	  	  The	   genes	   down-­‐regulated	   in	   BCR-­‐negative	   lymphoma	   cells	   were	   significantly	  (p<0.01)	  enriched	  in	  GO	  classes	  involved	  in	  lymphocyte	  differentiation	  and	  activation	  (Figure	   55,	   bottom	   panel).	   Moreover,	   despite	   not	   reaching	   statistical	   significance,	  down-­‐regulated	   genes	   were	   enriched	   in	   GO	   gene	   categories	   controlling	   cell-­‐cycle	  progression.	   	   Altogether,	   these	   results	   suggest	   that	   the	   BCR	   plays	   a	   central	   role	   to	  support	   survival	   and	   proliferation	   of	   c-­‐MYC	   transformed	   B	   cells	   through	   the	  inhibition	  of	  pro-­‐apoptotic	  genes	  and	  the	  induction	  of	  cell-­‐cycle	  genes.	  Moreover,	  BCR	  expression	  in	  lymphoma	  cells	  appears	  to	  control	  a	  B-­‐cell	  program	  that	  sustains	  B-­‐cell	  function.	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Figure	  55:	  Gene	  set	  enrichment	  analysis	  of	  genes	  differentially	  expressed	  in	  BCR-­‐	  lymphomas	  
Gene	  Set	  Enrichment	  analysis	  of	  up-­‐	  (upper	  panel)	  and	  down-­‐regulated	  (bottom	  panel)	  genes	  (fold	  change:	  ±1.5)	  upon	  BCR-­‐deletion	   in	  at	   least	   two	   independent	  λ-­‐MYC;B1-­‐8f	   tumors..	  Red	  dashed	   line	   indicates	   the	  threshold	  of	  significance	  (p<0.01).	  
7.4.9.2 BCR	  controls	  the	  expression	  of	  a	  subset	  of	  c-­‐MYC	  target	  genes	  We	   have	   shown	   that	   BCR	   expression	   limits	   the	   activity	   of	   GSK3β.	   GSK3β	   has	   been	  implicated	   in	   the	   phosphorylation	   of	   several	   substrates,	   including	   c-­‐MYC.	  Phosphorylation	   by	   GSK3β	   of	   c-­‐MYC	   on	   threonine-­‐58,	   promotes	   its	   subsequent	  degradation	   through	   the	   proteasome	   machinery.	   Hence,	   the	   BCR,	   through	   the	  inhibition	  of	  GSK3β,	  may	  sustain	  c-­‐MYC	  activity	  by	  preventing	  its	  degradation	  (Cohen	  and	   Frame,	   2001).	   To	   test	   this	   hypothesis,	   I	   assessed	   whether	   genes	   differentially	  expressed	  between	  BCR+	   and	  BCR-­‐	   lymphoma	  cells	  were	   regulated	  by	  MYC.	  To	   this	  aim,	  I	  intersected	  the	  list	  of	  BCR-­‐regulated	  genes	  in	  λ-­‐MYC	  lymphomas,	  with	  a	  dataset	  of	   MYC	   ChIP-­‐sequencing	   data	   of	   Eµ-­‐MYC	   primary	   B	   cell	   lymphomas	   recently	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generated	  by	  the	  group	  of	  B.	  Amati	  (European	  Institute	  of	  Oncology,	  Milan,	  personal	  communication).	   Importantly,	   BCR-­‐regulated	   genes	   were	   significantly	   (p<0.01)	  enriched	  for	  MYC	  targets	  (70%	  of	  BCR	  regulated	  genes	  bound	  MYC,	  i.e.	  292	  out	  of	  418	  genes)	   	   (Figure	   56).	   Both	   up-­‐	   and	   down-­‐regulated	   genes	   in	   BCR-­‐	   lymphomas	  were	  significantly	  enriched	  for	  MYC	  binding.	  Interestingly,	  when	  we	  analyzed	  the	  subset	  of	  BCR-­‐regulated	  genes,	  normalized	   in	  response	   to	  GSK3β	   inhibition	  (n=324),	   for	  MYC	  binding	   (n=227),	   only	   genes	   down-­‐regulated	   in	   BCR-­‐	   tumor	   cells	   (n=87)	   were	  significantly	  (p<0.05)	  enriched	  for	  MYC	  targets	  (n=60).	  This	  result	  points	  to	  a	  control	  exerted	  by	  the	  BCR	  on	  the	  ability	  of	  MYC	  to	  induce	  the	  expression	  of	  a	  core	  subset	  of	  its	  targets.	  
	  
Figure	  56:	  BCR	  controls	  the	  expression	  of	  a	  subset	  of	  MYC-­‐targets	  
Pie	   chart	   representation	   of	   genes	   differentially	   expressed	   in	   BCR-­‐	   lymphoma	   cells	   according	   to	   c-­‐MYC	   binding	  status.	  Percentage	  of	  genes	  bound	  (blue)	  or	  not	  (red)	  by	  MYC	  is	  shown	  (p-­‐value<0.01).	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8 DISCUSSION	  
The	  B	  cell	  antigen	  receptor	  is	  required	  throughout	  B	  cell	  development,	  as	  both	  B	  cell	  precursors	  and	  mature	  B	  cells	  are	  under	  continuous	  selection	  for	  the	  expression	  of	  a	  functional,	   non	   auto-­‐reactive	  BCR.	   Several	   genetic	   evidences	   over	   the	   course	   of	   the	  last	  20	  years	  support	  this	  concept.	  First,	  the	  failure	  to	  express	  a	  functional	  IgH	  chain	  in	   progenitor	   B	   cells	   was	   shown	   to	   prevent	   further	   development	   of	   the	   cells,	   thus	  establishing	  a	  B-­‐cell	   lymphopenic	  condition	  (Kitamura	  and	  Rajewsky,	  1992).	  Similar	  results	  were	  obtained	   through	   the	  disruption	  of	  other	   components	  of	   the	  pre-­‐BCR/	  BCR	  during	  early	  B-­‐cell	  lymphopoiesis	  (Kitamura	  et	  al.,	  1992;	  Kraus	  et	  al.,	  2001).	  The	  development	   of	   conditional	   gene	   targeting	   approaches	   led	   subsequently	   to	   the	  demonstration	   that	   surface	   expression	   of	   the	   BCR	   complex	   is	   essential	   for	   the	  survival	  of	  resting	  mature	  B	  cells.	  (Kraus	  et	  al.,	  2004;	  Lam	  et	  al.,	  1997;	  Srinivasan	  et	  al.,	   2009).	   The	   requirement	   for	   a	   signal	   emanating	   from	   the	   BCR	   in	   mature	   B-­‐cell	  survival	   was	   demonstrated	   with	   conditional	   inactivation	   of	   the	   BCR	   signalling	  effector,	  CD79a.	  (Kraus	  et	  al.,	  2004;	  Meffre	  and	  Nussenzweig,	  2002).	   	  More	  recently,	  Srinivasan	  and	  colleagues	  have	  extended	  this	  work,	  revealing	  the	  central	  role	  of	  the	  PI3K	   signaling	   cascade	   in	   the	   transmission	   of	   the	   survival	   signal	   emanating	   from	  surface	  BCR	  (Srinivasan	  et	  al.,	  2009).	  	  Several	  observations	  suggest	  that	  lymphomas	  and	  leukemias	  originating	  from	  mature	  B	   cells	   may	   also	   depend	   on	   expression	   and	   signalling	   competence	   of	   the	   BCR	   for	  survival	  and/or	  growth.	  	  Specifically:	  1)	  The	  integrity	  of	  BCR	  components	  is	  preserved	  in	  most	  forms	  of	  mature	  of	  NH	  B-­‐cell	  lymphomas	  and	  leukemia	  including	  BL,	  DLBCL,	  FL,	  MALT	  lymphomas	  and	  CLL.	  	  2)	  Genetic	  analysis	  of	  Ig	  V-­‐gene	  rearrangements	  in	  lymphoma	  B	  cells.	  	  In	  particular:	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   a)	   Early	   work	   on	   BL	   cell	   lines	   and	   primary	   BL	   tumors	   have	   revealed	   that	  t(8;14)	   translocations	   involve	   almost	   exclusively	   the	   chromosome	   14	   bearing	   a	  germline/non-­‐functional	   Ig	  V-­‐gene,	   thereby	  preserving	  structural	   integrity	  and	   thus	  functional	  competence	  of	   the	  BCR	  in	   lymphoma	  cells	  (Cleary	  et	  al.,	  1986;	  de	   Jong	  et	  al.,	  1989;	  Meeker	  et	  al.,	  1985).	  	  b)	   Analysis	   of	   the	   pattern	   of	   V-­‐gene	   mutations	   in	   several	   types	   of	   NHL,	  including	   BL,	   FL	   and	   DLBCL	   have	   revealed	   a	   peculiar	   selection	   for	   replacement	  mutations	  accumulating	  within	  CDR	  regions.	  In	  contrast,	  framework	  regions	  (that	  are	  important	   to	   preserve	   structural	   integrity	   of	   the	   BCR)	   are	   mainly	   subjected	   to	  silencing	   mutations	   (Cleary	   et	   al.,	   1986).	   Furthermore,	   these	   results	   suggest	   the	  selection	  in	  lymphomas	  showing	  ongoing	  SHM,	  for	  subclones	  carrying	  improved	  BCR	  specificities.	  c)	   Recent	   high	   throughput	   sequencing	   analyses	   in	   primary	   DLBCL	   have	  identified	  recurrent	  mutations	  in	  the	  gene	  coding	  for	  CD79a,	  an	  essential	  effector	  of	  BCR	  signalling	  in	  DLBCL	  cases	  (Davis	  et	  al.,	  2010).	  Importantly	  these	  mutations	  were	  found	   to	   mimic	   a	   constitutively	   activated	   BCR	   (Staudt,	   2010).	   Similar	   approaches	  have	   allowed	   the	   recent	   identification	   in	   primary	   BL	   cases	   of	   genetic	   mutations	  affecting	   the	   transcription	   factor	   TCF3/E2A,	   which	   controls	   Ig	   gene	   transcription	  (Schmitz	  et	  al.,	  2012).	  d)	  Work	  mainly	  performed	  by	  the	  group	  of	  Ron	  Levy	  has	  elucidated	  in	  the	  past	  20	  years	  the	  genetic	  basis	  for	  the	  acquired	  resistance	  of	  Follicular	  lymphoma	  B	  cells	  to	   the	   treatment	   with	   anti-­‐BCR	   idiotype	   antibodies.	   The	   administration	   of	   anti-­‐idiotype	   antibodies	   promoted	   the	   selection	   in	   FL	   patients	   of	   lymphoma	   subclones	  expressing	   	   “novel”	   BCRs	   	   (therefore	   confirming	   the	   need	   to	   express	   an	   antigen	  receptor)	   that	   escaped	   the	   treatment.	   Sequencing	   of	   the	   V-­‐genes	   coding	   for	   the	  variable	   region	   of	   the	   “resistant”	   BCRs,	   revealed	   the	   presence	   of	   the	   original	   Ig	   V-­‐
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genes	   that	   had	   acquired	   few	   key	   mutations	   that	   escaped	   recognition	   by	   the	   anti-­‐idiotype	  antibody	  (Meeker	  et	  al.,	  1985).	  3)	   The	   role	   of	   antigen	   in	   triggering	   lymphoma	   B-­‐cell	   survival	   and	   growth	  through	  the	  BCR	  has	  been	  suggested	  in	  several	  instances:	  a. MALT	  lymphomas	  occurring	  in	  gastric	  mucosa	  of	  patients	  infected	  with	  Helicobacter	   Pylori	   are	   currently	   treated	   with	   antibiotics.	   In	   most	   cases,	   the	  eradication	  of	  the	  bacteria	  leads	  to	  a	  complete	  clinical	  remission.	  Similar	  observations	  have	   been	   provided	   for	   marginal	   zone	   B-­‐cell	   malignancies	   affecting	   the	   ocular	  adnexae	  (Hermine	  et	  al.,	  2002;	  Wotherspoon	  et	  al.,	  1993).	  	  b. Both	  Hodgkin	  and	  Non-­‐Hodgkin	  B-­‐cell	  lymphomas	  can	  develop	  in	  close	  association	  with	  chronic	  hepatitis	  caused	  by	  infection	  with	  Hepatitis-­‐C	  Virus	  (HCV).	  Ig	  V-­‐gene	  analysis	  of	  lymphoma	  B	  cells	  have	  revealed	  the	  selection	  for	  clones	  expressing	  unique	   BCRs,	   possibly	   reactive	   against	   specific	   viral	   antigens	   (Chan	   et	   al.,	   2001).	  Importantly,	  treatment	  of	  lymphoma	  cases	  associated	  to	  chronic	  HCV	  infection,	  with	  anti-­‐viral	  drugs	  leads	  often	  to	  complete	  clinical	  remission.	  	  c. Chronic	  Lymphocytic	  Leukemia	  is	  characterized	  by	  the	  slow	  outgrowth	  of	  B-­‐cell	  clones	  expressing	  a	  limited,	  unique,	  subset	  of	  BCRs.	  These	  antigen	  receptors	  have	   been	   predicted	   to	   recognize	   common	   environmental	   antigens	   of	   microbial	  origin,	  possibly	  with	  some	  degree	  of	  cross-­‐reactivity	  with	  self-­‐antigens.	  An	  important	  recent	   study	   has	   contributed	   to	   shed	   light	   on	   the	   signaling	   property	   of	   stereotypic	  BCRs	  expressed	  by	  CLL	  cells.	  It	  was	  shown	  that	  BCRs	  expressed	  by	  CLL	  cells	  signal	  in	  a	  cell	  autonomous	  manner,	  in	  the	  absence	  of	  foreign	  antigen	  recognition.	  Instead	  the	  variable	   region	   of	   such	   BCRs	   recognizes	   an	   internal	   epitope	   present	  within	   all	   IgH	  chains	   thereby	   activating	   a	   downstream	   proliferative	   and	   survival	   signal	   (Duhren-­‐von	  Minden	  et	  al.,	  2012). 	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What	  type	  of	  signal	  is	  delivered	  to	  B-­‐lymphoma	  cells	  through	  the	  BCR?	  	  Studies	  in	  Eµ-­‐MYC	  lymphoma-­‐prone	  mice	  expressing	  a	  BCR	  of	  known	  specificity	  (hen	  egg	   lysozyme)	   have	   revealed	   an	   active	   role	   of	   the	   BCR	   in	   supporting	   MYC-­‐driven	  transformation,	   as	   a	   result	   of	   cognate	   antigen	   recognition	   (Refaeli	   et	   al.,	   2008).	  Whereas	  we	  cannot	  exclude	  a	  contribution	  of	  antigen	  to	  BCR-­‐controlled	  growth	  of	  BL,	  our	  own	  study	  demonstrates	  that	  a	  “tonic”,	  low-­‐strength,	  BCR	  signal	  is	  sufficient,	  and	  most	  importantly,	  required	  for	  MYC-­‐driven	  transformation.	  	  
In	   vitro	   studies	   performed	   on	   DLBCL	   lines	   have	   further	   contributed	   to	   our	  understanding	  of	  the	  signalling	  events	  active	  downstream	  of	  the	  BCR	  in	  these	  tumor	  cells.	   The	   identification	   of	   DLBCL	   lines	   sensitive	   to	   knock-­‐down	   of	   proximal	   BCR	  signalling	   effectors	   including	   Cd79a,	   Cd79b	   and	   the	   kinases	   SYK	   and	   BTK,	   have	  proposed	   the	   existence	   of	   a	   “chronic”	   BCR	   signal	   supporting	   the	   in	  vitro	   growth	   of	  lymphoma	   cells	   through	   the	   downstream	   activation	   of	   the	   NF-­‐κB	   transcription	  factors	   (Davis	   et	   al.,	   2010).	   Interestingly,	   the	   high	   sensitivity	   of	   DLBCL	   cells	   to	   the	  down	   regulation	   of	   effectors	   of	   BCR	   signalling	   was	   preferentially	   observed	   among	  tumor	   lines	  representing	  the	  more	  aggressive	  Activated	  B-­‐Cell	  (ABC)	  type	  of	  DLBCL	  (Davis	   et	   al.,	   2010).	   The	   precise	   nature	   of	   the	   so-­‐called	   “chronic”	   B	   cell	   signal	  measured	   in	  vitro	   in	  ABC	  DLBCL	   lines	  remains	  still	   to	  be	   fully	  elucidated.	  The	   latter	  signal	  is	  clearly	  distinct	  from	  the	  tonic	  signal	  emanating	  from	  the	  BCR	  that	  is	  required	  to	  sustain	  the	  survival	  of	  resting	  B	  cell,	  as	  the	  latter	  does	  not	  involve	  the	  activation	  of	  the	  NF-­‐κB	  pathway	  (Srinivasan	  et	  al.,	  2009;	  Thome,	  2004).	  	  The	  studies	  listed	  above	  share	  several	  limitations	  including	  the	  analysis	  of	  in	  vitro	  cell	  line	  systems	  or	  transgenic	  tumor-­‐prone	  lines	  engineered	  to	  express	  high-­‐affinity	  BCR.	  Moreover,	   possible	   off-­‐targets	   effects	   limit	   the	   interpretation	   of	   the	   data	   obtained	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with	   the	  use	  of	   shRNAs.	  Finally	   the	   specificity	  of	   small	  molecule	   inhibitors	  directed	  against	  BCR	  effectors	  cannot	  always	  be	  experimentally	  validated.	  	  With	  the	  present	  work,	  I	  have	  tried	  to	  overcome	  the	  above	  listed	  limitations.	  Using	  a	  genetic	  approach,	  I	  have	  addressed	  the	  contribution	  of	  the	  BCR	  in	  the	  λ-­‐MYC	  model	  of	  Burkitt	  lymphoma.	   λ-­‐MYC	  transgenic	  B	  cells	  were	  engineered	  to	  carry	  a	  loxP-­‐flanked	  pre-­‐rearranged	   VH	   gene	   (B1-­‐8f).	   This	   strategy	   enabled	   me	   to	   inactivate	   BCR	  expression	  in	  established	  BL	  cells	  by	  means	  of	  the	  Cre/loxP	  recombination	  system.	  	  Using	   this	   approach,	   I	   provided	   evidence	   that	   the	   BCR	   plays	   an	   essential	   role	   in	  controlling	  the	  survival	  and	  proliferation	  of	  established	  BL	  both	   in	  vitro	  and	   in	  vivo.	  	  BCR–	   BL	   cells,	   generated	   either	   by	   Cre-­‐mediated	   recombination	   of	   λ-­‐MYC;B1-­‐8f	  mouse	  transgenic	  tumor	  cells,	  or	  spontaneously	  from	  the	  human	  BL	  cell	  line	  RAMOS	  (possibly	   due	   to	   BCR	   crippling	   mutations	   caused	   by	   ongoing	   SHM	   (Sale	   and	  Neuberger,	  1998),	  were	  rapidly	  counter	  selected	  in	  vitro	  by	  their	  BCR+	  counterparts.	  In	   accordance	   with	   these	   results,	   competitive	   transplantation	   assays	   of	   BCR+	   and	  BCR–	  mouse	  BL	  cells	  into	  syngeneic	  recipients	  led	  to	  the	  preferential	  outgrowth	  of	  the	  BCR+	  tumor	  subset.	  Surprisingly,	  the	  loss	  of	  BCR-­‐	  lymphomas	  was	  strictly	  dependent	  on	  the	  concomitant	  presence	  of	  their	  BCR+	  counterparts,	  as	  purified	  BCR–	  tumor	  cells	  were	   able	   to	   expand	   indefinitely	   in	   vitro	  and	   give	   rise	   to	   secondary	   tumors	   in	   vivo	  (although	   with	   a	   longer	   latency)	   when	   grown	   in	   the	   absence	   of	   their	   BCR+	  counterparts.	  The	  presence	  of	  BCR+	  BL	  cells	   influenced	  the	  proliferation	  of	  the	  BCR-­‐	  counterparts,	   as	   revealed	   by	   their	   delay	   in	   the	   G1-­‐to-­‐S	   transition	   of	   the	   cell-­‐cycle.	  Moreover,	   the	  presence	  of	  BCR+	  BL	   cells	   rendered	   their	  BCR-­‐deficient	   counterparts	  more	   prone	   to	   undergo	   apoptosis	   both	   in	   the	   mouse	   (λ-­‐MYC;B1-­‐8f)	   and	   human	  (RAMOS)	  system.	  	  	  Importantly,	   complementation	   of	   BCR-­‐	   tumor	   cells	   with	   a	   novel	   antigen	   receptor	  promptly	   rescued	   the	   failure	   of	   these	   cells	   to	   expand	   in	   vitro	   and	   in	   vivo	   under	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competitive	   conditions,	   excluding	   thereby	   the	   existence	   of	   additional	   genetic	  alterations	  contributing	  to	  the	  disappearance	  of	  such	  cells.	  	  The	  biochemical	   analysis	   of	   proximal	   signalling	   events	   (phosphorylation	   of	   the	   Syk	  kinase)	  triggered	  by	  the	  antigen	  receptor	  in	  λ-­‐MYC	  BL	  cells,	  revealed	  a	  signal	  of	  weak	  intensity,	   resembling	   that	   of	   small	   resting	  mature	  B	   cells.	   This	   result	   is	   compatible	  with	   a	   scenario	   whereby	   the	   basal	   signal	   emanating	   from	   BCR	   represents	   a	   key	  permissive	   factor	   to	   sustain	   survival	   and	   growth	   of	   BL	   cells	   under	   competitive	  conditions.	  To	   investigate	   the	   contribution	   of	   the	   BCR	   to	   BL	   biology,	   in	   collaboration	  with	   the	  group	  of	  Dr.	  Bonaldi	  (European	  Institute	  of	  Oncology),	  we	  performed	  a	  quantitative	  proteome	  analysis	  of	  λ-­‐MYC	  BL	  cells	   respectively	  before	  and	  after	  BCR	   inactivation.	  This	   experiment,	   the	   first	   of	   its	   kind,	   allowed	   us	   to	   quantify	   over	   4000	   proteins	   of	  which	   around	   5%	  were	   influenced	   by	   BCR	   expression.	   A	   large	   fraction	   of	   enzymes	  involved	   in	  glucose	  metabolism	  were	  down	  regulated	   in	  BCR-­‐less	   lymphomas,	  with	  an	  average	  10	  to	  20%	  reduction	  in	  protein	  levels,	  that	  resulted	  statistical	  significant.	  	  Tumor	  cells,	   especially	  MYC-­‐transformed	  cells,	   rewire	   their	  metabolism	   to	  ensure	  a	  steady	  supply	  of	  metabolites	  to	  sustain	  the	  heightened	  anabolism,	  as	  well	  as	  for	  the	  generation	  of	  ATP.	  This	  energetic	  adaptation	  is	  achieved	  through	  a	  metabolic	  switch	  from	  mitochondrial	   respiration	   to	   a	  massive	   aerobic	   glycolysis,	   a	  phenomenon	  also	  known	  as	  the	  Warburg	  effect	  (Warburg,	  1956).	  Consequently,	  the	  apparently	  modest	  down-­‐modulation	  of	   the	   glycolytic	  pathway	  may	   represent	   a	   key	   limiting	   factor	   for	  the	   growth	   of	   BCR-­‐less	   tumor	   cells	   in	   the	   presence	   of	   their	   BCR+	   counterparts	  especially	   under	   conditions	   of	   nutrient	   deprivation.	  This	   hypothesis	  was	   confirmed	  by	   the	   accelerated	   loss	   of	   BCR-­‐	   BL	   cells	   when	   BCR+/BCR-­‐	   tumor	   mixtures	   were	  cultured	  under	  conditions	  of	   limited	  growth	  factor	  and	  nutrient	  availability,	  such	  as	  those	  achieved	   in	   serum	  starvation	  assays,	  or	  when	   the	  same	   tumor	  mixtures	  were	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treated	  with	  Rapamycin,	  a	  specific	  inhibitor	  of	  the	  nutrient-­‐sensitive	  mTOR	  pathway	  (Peng	  et	  al.,	  2002).	  	  At	  the	  same	  time,	  I	  excluded	  a	  specific	  defect	  of	  BCR-­‐	  tumor	  cells	  respectively	   in	   glucose	   uptake,	   LDH	   activity	   or	  mitochondrial	   respiration	   (however	  the	  latter	  two	  assays	  could	  not	  be	  performed	  under	  competitive	  conditions).	  Whereas	  increased	  glucose	  metabolism	  is	  essential	  to	  sustain	  the	  bioenergetic	  needs	  of	  cancer	  cells,	  it	  is	  now	  becoming	  clear	  that	  tumor	  cells	  with	  a	  high	  proliferation	  rate	  (such	   as	   MYC-­‐transformed	   cells)	   require	   additional	   supplies	   of	   biosynthetic	  precursors,	   such	   as	   glutamine,	   to	   sustain	   their	   energetic	   and	   anabolic	   processes.	  (DeBerardinis	   et	   al.,	   2008;	   DeBerardinis	   et	   al.,	   2007;	   Yuneva	   et	   al.,	   2007).	   Future	  experiments	  will	  reveal	  whether	  the	  BCR	  can	  influence	  the	  rate	  of	  glutaminolysis	  in	  c-­‐MYC	  transformed	  B-­‐lymphoma	  cells.	  The	  use	   of	   small	  molecule	   inhibitors	   allowed	  me	   to	   identify	  GSK3β	   	  as	   an	   essential	  modulator	  of	  the	  survival	  signal	  triggered	  in	  BL	  cells	  by	  the	  BCR.	  In	  support	  of	  this,	  I	  observed	   reduced	   levels	   of	   the	   phosphorylated,	   inactive,	   form	   of	   GSK3β	   in	   BCR-­‐	  lymphomas.	   Synthetic	   inhibition	   of	   GSK3β	   prevented	   the	   counter	   selection	   of	   BCR-­‐deficient	   lymphoma	   cells	   in	   the	  presence	  of	   their	  BCR+	   counterparts.	   The	   rescue	  of	  BCR-­‐	   lymphomas	   resulted	   from	   the	   normalization	   of	   cell	   cycle	   progression	   and	  acquired	  resistance	  to	  apoptosis.	  These	  data	  indicate	  that	  heightened	  GSK3β	  activity	  in	  BCR-­‐	  tumor	  cells,	  likely	  resulting	  from	  impaired	  PI3K	  activity,	  is	  the	  primary	  cause	  for	  theirs	  preferential	  loss	  when	  grown	  in	  competition	  with	  BCR+	  tumors.	  	  GSK3β	   phosphorylates	   a	   variety	   of	   substrates	   participating	   to	   important	   signalling	  pathways	   that	   respond	   to	   environmental	   signals,	   such	   as	   growth	   factors,	   nutrients	  and	  other	  soluble	  factors	  including	  cytokines	  (Cohen	  and	  Frame,	  2001).	  	  GSK3β	   inhibits	   cell	   cycle	   progression	   and	   thus	   interferes	  with	   cell	   proliferation	   by	  controlling	  the	  stability	  of	  cyclin	  E	  (CcnE)	  and	  cyclin	  D1	  (CcnD1)	  proteins	  (Xu	  et	  al.,	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2009).	  Thus,	  through	  the	  inhibition	  of	  GSK3β	  activity,	  the	  BCR	  may	  facilitate	  cell	  cycle	  progression	  in	  lymphoma	  B	  cells	  stabilizing	  respectively	  D-­‐type	  and	  E	  cyclins.	  	  Another	  attractive	  target	  of	  GSK3β	   is	  MYC	  itself	  (Adhikary	  and	  Eilers,	  2005).	  GSK3β	  phosphorylation	  of	  c-­‐MYC	  on	  threonine-­‐58	  leads	  to	  c-­‐MYC	  ubiquitylation	  by	  SCFFbw7,	  followed	  by	  proteosomal	   degradation	   (Adhikary	   and	  Eilers,	   2005).	   Elegant	  work	   in	  Drosophila	   has	   unraveled	   a	   cell	   competition	   system	   regulated	   by	   c-­‐MYC	   protein	  levels.	   	   Larval	   cells	   expressing	   higher	   dMYC	   levels	   could	   rapidly	   outcompete	  neighboring	  cells,	  expressing	  lower	  dMYC	  levels	  (Rhiner	  et	  al.,	  2010).	  	  Could	  BCR	  loss	  influence	   MYC	   levels	   (and	   thereby	   its	   biological	   function)	   to	   ultimately	   limit	   the	  growth	   of	   BCR-­‐less	   tumor	   cells?	   	   I	   failed	   to	   observe	   major	   changes	   in	   total	   MYC	  protein	  levels	  in	  response	  to	  BCR	  inactivation.	  I	  am	  however	  aware	  of	  the	  relatively	  low	  sensitivity	  of	  immunoblotting	  analyses	  that	  may	  not	  allow	  the	  detection	  of	  subtle,	  yet	  biologically	  relevant,	  changes	  in	  MYC	  protein	  levels.	  I	  therefore	  decided	  to	  tackle	  this	   question	   measuring	   the	   effects	   of	   BCR	   loss	   on	   the	   gene	   expression	   profile	   of	  tumor	   cells,	   pointing	   our	   attention	   primarily	   to	   the	   levels	   of	   putative	   MYC	   target	  genes.	   Gene	   chip	   microarray	   analysis	   performed	   on	   three	   independent	   BL	   tumors	  identified	   more	   than	   400	   genes	   differentially	   expressed	   between	   BCR+	   and	   BCR-­‐	  tumor	  cells.	  BCR-­‐regulated	  transcripts	  fell	  primarily	  within	  gene	  ontology	  categories	  controlling	  cell	  survival	  and	  apoptosis.	  Importantly,	  the	  vast	  majority	  of	  differentially	  expressed	   genes	   were	   normalized	   by	   the	   treatment	   of	   lymphoma	   cells	   with	   the	  GSK3β	  small	  molecule	  inhibitor,	  confirming	  the	  central	  role	  exerted	  by	  this	  kinase	  in	  the	  modulation	  of	  BCR-­‐dependent	  gene	  transcription.	  	  In	   collaboration	   with	   the	   group	   of	   B.	   Amati	   that	   provided	   us	   with	   chromatin	  immunoprecipitation	   data	   on	   the	   status	   of	   MYC-­‐binding	   (established	   in	   Eµ-­‐MYC	  lymphomas)	   to	   genes	   differentially	   expressed	   between	   BCR+	   and	   BCR-­‐	   lymphomas,	  we	  recognized	  that	  most	  of	   the	  BCR	  controlled	  genes	  were	   indeed	  bound	  by	  c-­‐MYC.	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These	   yet	   preliminary	   observations	   point	   to	   a	   possible	   regulation	   of	   the	  BCR	  on	   c-­‐MYC	   function,	   through	   the	   inactivation	   of	   GSK3β	   activity	   in	   c-­‐MYC	   transformed	   B	  cells.	   We	   are	   currently	   testing	   this	   possibility	   by	   chromatin	   immunoprecipitation	  assays	  performed	  on	  specific	  genes	  (ChIP-­‐qPCR),	  and	  eventually	  extended	  at	  genome	  wide	  level	  (ChIP-­‐seq).	  This	  approach	  will	  reveal	  the	  degree	  to	  which	  BCR	  expression	  controls	  MYC	  transcriptional	  activity	  in	  MYC-­‐transformed	  B	  lymphoma	  cells.	  Finally,	  complementation	  of	  BCR-­‐deficient	  tumor	  cells	  with	  a	  Threonine-­‐58	  mutant	  isoform	  of	  MYC,	   resistant	   to	   GSK3β	   induced	   degradation,	   will	   further	   demonstrate	   the	  stabilization	  of	  MYC	  through	  the	  BCR-­‐GSK3β	  axis,	  and	  the	  involvement	  of	  MYC	  in	  the	  control	  of	  survival	  of	  transformed	  mature	  B	  cells.	  	  In	  the	  past	  year,	  a	  series	  of	  relevant	  studies	  have	  improved	  our	  understanding	  on	  the	  genetics	   of	   BL.	   	   Work	   performed	   by	   the	   Rajewsky	   group	   have	   attempted	   to	  reconstruct	  BL	   in	   the	  mouse	  through	  the	  complementation	  of	  GC	  B	  cells	  with	  genes	  that	   are	   recurrently	   deregulated	   in	   hBL.	   Interestingly	   (and	   surprisingly),	   c-­‐MYC	  deregulation	   induced	   in	   GC	   B	   cells	   was	   not	   sufficient	   to	   trigger	   BL.	   Instead,	   clonal	  outgrowth	  of	  B-­‐cells	  resembling	  BL	  were	  observed	  only	  upon	  concomitant	  induction	  of	  deregulated	  c-­‐MYC	  and	  activation	  of	  the	  PI3K	  pathway	  (Sander	  et	  al.,	  2012).	  Tumor	  B	   cells	   generated	   in	   compound	   mutant	   mice	   resembled	   closely	   hBL	   based	   on	  immunophenotype,	   histological	   appearance,	   gene	   expression	   profile	   and	   most	  importantly	  germinal	  center	  origin	  (Sander	  et	  al.,	  2012).	   	  These	  results	  highlight	  the	  central	  role	  exerted	  by	  the	  PI3K	  pathway	  in	  BL	  pathogenesis.	  The	  requirement	  for	  the	  PI3K	   signaling	   pathway	   to	   support	   BCR-­‐mediated	   survival	   of	   mature	   B	   cells	  (Srinivasan	  et	  al.,	  2009)	  suggests	  a	  direct	  contribution	  of	  the	  BCR	  to	  BL	  pathogenesis.	  	  This	  scenario	  is	  further	  supported	  by	  recent	  high-­‐throughput	  RNA	  sequencing	  efforts	  performed	  on	  sporadic	  BL	  by	   the	  Staudt	  group.	   In	   this	  study,	  authors	   identified	   the	  transcription	   factor	   TCF3/E2A	   as	   frequently	   mutated	   in	   BL	   cells.	   TCF3	   mutations	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found	  in	  tumor	  cells	  altered	  its	  transcriptional	  activity.	  In	  accordance	  with	  a	  central	  role	  of	  TCF3	  in	  BL	  pathogenesis,	  bi-­‐allelic	  inactivating	  mutations	  in	  the	  TCF3	  inhibitor	  ID3	  were	  readily	   identified	   in	  BL	  cells.	  Deregulated	  TCF3	  activity	  was	  associated	   to	  increased	  expression	  of	  Ig	  genes,	  suggesting	  a	  possible	  contribution	  of	  altered	  TCF3	  activity	   to	   the	   enforcement	   of	   BCR	   function.	   	   Importantly,	   in	   vitro	   knock-­‐down	   of	  proximal	  BCR	  signaling	  components	  (CD79a	  and	  SYK),	  resulted	  in	  impaired	  activation	  of	  the	  PI3K	  pathway	  and	  ultimately	  in	  the	  death	  of	  BL	  cell	  lines	  (Schmitz	  et	  al.,	  2012).	  Altogether	  these	  results	  are	  consistent	  with	  our	  own	  findings	  and	  confirm	  the	  central	  role	   of	   the	   BCR	   in	   sustaining	   the	   growth	   of	   BL	   cells.	   	   Importantly,	   our	   work	  implements	   the	   current	   understanding	   of	   the	   role	   of	   the	   BCR	   in	   BL	   pathogenesis	  identifying	  GSK3β	  as	  an	  essential	  downstream	  target	  of	  the	  PI3K	  pathway.	  	  Interestingly,	   the	  Rajewsky	  group	  reported	  that	  mouse	  BL	  identified	   in	  c-­‐MYC/PI3K	  conditional	   transgenic	  mice	   retained	   surface	   BCR	   expression	   (Sander	   et	   al.,	   2012).	  This	  result	  thus	  suggests	  possible	  additional,	  PI3K-­‐independent,	  contributions	  of	  the	  BCR	  to	  BL	  pathogenesis.	  	  Results	   from	   RNA	   sequencing	   efforts	   on	   hBL	   that	   were	   later	   confirmed	   in	   the	   c-­‐MYC/PI3K	  BL	  mouse	  model	  identified	  recurrent	  mutations	  stabilizing	  Cyclin	  D3.	  This	  result	  highlights	  the	  relevance	  of	  the	  germinal	  center	  origin	  of	  BL	  as	  Cyclin-­‐D3	  is	  the	  main	  D-­‐type	   cyclin	   expressed	   by	   these	   cells.	   	   It	   remains	   to	   be	   investigated	  why	  BL	  cells	  select	  mutations	  stabilizing	  Cyclin	  D3,	  as	  MYC	  expression	  is	  predicted	  to	  induce	  other	  D-­‐type	  cyclins	  that	  are	  functionally	  redundant	  with	  Cyclin	  D3	  (Musgrove	  et	  al.,	  2011).	   The	   importance	   in	   the	   regulation	   of	   G1-­‐to-­‐S	   transition	   in	   BL	   cells	   is	   in	  accordance	  with	   our	   own	   data	   showing	   a	   delay	   in	   cell	   cycle	   progression	   of	   λ-­‐MYC	  lymphomas	  as	  a	  result	  of	  Cyclin	  E	  down-­‐regulation.	  The	  ability	  of	  the	  BCR	  to	  regulate	  G1-­‐type	   cyclins	   in	   the	   λ-­‐MYC	   BL	   model	   revealed	   by	   our	   study	   warrants	   further	  investigations	  in	  hBL.	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Schmitz	  and	  colleagues	  have	  also	  proposed	  a	  role	  for	  the	  PI3K	  pathway	  in	  the	  control	  the	  mTOR	  axis,	   to	   ultimately	   sustain	  BL	   growth.	   Indeed,	  most	  BL	   cell	   lines	   showed	  constitutive	  phosphorylation	  of	  the	  mTOR	  substrate,	  S6	  kinase,	  which	  was	  reduced	  in	  response	   to	   pharmacological	   inhibition	   of	   PI3K.	   Importantly,	   BL	   lines	   were	   highly	  sensitive	  to	  Rapamycin	  indicating	  a	  strict	  dependence	  of	  the	  tumor	  cells	  on	  the	  mTOR	  pathway.	  Interestingly,	  this	  effect	  was	  also	  observed	  in	  BL	  lines	  that	  did	  not	  depend	  on	   BCR	   signals	   (Schmitz	   et	   al.,	   2012).	   	   Our	   work	   integrates	   and	   complements	   the	  above	   findings.	   	   Indeed,	   we	   could	   show	   that	   loss	   of	   antigen	   receptor	   expression	  rendered	   c-­‐MYC	   transformed	  B	   cells	   particularly	   sensitive	   to	   Rapamycin	   treatment	  and	   thus	   preferentially	   dependent	   on	   the	   mTOR	   pathway.	   This	   condition	   led	   to	  acceleration	  in	  the	  counter	  selection	  of	  BCR-­‐	  lymphomas	  when	  grown	  in	  competition	  with	  their	  BCR+	  counterparts.	  	  Based	   on	   published	  work	   and	   our	   own	   results,	   we	  would	   like	   to	   propose	   a	  model	  whereby	  BL	   cells	   depend	   critically	   on	   two	   independent	   pathways	   for	   their	   growth.	  The	   first	   is	   the	  BCR/PI3K	  pathway	   that	   is	   required	   to	   inhibit	   the	   activity	   of	  GSK3β	  facilitating	   the	   stabilization	   of	   the	   c-­‐MYC	   oncoprotein.	   In	   the	   absence	   of	   BCR	  expression,	   BL	   cells	   become	   strictly	   dependent	   on	   the	   second	   main	   pathway	  supporting	  tumor	  growth	  centered	  on	  the	  nutrient-­‐sensitive	  mTOR	  axis.	  	  This	  model	  predicts	  that	  BL	  cells	  are	  able	  to	  sustain	  their	  growth	  through	  constitutive	  activation	  of	   the	  mTOR	  pathway	  as	   long	  as	  nutrients	  are	  unlimited.	   In	  conditions	  of	  nutrient	  restrictions,	  such	  as	  those	  found	  in	  lymphomas	  with	  a	  high	  proliferation	  rate,	  tonic	   BCR	   signalling	  may	   represent	   a	   crucial	   determinant	   to	   sustain	   tumor	   growth	  through	  the	  activation	  of	  the	  PI3K	  pathway,	  which	  will	  sustain	  both	  mTOR	  activation	  and	  GSK3	  inhibition.	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Figure	  57:	  Pathways	  controlled	  by	  the	  BCR	  to	  sustain	  BL	  proliferation	  and	  survival	  	  
Model	  revealing	  the	  main	  pathways	  regulated	  by	  the	  BCR	  to	  support	  the	  growth	  of	  c-­‐MYC	  transformed	  B	  cells.	  The	  BCR	   complex	   is	   depicted	   in	   green;	   amino	   acid\nutrient-­‐sensitive	   receptors	   are	   depicted	   in	   red.	   Dashed	   line	  indicates	  a	  possible	  regulation	  of	  mTOR	  by	  BCR-­‐dependent	  PI3K/Akt	  activity.	  
Altogether	  my	  results	  provide	  experimental	  evidence	  for	  an	  essential	  role	  of	  the	  BCR	  in	   the	   pathogenesis	   of	   BL.	   BCR	   signalling	   competence	   may	   exert	   its	   function	   at	  multiple	   stages	   of	   BL	   pathogenesis.	   During	   tumor	   initiation,	   the	   expression	   of	   a	  functional	  BCR	  is	  required	  to	  sustain	  the	  survival	  of	  GC	  B	  cells	  that	  acquire	  the	  t(8:14)	  translocation.	   This	   is	   confirmed	   by	   the	   selection,	   among	   BL	   precursors,	   of	   cells	  carrying	   a	   MYC	   translocation	   involving	   almost	   exclusively	   the	   non-­‐functional	   IgH	  chromosome.	  Continuous	  BCR	  expression	  is	  then	  expected	  to	  sustain	  the	  survival	  of	  t(8:14)	  bearing	  BL	  precursors	  until	  additional	  mutations	  have	  been	  selected	  to	  give	  rise	  to	  a	  clonal	  malignancy.	  Finally,	  as	  BL	  cells,	  the	  continuous	  expression	  of	  the	  BCR	  will	   provide	   a	   selective	   growth	   advantage,	   especially	   under	   conditions	   of	   limited	  nutrient	  supply.	  This	  scenario	   is	   indeed	  compatible	  with	  the	  continuous	  elimination	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from	   the	   tumor	  mass	   of	   BCR-­‐deficient	   lymphoma	   cells	   generated	   by	   ongoing	   SHM,	  through	  the	  acquisition	  of	  Ig	  crippling	  mutations.	  	  
Our	  study	  has	   implications	   for	   the	   therapy	  of	  Burkitt	   lymphoma	  and	  possibly	  other	  mature	  B-­‐cell	  malignancies	  expressing	  a	  functional	  BCR.	  	  Small	  molecule	  inhibitors	  of	  proximal	   BCR	   signalling	   components	   are	   predicted	   to	   contribute	   to	   the	   efficacy	   of	  current	  chemotherapeutic	  protocols	  used	  to	  treat	  aggressive	  forms	  of	  NHL	  including	  BL,	   as	   recently	   suggested	   (Chen	   et	   al.,	   2008;	   Honigberg	   et	   al.,	   2010;	   Young	   et	   al.,	  2009).	  	  	  At	   the	   same	   time,	   our	   study	   provides	   a	   warning	   for	   future	   monotherapies	   based	  exclusively	   on	   inhibitors	   of	   BCR	   signalling.	   Indeed,	   these	   conditions	   are	   likely	   to	  promote	  the	  outgrowth	  of	  BCR-­‐deficient	   lymphomas	  that	  would	  otherwise	  never	  be	  identified	  due	  to	   their	  rapid	  counter	  selection.	  To	  avoid	   this	  outcome,	  based	  on	  our	  results	   in	   the	   λ-­‐MYC	  model,	   we	   propose	   a	   combinatorial	   treatment	   based	   on	   BCR	  inhibitors	   coupled	   to	  Rapamycin	   against	  which	  BCR-­‐less	   lymphomas	   have	   shown	   a	  preferential	  sensitivity.	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